## **Epilogue**

It is 50 years since the discovery of the double helical structure of DNA, an event that marks the beginning of molecular biology. The structure of DNA represents the seed that germinated, grew rapidly, flowered and bore fruit. It has led to descriptions of the flow of information from gene to protein. Molecular biology, expanded from a small isolated research area into a major, all embracing, discipline. As this book is being published close to the 50th anniversary it is timely to reflect that during this period biochemistry has been marked by several defining discoveries based on the structure and function of proteins. The list of significant discoveries could provide the bulk of the content of another book but a brief and selective description of these events might include:

- The elucidation of the structure of myoglobin and haemoglobin by Perutz and Kendrew using X-ray crystallography. This work paved the way for all future crystallographic studies of proteins and established the basis for allostery.
- The structure of the first enzyme, lysozyme, by Phillips. Structural characterization defined an active site and the geometry of residues that facilitated biological catalysis and pointed towards molecular enzymology.
- Protein folding is encoded entirely by the primary sequence. Anfinsen proved that proteins could fold to reach the native state whilst in cells large macromolecular complexes known as chaperones were shown much later to assist folding by forming environments known as the Anfinsen cage that limit unfavourable protein interactions.

- Crystallization of the photosynthetic reaction centre by Michel, Diesenhofer and Huber. The helical structure of transmembrane segments was confirmed and showed that membrane proteins could be crystallized and subjected to the same high resolution methods applied previously to soluble proteins.
- The architecture of the ribosome. A daunting experimental problem revealed catalysis of the peptidyl transferase was performed by RNA and the ribosome is a ribozyme. The structure of the ribosome confirmed that biological catalysis could proceed in the absence of protein-based enzymes redefining our traditional view of nucleic acid and proteins.
- p53 and the molecular basis of cancer. The demonstration that over 60 percent of all tumours are associated with mutations in p53 elucidated a direct link between molecular defects in a protein and subsequent development of cancer.
- *The prion hypothesis*. Consequently the prion hypothesis showed that some proteins 'corrupt' native conformations promoting protein aggregation; a hallmark of many neurodegenerative disorders.

By reading the preceding 12 chapters, where these discoveries are described in more detail, I hope the reader will gain an impression of the rapidly expanding and advancing area of protein biochemistry. This area offers the potential to revolutionize treatment of human health and to eradicate diseases in all avenues of life. The next 50 years will see the complete description of

482 EPILOGUE

URL	Description
www.rcsb.org/pdb	The repository for the deposition of biomolecular
	structures mainly nucleic acids and proteins
www.hgmp.mrc.ac.uk	The human genome mapping project centre in the UK
www.nhgri.nih.gov	The human genome mapping research institute of the NIH
www.expasy.ch	The ExPASy (Expert Protein Analysis System)
	proteomics server of the Swiss Institute of
	Bioinformatics (SIB)
www.ebi.ac.uk	European Bioinformatics Institute containing access to
	databases and software for studying proteins
www.ncbi.nlm.nih.gov	A national resource for molecular biology information in
	USA
www.srs.ebi.ac.uk	Sequence retrieval system for a wide variety of databases
rebase.neb.com/rebase/rebase.html	Restriction enzyme database
bimas.dcrt.nih.gov/sql/BMRBgate.html	Biomolecular Nuclear Magnetic Resonance databank
tolweb.org/tree/phylogeny.html	Tree of Life web page
www.ncbi.nlm.nih.gov/Omim	On line Mendelian Inheritance in Man
www.biochem.ucl.ac.uk/bsm/biocomp/index.html	A collection biocomputing resources at University
	College London
www.ensembl.org	A database annotating sequenced genomes
www.embl-heidelberg.de/predictprotein/predictprotein.html	Protein prediction server for secondary structure
www-nbrf.georgetown.edu/pirwww/pirhome3	Protein Information resource centre
archive.uwcm.ac.uk/uwcm/mg/hgmd0.html/	Human gene mutation database
gdbwww.gdb.org/	Another genome database
www.ornl.gov/hgmis	US Human Genome Project Information

See home page of this book for latest web-based or on-line resources.

other proteomes and promises the possibility of equally devastating discoveries to match those of the previous 50 years.

The following universal resource locators (URL) represent web addresses of sites that offer very useful information of relevance to the subject of this book.

The author is not responsible for their content and due to the transitory nature of the web these sites may not always be accessible, maintained or presenting the latest information. However, all (as of April 2004) had potentially useful information that provides an ideal learning resource.

## **Glossary**

 $\alpha$  helix regular unit of secondary structure shown by polypeptide chains characterised by 3.6 residues per turn in a right-handed helix with a pitch of 0.54 nm.

 $\beta$  sheet collection of  $\beta$  strands assembled into planar sheet like structure held together by hydrogen bonds.

 $3d_{10}$  helix a form of secondary structure containing three residues per turn and hydrogen bonds separated by 10 backbone atoms.

*Ab initio* from the beginning (*Latin*).

**Acid-base catalysis** reactions in which the transfer of a proton catalyses the overall process.

**Acidic solution** a solution whose pH is less than pH 7.0.

**Active site** part of an enzyme in which the amino acid residues form a specific three-dimensional structure containing the substrate binding site.

**ADP** adenosine diphosphate.

**Affinity chromatography.** separation of proteins on the basis of the specific affinity of one protein for an immobilized ligand covalently attached to an inert matrix.

**AIDS** disease ultimately resulting from infection with HIV, sometimes called advanced HIV disease.

**Allosteric effectors** molecules which promote allosteric transitions in a protein.

**Allostery** with respect to proteins, a phenomenon where the activity of an enzyme's active site is influenced by binding of an effector to a different part of the enzyme.

**Alzheimer's** a disease characterized by formation of protein deposits with the brain and classified as a neurodegenerative disorder.

**Amino acid** an organic acid containing an amino group, carboxyl group, side chain and hydrogen on a central  $\alpha$  carbon. The building blocks of proteins.

**Amphipathic** for a molecule, the property of having both hydrophobic and hydrophilic portions. Usually one end or side of the molecule is hydrophilic and the other end or side is hydrophobic.

**Ampholyte** a substance containing both acidic and basic groups.

**Amyloid** accumulation of protein into an insoluble aggregate often a fibre in tissue such as the brain.

**Anabolism** process of synthesis from small simple molecules to large often polymeric states.

**Antigen** a substance that can elicit a specific immune response.

**Anaerobe** organism capable of living in the absence of oxygen.

**Antibody** protein component of immune system produced in response to foreign substance and consisting of two heavy and two light chains.

**Anticodon** sequence of three nucleotide bases found in tRNA that recognizes codon via complementary base pairing interactions.

**Antigenic determinant** a specific part of an antigen that elicits antibody production.

**Antiparallel** running in opposite directions as in DNA strands or  $\beta$  sheets.

**Apoprotein** protein lacking co-factor or coenzyme. Apoprotein often show decreased or negligible activity.

Apoptosis programmed cell death.

**Archae** one of the two major groupings within the prokaryotes, also called archaebacteria.

**Asymmetric centre** a centre of chirality. A carbon atom that has four different substituents attached to it.

ATP adenosine triphosphate.

**ATPase** an enzyme hydrolysing ATP to ADP and Pi.

**Association constant/Affinity constant** given by 'K', in the oxygen binding reaction of myoglobin, K is calculated as the concentration of myoglobin bound to oxygen divided by the product of the free oxygen concentration and the free myoglobin concentration.

**B cells** lymphatic cells produced by B lymphocytes.

**Backbone** part of the polypeptide chain consisting of  $N-C_{\alpha}-C$  portion (distinct from side chain)

**Bacteriophage** virus that specifically infects a bacterium.

**Basic solution** a solution whose pH is greater than pH 7.0.

**BSE** bovine spongiform encephalopathy, a prion-based disease first seen in cattle in the UK.

**bp** base pair, often used to describe length of DNA molecule.

**Buffer** a mixture of an acid and its conjugate base at a pH near to their pK. Buffer solution composed of an acid and conjugate base resist changes in pH.

**Cahn-Ingold-Prelog** system of unambiguous nomenclature of molecules with one or more asymmetric centres via a priority ranking of substituents. Also known as RS system.

**Cap** a 7-methyl guanosine residue attached to the 5' end of eukaryotic mRNA.

Capsid protein coat or covering of nucleic acid in viral particles.

Catabolism metabolic reactions in which larger molecules are broken down to smaller units. Proteins are broken down into amino acids.

**cDNA** complementary DNA derived from reverse transcription of mRNA.

**Chaotrope** a substance that increases the disorder (chaos). Frequently used to describe agents that cause proteins to denature. An example is urea.

**Chaperonins** proteins which assist in the assembly of protein structure. They include heat-shock proteins and GroEL/ES of *E. coli*.

**Charge-charge interactions** interactions between positively and negatively charged side chain groups.

**Chiral** possessing an asymmetric center due to different substituent groups and exist in two different configurations.

**Chloroplasts** plant organelles performing photosynthesis.

**Clathrate structures** hydrophobic molecules that dissolve in aqueous solutions form regular icelike structures called clathrate structures rather than the hydration shells formed by hydrophilic molecules.

**Cloning** process of generating an exact copy.

**Coding strand** analogous to sense strand.

**Co-factor** a small organic molecule or sometimes a metal ion necessary for the catalytic activity of enzymes.

**Coiled coil** arrangement of polypeptide chains where two helices are wound around each other.

**Configuration** arrangement of atoms that cannot be altered without breaking and reforming bonds.

**Conformational entropy** a protein folding process, which involves going from a multitude of random-coil conformations to a single, folded structure. It involves a decrease in randomness and thus a decrease in entropy.

**Codon** sequence of three nucleotide bases found in mRNA that determines a single amino acid.

**Conformation** proteins and other molecules occur in different spatial arrangements because of rotation about single bonds that leads to a variety of different, close related states.

Conservative amino acid changes Mutations in coding sequences for proteins which convert a codon for one amino acid to a codon for another amino acid with very similar chemical properties.

**Cooperative transition** a transition in a multipart structure such that the occurrence of the transition in one part of the structure makes the transition likelier to happen in other parts.

**Covalent bonds** the chemical bonds between atoms in an organic molecule that hold it together are referred to as covalent bonds.

**Cristae** invaginations of inner mitochondrial membrane involved in oxidative phosphorylation.

**Cryo-EM** cryoelectron microscopy a technique for the visualization of macromolecules achieved by rapid freezing of a suspension of the biomolecule without the formation of ice.

**Cystine** the amino acid cysteine can form disulfide bonds and the resulting structure is sometimes called a cystine, particularly in older textbooks.

**Denaturation** loss of tertiary and secondary structure of a protein leading to a less ordered state that is frequently inactive.

**Da** Dalton or a unit of atomic mass equivalent to 1/12th the mass of the <sup>12</sup>C atom.

**Debye–Huckel radius** a quantitative expression of the screening effect of counterions on spherical macro ions.

**Dihedral angle** an angle defined by the bonds between four successive atoms. The backbone dihedral angle  $\phi$  is defined by C'-N-C<sub>a</sub>-C'.

**Dimer** assembly consisting of two subunits.

**Dipeptide** a molecule containing two amino acids joined by a single peptide bond.

**Dipolar ion** term synonymous with zwitterions.

**Dipole Moment** molecules which have an asymmetric distribution of charge are dipoles. The magnitude of the asymmetry is called the dipole moment of the molecule.

**Disulfide bond** a covalent bond between two sulfur atoms formed from the side chains of cysteine residues, for example.

**DNA** deoxyribose nucleic acid – the genetic material of almost all systems.

**Domain** a compact, locally folded region of tertiary structure in a protein.

**Elution** removal of a molecule from chromatographic matrix.

**Edman degradation** procedure for systematically sequencing proteins by stepwise removal and identification of N terminal amino acid residue.

**EF** elongation factor, one of several proteins involved in protein synthesis enhancing ribosomal activity.

**Enantiomers** also called optical isomers or stereoisomers. The term optical isomers arises from the fact that enantiomers of a compound rotate polarized light in opposite directions.

**Endergonic reaction** process that has a positive overall free energy process ( $\Delta G > 0$ ).

Enzymes catalytic proteins.

**Electrophile** literally electron-lover and characterized by atoms with unfilled electron shells.

**Eubacteria** one of the two major groupings within the prokaryotes.

**Eukaryote** a cell containing a nucleus that retains the genetic material in the form of chromosomes. Often multicellular and with cells showing compartmentation.

**Exons** a region in the coding sequence of a gene that is translated into protein (as opposed to introns, which are not). The name comes from the fact that exons are the only parts of an RNA transcript that are seen outside the nucleus of eukaryotic cells.

Fc fragment a proteolytic fragment of an antibody molecule

**Fibrous proteins** a class of proteins distinguished by a filamentous or elongated three dimensional structure such as collagen.

**First order** a reaction whose rate is directly proportional to the concentration (activity) of a single reactant.

FT Fourier transform.

FT-IR Fourier transform infrared spectroscopy.

g estimate of centrifugal force so that 5000 g is 5000 times the force of gravity.

**G protein** a protein that binds guanine nucleotides such as GTP/GDP.

**Gel filtration chromatography** also called size exclusion chromatography. Separates biomolecules such as proteins through the use of closely defined pore sizes within an innert matrix according to the molecular mass.

**Globular proteins** proteins containing polypeptide chains folded into compact structures that are not extended or filamentous and have little free space on the inside.

**Heme** prosthetic oxygen binding site of globin (and other) proteins. Is a complex of protoporphyrin IX and Fe (II). Carries oxygen in globin proteins

**Henderson–Hasselbach equation** describes the dissociation of weak acids and bases according to the equation  $pH = pK_a + \log ([A-]/[HA])$ .

**Heterodimer** a complex of two polypeptide chains in which the two units are non-identical.

**HIV** human immunodeficiency virus; retrovirus responsible for AIDS.

**HLH** helix-loop-helix motif found in several eukaryotic DNA binding proteins.

**Hormone** molecule often but not exclusively protein that is secreted into blood stream and carried systemically where it elicits a physiological response in another tissue.

**Hydrolysis** cleavage of covalent chemical bond involving water.

**Homeobox** a DNA binding motif that is widely found in eukaryotic genomes where it encodes a transcription factor whose activity modulates the development, identity and fate of embryonic cell lines.

**Homodimer** a complex of two units in which both units are identical.

**Hsp** heat-shock protein – name given to a large group of molecular chaperone proteins.

HTH helix-turn-helix motif found in several DNA binding proteins in which the two helices cross at an angle of  $\sim 120^{\circ}$ .

**Huntingtin** the mutant protein contributing to Huntington's disease.

**Hydrogen bond** an attractive interaction between the hydrogen atom of a donor group, such as OH or =NH, and a pair of nonbonding electrons on an acceptor group, such as O=C. The donor group atom that carries the hydrogen must be fairly electronegative for the attraction to be significant.

**Hydrophilic** refers to the ability of an atom or a molecule to engage in attractive interactions with water molecules. Substances that are ionic or can engage in hydrogen bonding are hydrophilic. Hydrophilic substances are either soluble in water or, at least, wettable.

**Hydrophobic** the molecular property of being unable to engage in attractive interactions with water molecules. Hydrophobic substances are nonionic and nonpolar; they are nonwettable and do not readily dissolve in water.

**Hydrophobic effect** stabilization of protein structure resulting from association of hydrophobic groups with each other, away from water.

**IF** initiation factor involved in start of protein synthesis and ribosomal assembly and activation.

**Ig** immunoglobulin and another name for an antibody group such as IgG.

**Importins** generic group of proteins with homology to importin  $\alpha$  and  $\beta$  that function as heterodimer binding NLS-proteins prior to import into nucleus.

*In vitro* normally means in the laboratory, but literally in glass.

In vivo in a living organism.

**Integral protein** a membrane bound protein that can only be removed from the lipid bilayer by extreme treatment. Also called intrinsic protein.

**Intron(s)** a region in the coding sequence of a gene that is not translated into protein. Introns are common in eukaryotic genes but are rarely found in prokaryotes. They are excised from the RNA transcript before translation.

**Ionic strength** an expression of the concentration of all ions. In the Debye-Huckel theory  $I = 1/2 \Sigma m_i z_i^2$ 

**Isoelectric focusing** a technique for separating ampholytes and polyampholytes based on their pI. Also used to determine pI.

**Isoelectric point** the pH at which an ampholyte or polyampholyte has a net charge of zero. Same as pI.

**Isoenzymes** also called isozymes. Represent different proteins from the same species that catalyse identical reactions.

**kDa** kilodaltons; equivalent to 1000 daltons or approximately 1000 times the mass of a hydrogen atom.

**Keratins** major fibrous proteins of hair and fingernails. They also compose a major fraction of animal skin.

**Kinases** enzymes that phosphorylate or transfer phosphorus groups to substrates including other proteins (e.g. protein kinases)

 $\textit{K}_{m}$  the Michaelis constant. It is the concentration of substrate at which the enzyme-catalysed reaction proceeds with half maximal velocity

**Leader sequence** a short N-terminal hydrophobic sequence that causes the protein to be translocated into or through a membrane often called a signal sequence.

**Mesophile** an organism living at normal temperatures in comparison with a thermophile.

**Module** a sequence motif of between 40-120 residues that occurs in unrelated proteins or as multiple units within proteins.

Molten globule state intermediate structures of a protein in which the overall tertiary framework of the protein is established, but the internal side chains are still free to move about.

Mutation a change in the sequence of DNA.

**NES** nuclear export signal – a signal consisting of several leucine residues found in proteins and indicating export.

NLS nuclear localization signal – a short stretch of basic amino acid residues that targets proteins for import into the

nucleus. The sequence can have bipartite structure consisting of two short sequences of basic residues separated by #10 intervening residues.

**NMR spectroscopy** acronym for nuclear magnetic resonance spectroscopy, a technique useful in the elucidation of the three-dimensional structure of soluble proteins.

**Non-covalent interactions** attractive or repulsive forces, such as hydrogen bonds or charge-charge interactions, which are non-covalent in nature, are called non-covalent interactions.

**NPC** nuclear pore complex – a very large assembly of protein concerned with regulating flux of macromolecules between nucleus and cytoplasm.

**Nucleophile** atom or group that contains an unshared pair(s) of electrons and is attracted to electrophilic (electron deficient) groups.

Nucleoporins proteins found in the nuclear pore complex.

**Oncogene** a gene which in a mutated form gives rise to abnormal cell growth or differentiation.

**Oncoprotein** the product of an oncogene that fails to perform its normal physiological role.

**Operator** element of DNA at the transcriptional site that binds repressor.

**Operon** a genetic unit found in prokaryotes that is transcribed as a single mRNA molecule and consisting of several genes of related function.

**Oxidative phosphorylation** process occurring in mitochondria and bacteria involving oxidation of substrates and the generation of ATP.

Oxidoreductase catalyse redox reactions.

**PAGE** polyacrylamide gel electrophoresis – a technique for the electrophoretic separation of proteins through polyacrylamide gels.

**PCR** polymerase chain reaction – a method involving the use of thermostable DNA polymerases to amplify in a cyclic series of primer driven reactions specific DNA sequences from DNA templates.

**PDI** protein disulfide isomerase – an enzyme catalysing disulfide bond formation or re-arrangement.

**Peptide** molecules containing peptide bonds are referred to generically as peptides usually less than 40 residues in length.

Peptidase an enzyme that hydrolyses peptide bonds.

**Peptide bond** the bond that links successive amino acids in a peptide; it consists of an amide bond between the carboxyl group of one amino acid and the amino group of the next.

**Peripheral protein** also called extrinsic protein and refers to protein weakly associated with membrane.

**pH** the negative logarithm of the hydrogen ion concentration in an aqueous solution.

**Phage** shortened version of bacteriophage.

**p***I* the isoelectric point or the pH at which an ampholyte or polyampholyte has a net charge of zero.

**Pitch** the spacing distance between individual adjacent coils of a helix.

pK a measure of the tendency of an acid to donate a proton; the negative logarithm of the dissociation constant for an acid. Also called  $pK_a$ 

**Polypeptide** a polypeptide is a chain of many amino acids linked by peptide bonds.

**Polyprotic acids** acids which are capable of donating more than one proton.

**Porphyrins** a class of compounds found in chlorophyll, the cytochrome proteins, blood, and some natural pigments. They are responsible for the red color of blood and the green color of plants.

**Prebiotic era** the time span between the origin of the earth and the first appearance of living organism ( $\sim 4.6 \times 10^9 - 3.6 \times 10^9$  years ago)

**Preinitiation complex** the multiprotein complex of transcription factors bound to DNA that facilitates transcription by RNA polymerase.

**Preproprotein** a protein contain a prosequence in addition to the signal sequence.

**Preprotein** a protein containing a signal sequence that is cleaved to yield the active form.

**Pribnow box** prokaryotic promoter region located 10 bases upstream of the transcription start site with a consensus sequence TATAAT.

**Primary structure** for a nucleic acid or a protein, the sequence of the bases or amino acids in the polynucleotide or polypeptide.

**Protoporphyrin IX** a tetrapyrrole ring which chelates Fe(II) and other transition metals.

**Primary structure or sequence** the linear order or sequence of amino acids along a polypeptide chain in a protein.

**Prions** a class of proteins that causes serious disease without the involvement of DNA/RNA.

**Procollagen** a newly translated form of collagen in which hydroxylation and addition of sugar residues has occurred, but the triple helix has not formed.

**Prokaryote** a simple normally unicellular organism that lacks a nucleus. All bacteria are prokaryotes.

**Prosequence** region of a protein at the N terminal designed to keep the enzyme inactive. The pro sequence is removed in zymogen processing.

**Prosthetic group** a co-factor such as a metal ion or small molecule such as a heme group. It can be bound covalently or non-covalently to a protein and is usually essential for proper protein function.

**Protease** a generic group of enzymes that hydrolyse peptide bonds cleaving polypeptide chains into smaller fragments (the term proteinase is also used interchangeably). Often show a specificity for a particular amino acid sequence.

**Proteasome** assembly of proteins based on a core structure of four heptameric rings that functions to degrade proteins into small peptide fragments.

**Proteins** biomolecule composed of one or more polypeptide chains containing amino acid residues linked together via peptide bonds.

**Proto-oncogene** the normal cellular form of an oncogene with the potential to be mutated. Mutation of the gene yields an oncogene and may lead to cancer.

**PrP** the protein believed to be responsible for transmitting the disease of prions. The protein is encoded by the host's genome and exists in two forms, only one of which causes the disease.

**Purine** planar, heterocyclic aromatic rings with adenine and guanine being two important bases found in cells.

Quantum a packet of energy

**Quaternary structure** the level of structure that results between separate, folded polypeptide chains (subunits) to produce the mature or active protein.

**R group** one of the 20 side chains found attached to the backbone of amino acids.

**R** state the relaxed state describing the activity of an allosteric enzyme or protein.

Ramachandran plot usually shown as a plot of dihedral angle  $\phi$  against  $\psi$ .

**Random coil** refers to a linear polymer that has no secondary or tertiary structure but instead is wholly flexible with a randomly varying geometry. This is the state of a denatured protein or nucleic acid.

**Redox** reduction—oxidation reactions.

**Renaturation** refolding of a denatured protein to assume its active or native state.

**RER** rough endoplasmic reticulum – characterized by ribosomes attached to this membrane involved in cotranslational targeting.

**Residue** a name for a monomeric unit with a polymer such as an amino acid within a protein.

**Reverse turn** a short sequence of 3-5 residues that leads to a polypeptide chain altering direction and characterised by occurrence of certain amino acid residues with distinct dihedral angles. Also called a  $\beta$  bend.

**Ribozyme** a enzyme based on RNA capable of catalysing a chemical reaction.

S Svedburg unit of sedimentation with the units of  $10^{-13}$  s. An example is the 30S ribosome particle. It is an estimate of how rapidly a protein or protein complex sediments during ultracentrifugation.

**Salting in** the effect of moderate amounts of ions, which increases the solubility of proteins in solution.

**Salting out** the effect of an extreme excess of ions which makes proteins precipitate from solution.

**Scurvy** a condition that occurs with vitamin C deficiency and reflects deficiency in connective tissue and collagen cross linking.

**Secondary structure** the spatial relationship of amino acid residues in a polypeptide chain that are close together in the primary sequence.

Serpin serine protease inhibitor.

**Sheet** a fundamental protein secondary structure (ribbonlike) discovered by Linus Pauling. It contains two amino acid residues per turn and forms hydrogen bonds with residues on adjacent chains.

**Site-directed mutagenesis** technique for altering the sequence of a DNA molecule. If the alteration occurs in a region coding for protein, the amino acid sequence of the protein may be altered as a consequence.

**Snurps** proteins found in spliceosomes with small nuclear RNAs.

**SRP** signal recognition particle. A ribonucleoprotein complex involved in cotranslational targeting of nascent polypeptide chains to membranes.

**Stereoisomers** molecules containing a center of asymmetry that possess same chemical formula but exist with different configuration or arrangement of atoms.

**Substrate** a reactant in an enzyme catalysed reaction that binds to active site and is converted into product.

**T cells** cells of the immune system derived from the thymus and concerned with fighting pathogens based on two types killer: T cells and helper T cells.

**TATA box** A/T rich region of genes that is involved in the binding of RNA polymerase to eukaryotic DNA sequences.

**Tertiary structure** large-scale folding structure in a linear polymer that is at a higher order than secondary structure. For proteins and RNA molecules, the tertiary structure is the specific three-dimensional shape into which the entire chain is folded.

**Thermophile** bacteria capable of living at high temperatures sometimes in excess of 90 °C.

**Thermosome** name given to the proteasome in thermophiles such as *T. acidophilum*.

Tic analogous system to Tim found in chloroplast inner membrane

**Tim** translocation inner membrane – a collection of proteins forming a protein import pathway in the inner mitochondrial membrane.

TMV tobacco mosaic virus.

Toc analogous system to Tom found in chloroplast outer membrane

**Tom** translocation outer membrane – a collection of proteins forming a protein import pathway in the outer mitochondrial membrane.

**Torsion angle** also known as dihedral angle.

**Transcription** the process of RNA synthesis from a DNA template performed by RNA polymerase and associated proteins known as transcription factors.

**Transition state** all reactions proceed through a transition state that represents the point of maximum free energy in a reaction coordinate linking reactants and products.

**Transition state analogue** a stable molecule that resembles closely the transition state complex formed at the active site of enzymes during catalysis.

**Translation** the process of converting the genetic code as specified by the nucleotide base sequence of mRNA into a corresponding sequence of amino acids within a polypeptide chain.

**Transmembrane** a protein or helix that completely spans the membrane.

**Tropocollagen** basic unit of collagen fibre. It is a triple helix of three polypeptide chains, each about 1000 residues in length.

**TSE** transmissible spongiform encephalopathy – any agent causing spongiform appearance in brain.

UV region of the electromagnetic spectrum extending from  $\sim 200$  to  $\sim 400$  nm

van der Waals interactions weak interactions between uncharged molecular groups that help stabilize a protein's structure.

**Variable domain** a part of an immunoglobulin that varies in amino acid sequence and tertiary structure from one antibody to another.

**vCJD** new variant CJD that arose from BSE and is a transmissible spongiform encephalopathy.

 $V_{\text{max}}$  the maximal velocity in an enzyme-catalysed reaction.

 $\boldsymbol{v_0}$  the initial velocity associated with an enzyme-catalysed reaction

**Zwitterion** a molecule containing both positively and negatively charged groups but has no overall charge. Amino acids are zwitterionic at  $\sim$ pH 7.0.

**Zymogen** an inactive precursor (proenzyme) of a proteolytic enzyme.

## **Appendices**

# Appendix 1 The International System (SI) of units related to protein structure

Physical quantity	SI unit	Symbol
Length	Metre	m
Time	Second	S
Temperature	Kelvin	K
Electric potential	Volt	V
Energy	Joule	J
Mass	Kilogram	Kg

## Appendix 2 Prefixes associated with SI units

Prefix	Power of 10 (e.g. $10^n$ )
Tera	12
Giga	9
Mega	6
Kilo	3
Milli	-3
Micro	-6
Nano	<b>-9</b>
Pico	-12
Femto	-15
Atto	-18

Frequently when discussing protein structure bond lengths will be expressed in nanometres (nm). For example, the average distance between two carbon atoms in an aliphatic side chain is  $\sim$ 0.14 nm or  $0.14 \times 10^{-9}$  m. Occasionally a second (non SI) unit is used and is named after the Swedish physicist, Anders J Ångström. It is called the Ångström (Å) and is equivalent to 0.1 nm or  $10^{-10}$  m. Both units are widely and interchangeably used in protein biochemistry and in this textbook.

## Appendix 3 Table of important physical constants used in biochemistry

Planck constant	h	$6.6260755 \times 10^{-34} \text{ J s}$
	$h/2\pi$	$1.05457266 \times 10^{-34} \text{ J s}$
Boltzmann constant	k	$1.380658 \times 10^{-23} \text{ J K}^{-1}$
Elementary charge	e	$1.60217733 \times 10^{-19}$ C
Avogadro number	N	$6.0221367 \times 10^{23}$
		particles/mol
Speed of light	c	$2.99792458 \times 10^{8} \text{ ms}^{-1}$
<sup>1</sup> H gyromagnetic ratio		$2.67515255 \times 10^{8} \text{ T s}^{-1}$
Atomic mass unit	amu	$1.66057 \times 10^{-27} \text{ kg}$
Gas constant	R	$8.31451~\mathrm{J}\mathrm{mol}^{-1}~\mathrm{K}^{-1}$
Faraday constant	F	$96485.3 \text{ C}  \text{mol}^{-1}$

492 APPENDICES

# Appendix 4 Derivation of the Henderson – Hasselbalch equation concerning the dissociation of weak acids and bases

The Henderson-Hasselbalch equation reflects the logarithmic transformation of the expression for the dissociation of a weak acid or base.

$$HA \leftrightarrow A^- + H^+$$
 $K = [H^+] [A^-]/[HA]$ 

Rearranging this equation leads to

$$[H^+] = K [HA]/[A^-]$$

and by taking negative logarithms this leads to

$$-\log [H^+] = -\log K - \log [HA]/[A^-]$$

Since  $pH = -\log [H^+]$  and we can define pK as  $-\log K$  this leads to the following equation

$$pH = pK - \log [HA]/[A^-]$$

that is related to the Henderson-Hasselbalch equation by a simple changing of signs

$$pH = pK + log [A^-]/[HA]$$

Expressed more generally and using the Bronsted Lowry definition of an acid as a proton donor and a base as a proton acceptor this equation can be re-written as

$$pH = pK + log [proton acceptor]/[proton donor]$$

The Henderson-Hasselbalch equation is fundamental to the application of acid-base equilibria in proteins or any other biological system. It is used to calculate the pH formed by mixing known concentrations of

proton acceptor and donor whose  $pK_a$ 's are known. Alternatively this equation can be used to calculate the molar ratio of donor and acceptor given the pH and pK, or to calculate the pK at a particular pH given the concentrations relative or absolute of proton donor and acceptor.

## Appendix 5 Easily accessible molecular graphic software

- Koradi, R., Billeter, M., and Wüthrich, K. (MOLMOL: a superlative program for display and analysis of macromolecular structures. (obtainable from http://www.mol.biol.ethz.ch/groups/Wuthrichgroups/software/) *J. Mol. Graphics* 1996, 14, 51–55.
- Roger Sayle developed Rasmol although no formal citation exists. Rasmol is a very suitable introduction to molecular visualization software. An adaptation of Rasmol for use in web browsers called Chime is available from http://www.mdli.com or http://www.mdli.co.uk.
- Kraulis, P.J. MOLSCRIPT: A Program to produce both Detailed and Schematic Plots of Protein Structures. J. Appl. Crystallogr. 1991, 24, 946–950.
- Molecular graphic software such as VMD produced by the Theoretical Biophysics group, an NIH
  Resource for Macromolecular Modeling and Bioinformatics, at the Beckman Institute, University of
  Illinois at Urbana-Champaign.
- Guex, N. and Peitsch, M.C. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling *Electrophoresis* 1997, 18, 2714–2723. Official site for software http://www. expasy.ch/spdbv.

A wide range of commercial software has also been produced.

APPENDICES 493

#### Appendix 6 Enzyme nomenclature

Enzyme classes and subclasses

E	C	1	Oxi	doı	educ	ctases

- EC 1.1 Acting on the CH-OH group of donors
- EC 1.2 Acting on the aldehyde or oxo group of donors
- EC 1.3 Acting on the CH-CH group of donors
- EC 1.4 Acting on the CH-NH<sub>2</sub> group of donors
- EC 1.5 Acting on the CH-NH group of donors
- EC 1.6 Acting on NADH or NADPH
- EC 1.7 Acting on other nitrogenous compounds as donors
- EC 1.8 Acting on a sulfur group of donors
- EC 1.9 Acting on a heme group of donors
- EC 1.10 Acting on diphenols and related substances as donors
- EC 1.11 Acting on a peroxide as acceptor
- EC 1.12 Acting on hydrogen as donor
- EC 1.13 Acting on single donors with incorporation of molecular oxygen (oxygenases)
- EC 1.14 Acting on paired donors, with incorporation or reduction of molecular oxygen
- EC 1.15 Acting on superoxide radicals as acceptor
- EC 1.16 Oxidising metal ions
- EC 1.17 Acting on CH<sub>2</sub> groups
- EC 1.18 Acting on reduced ferredoxin as donor
- EC 1.19 Acting on reduced flavodoxin as donor
- EC 1.97 Other oxidoreductases

#### **EC 2 Transferases**

- EC 2.1 Transferring one-carbon groups
- EC 2.2 Transferring aldehyde or ketonic groups
- EC 2.3 Acyltransferases
- EC 2.4 Glycosyltransferases
- EC 2.5 Transferring alkyl or aryl groups, other than methyl groups
- EC 2.6 Transferring nitrogenous groups
- EC 2.7 Transferring phosphorus-containing groups

- EC 2.8 Transferring sulfur-containing groups
- EC 2.9 Transferring selenium-containing groups

#### EC 3 Hydrolases

- EC 3.1 Acting on ester bonds
- EC 3.2 Glycosylases
- EC 3.3 Acting on ether bonds
- EC 3.4 Acting on peptide bonds (peptidases)
- EC 3.5 Acting on carbon-nitrogen bonds, other than peptide bonds
- EC 3.6 Acting on acid anhydrides
- EC 3.7 Acting on carbon-carbon bonds
- EC 3.8 Acting on halide bonds
- EC 3.9 Acting on phosphorus-nitrogen bonds
- EC 3.10 Acting on sulfur-nitrogen bonds
- EC 3.11 Acting on carbon-phosphorus bonds
- EC 3.12 Acting on sulfur-sulfur bonds

#### EC 4 Lyases

- EC 4.1 Carbon–carbon lyases
- EC 4.2 Carbon–oxygen lyases
- EC 4.3 Carbon-nitrogen lyases
- EC 4.4 Carbon-sulfur lyases
- EC 4.5 Carbon-halide lyases
- EC 4.6 Phosphorus—oxygen lyases
- EC 4.99 Other lyases

#### EC 5 Isomerases

- EC 5.1 Racemases and epimerases
- EC 5.2 *cis-trans*-isomerases
- EC 5.3 Intramolecular isomerases
- EC 5.4 Intramolecular transferases (mutases)
- EC 5.5 Intramolecular lyases
- EC 5.99 Other isomerases

#### EC 6 Ligases

- EC 6.1 Forming carbon-oxygen bonds
- EC 6.2 Forming carbon-sulfur bonds
- EC 6.3 Forming carbon–nitrogen bonds
- EC 6.4 Forming carbon-carbon bonds
- EC 6.5 Forming phosphoric ester bonds

## **Bibliography**

#### General reading

- Alberts B., Bray, D., Lewis, J., Raff, M., Roberts, K. & Watson J.D. *Molecular Biology of the Cell*, 3rd edn. Garland Publishing, New York, 1994.
- Barrett, G. C. Chemistry and Biochemistry of Amino Acids. Chapman & Hall, London, 1985.
- Branden, C. & Tooze, J. *Introduction to Protein Structure*. Garland Publishing, New York, 1991.
- Cornish-Bowden, A. Fundamentals of Enzyme Kinetics. Butterworths, Oxford, 1979.
- Creighton, T. E. Proteins Structures and Molecular Properties, 2nd edn. W.H. Freeman, London, 1993.
- Darnell, J., Lodish, H. & Baltimore, D. Molecular Cell Biology, 2nd edn. Scientific American Books, New York, 1990.
- Fersht, A. *Enzyme Structure and Mechanism*, 2nd edn. W.H. Freeman, New York, 1985.
- Frausto da Silva, J. J. R. & Williams, R. J. P. The Biological Chemistry of the Elements. Oxford University Press, Oxford, 1991.
- Gutfreund, H. *Enzymes: Physical Principles*. Wiley-Interscience, New York, 1972
- Lehninger, A., Nelson, D. L. & Cox, M. M. (eds) *Principles of Biochemistry*, 3rd edn. Worth Publishers, New York, 2000.
- Lippard, S. J. & Berg, J. M. Principles of Bioinorganic Chemistry. University Science Books, 1994.
- Voet, D. Voet, J. G. & Pratt, C. W. Fundamentals of Biochemistry. John Wiley & Sons, Chichester, 1999.
- Watson, J. D. et al. Molecular Biology of the Gene. Benjamin Cummings, New York, 1988.

#### Chapter 1

Ingram, V. A case of sickle-cell anemia. *Biochem. Biophys. Acta* 1989, **1000**, 147–150.

- Kendrew, J. The Thread of Life. G. Bell, 1966.
- Mirsky, A. E. The discovery of DNA. *Sci. Am.* 1968, **218**, 78–88.
- Olby, R. E. The Path to the Double Helix: the Discovery of DNA. Dover Publications, 1995.
- Rutherford, N. J. A Documentary History of Biochemistry 1770–1940. Fairleigh Dickinson University Press, 1992.
- Schrodinger, E. What is Life? Cambridge University Press, Cambridge, 1944.

#### Chapter 2

- Barrett, G.C. (ed) Chemistry and Biochemistry of amino acids. Chapman & Hall, New York, 1985.
- Barrett, G.C. & Elmore, D.T. *Amino Acids and Peptides*. Cambridge University Press, 1998.
- Creighton, T.E. *Proteins: Structure and molecular properties*, 2nd edn. Chapters 1–7. W.H. Freeman, New York, 1993.
- Creighton, T.E. (ed) *Protein Function: A practical approach*. IRL Press, Oxford, 1989.
- Hirs, C.H.W. & Timasheff, S.N. (eds) Enzyme Structure part 1. *Methods Enzymology*, 91. Academic Press, 1983.
- Jones, J. Amino Acids and Peptide Synthesis (Oxford Chemistry Primers). Oxford University Press, 2002.
- Lamzin, V.S., Dauter, Z. & Wilson, K.S. How nature deals with stereoisomers. *Curr. Opin. Struct. Biol.* 1995, 5, 830–836.
- Means, G.E. & Feeney, R.E. Chemical Modification of Proteins. Holden-Day, 1973.

#### Chapter 3

Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N. & Bourne, P.E. The Protein Data Bank. *Nucl. Acids Res.* 2000, **28**, 235–242.

496 BIBLIOGRAPHY

- Davies, D.R., Padlan, E.A. & Sheriff, S. Antibody-antigen complexes. *Annu. Rev. Biochem.* 1990, 59, 439–473.
- Doolittle, R.F. Proteins. Sci.Am. 1985, 253, 88-96.
- Goodsell, D.S. & Olson, A.J. Soluble proteins: Size, shape and function. *Trends Biochem. Sci.* 1993, 18, 65–68.
- Kuby, J. Immunology. W.H. Freeman, London, 1997.
- Lesk, A.M. *Introduction to protein architecture*. Oxford University Press, 2001.
- Perutz, M.F. *Hemoglobin structure and respiratory transport*. *Sci. Am.* 1978, **239**, 92–125.
- Richardson, J.S. The anatomy and taxonomy of protein structure. *Adv. Prot. Chem.* 1981, **34**, 167–339.
- Trabi, M., & Craik, D.J. Circular proteins no end in sight. Trends Biochem. Sci. 2002, 27, 132–138.

#### Chapter 4

- Baum, J. & Brodsky, B., Folding of peptide models of collagen and misfolding in disease. *Curr. Opin. Struct. Biol.* 1999, 9, 122–128.
- Downing, A. K., Knott, V., Werner, J. M., Cardy, C. M., Campbell, I. D., & Handford, P. A. Solution structure of a pair of Ca<sup>2+</sup> binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders. *Cell* 1996, **85**, 597–605.
- Glover, J. N., Harrison, S. C. Crystal structure of the heterodimeric bZIP transcription factor *c-Fos c-Jun* bound to DNA. *Nature* 1995, 373, 257.
- Handford, P. A. Fibrillin-1, a calcium binding protein of extracellular matrix. *Biochim. Biophys. Acta* 2000, 1498, 84–90.
- Kaplan, D., Adams, W. W., Farmer, B. & Viney, C. Silk Polymers. American Chemical Society, 1994.
- Lupas, A. Coiled coils new structures and new functions. *Trends Biochem. Sci.* 1996. **21** 375–382.
- Martin, G. R. Timple, R., Muller, P. K. & Kuhn, K. The genetically distinct collagens. *Trends Biochem. Sci.* 1985, 10, 285–287.
- O'Shea, E. K. Rutkowski, R. & Kim, P. S. Evidence that the leucine zipper is a coiled coil. *Science* 1989, **243**, 538–542.
- Parry, D. A. D. The molecular and fibrillar structure of collagen and its relationship to the mechanical properties of connective tissue. *Biophys. Chem.* 1988, **29**, 195–209.
- Porter, R. M. & Lane E. B. Phenotypes, genotypes and their contribution to understanding keratin function. *Trends Genet*. 2003, 19, 278–285.
- Prockop, D. J. & Kivirikko, K. I. Collagens molecularbiology, diseases, and potentials for therapy. *Annu. Rev. Biochem.* 1995, 64, 403–434.

- Royce, P.M. & Steinmann, B. (eds) Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects. John Wiley & Sons, 2002.
- Van der Rest, M. & Bruckner, P. Collagens: Diversity at the molecular and supramolecular levels. *Curr. Opin. Struct. Biol.* 1993, **3**, 430–436.

#### Chapter 5

- Benz R. (ed) Bacterial and Eukaryotic Porins: Structure, Function, Mechanism. John Wiley & Sons, 2004.
- Blankenship, R.E. *Molecular Mechanism of Photosynthesis*. Blackwell Science, 2001.
- Capaldi, R.A & Aggeler, R. Mechanism of the  $F_1F_0$ -type ATP synthase, a biological rotary motor. Trends Biochem. Sci. 2002, **27**, 154–160.
- Gennis, R.B. Biomembranes. Springer Verlag, New York, 1989.
- Hamm, H.E. The many faces of G protein signaling. *J. Biol. Chem.* 1998, **273**, 669–672.
- Lehninger, A. *Principles of Biochemistry*. 3rd edn. (Nelson, D.L. and Cox, M.M., eds.) *Oxidative Phosphorylation and Photophosphorylation*, pp. 659–690. Worth Publishers
- Nicholls, D.G. & Ferguson, S.J. *Bioenergetics* 2, Academic Press, 1992.
- Scheffler, I.E. Mitochondria. John Wiley & Sons Inc, 1999.Vance, D.E. & Vance, J.E. Biochemistry of lipids, lipoproteins and membranes. 4th edn. Elsevier, 2002.
- Torres, J., Stevens, T.J. & Samso, M. Membrane proteins: the 'Wild West' of structural biology. Trends Biochem. Sci. 2003, 28, 137–144.
- Von Jagow, G., Schaegger, H., & Hunte, C. (eds) Membrane Protein Purification and Crystallization: A Practical Guide. Academic Press, 2003.

#### Chapter 6

- Baxevanis, A.D. & Ouellette, B.F.(eds) *Bioinformatics: A practical guide to the analysis of genes and proteins*. John Wiley & Sons Inc, 2004.
- Findlay, J.B.C. & Geisow, M.J. (eds) *Protein Sequencing*. A practical approach. IRL press 1989.
- Margulis, L & Sagan, C. What is Life. Simon & Schuster, New York, 1995.
- Miller, S.J. & Orgel, L.E. *The Origins of Life*. Prentice-Hall, New Jersey, 1975.
- Mount, D.W. Bioinformatics: Sequence and Genome Analysis. Cold Spring Harbor Laboratory Press, 2001.
- Orengo, C.A., Thornton, J.M & Jones, D.T. *Bioinformatics* (Advanced Texts Series). BIOS Scientific Publishers, 2002.

BIBLIOGRAPHY 497

- Primrose, S.B. Principles of Genome Analysis: A Guide to Mapping and Sequencing DNA from Different Organisms. Blackwell Science, 1998.
- Sanger, F. Sequences, sequences, sequences. Annu. Rev. Biochem. 1988, 57, 1–28.
- Volkenstein, M.V. *Physical Approaches to Biological Evolution*. Springer Verlag, Berlin, 1994.
- Webster, D.M. Protein Structure Prediction: Methods and Protocols. Humana Press, 2000.

#### Chapter 7

- Bairoch, A. The enzyme databank. *Nucl. Acids. Res.* 1994, **22**, 3626–3627.
- Fersht, A.R. Structure and Mechanism in Protein Science: Guide to Enzyme Catalysis and Protein Folding. W.H. Freeman and Company, New York, 1999.
- Gutfreund, H. Kinetics for the Life Sciences: Receptors, Transmitters and Catalysts. Cambridge University Press, Cambridge, 1995.
- Kovall, R.A. & Matthews, B.W. Type II restriction endonucleases: structural, functional and evolutionary relationships. Curr. Opin. Chem. Biol. 1999, 3, 578–583.
- Kraut, J. How do enzymes work? *Science* 1988, **242**, 533–540.
- Martins, L.M. & Earnshaw, W.C. Apoptosis: Alive and kicking in 1997. *Trends Cell Biol.* 1997, 7, 111–114.
- Moore, J.W. & Pearson, R.G. *Kinetics and Mechanism*. John Wiley & Sons, Chichester, 1981.
- Vaux, D.L. & Strasser, A. The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA 1996, 93, 2239–2244.
- Wold, F. & Moldave, K. Posttranslational modifications. Methods Enzymol. 106 and 107. Academic Press, 1985.

#### Chapter 8

- Dodson, G. & Wlodawer, A. Catalytic triads and their relatives. *Trends Biochem. Sci.* 1998, **23**, 347–352.
- Kornberg, A., & Baker. T.A. DNA Replication, 2d ed. W. H. Freeman, San Francisco, 1992.
- Murray A.W., & Hunt T, eds. *The Cell Cycle: An Introduction*. Oxford University Press. 1993.
- Norbury C, & Nurse P. Animal Cell Cycles and Their Control. *Annu. Rev. Biochem.* 1992, **61**, 441–470.
- Spirin, A.S. Ribosomes. Kluwer Academic, New York, 1999.Stein G. S, (ed.) The Molecular Basis of Cell Cycle and Growth Control. John Wiley & Sons Inc, New York, 1999.
- Stillman, B. (ed.) *The Ribosome*. Cold Spring Harbor Symp. **66**. Cold Spring Harbor Laboratory Press, 2001.

*Trends Biochem. Sci.* 1997, **22**, 371–410. Issue devoted to proteasome and proteolytic processes.

- Watson, J.D. The Double Helix: Personal Account of the Discovery of the Structure of DNA. Penguin 1999.
- Zwickl, P. & Wolfgang Baumeister, W. The Proteasome-Ubiquitin Protein Degradation Pathway. Springer Verlag, Berlin, 2002.

#### Chapter 9

- Brown, T.A. Gene Cloning and DNA Analysis: An Introduction. Blackwell, 4th edn, 2001.
- Deutscher, M.P., Colowick, S.P. & Simon, M.I. (eds). Guide to protein purification. *Methods Enzymol.* 182. Academic Press, London, 1990.
- Dunn, B.M. Speicher, D.W., Wingfield, P.T. & John E. Coligan, J.E. (eds) *Short Protocols in Protein Science*. John Wiley & Sons, 2003.
- Freifelder, D. Physical Biochemistry: Applications to Biochemistry and Molecular Biology. W.H.Freeman, 1982.
- Hames, B.D. & Rickwood. (eds) Gel Electrophoresis of Proteins, A practical approach, 2nd edn. IRL press, 1990.
- Jansen, J-C. & Ryden, L. (eds) Protein Purification: Principles, High Resolution Methods and Applications. John Wiley & Sons Inc, 1998.
- Meyer, V.R. Practical High-Performance Liquid Chromatography, 4th edn. John Wiley & Sons, 2004.
- Scopes, R. *Protein purification: Principles and Practice*. Springer-Verlag, Berlin, 1993.
- Tanford, C. *The hydrophobic effect; formation of micelles and biological membranes*, 2nd edn. John Wiley & Sons, Chichester, 1980.
- Voet, D., Voet, J.G. & Pratt, C.W. Fundamentals of Biochemistry, John Wiley & Sons, Ltd, Chichester, 1999.

#### Chapter 10

- Campbell, I.D. & Dwek, R. Biological Spectroscopy. Benjamin Cummings, New York, 1984.
- Cavanagh, J., Fairbrother, W.J., Palmer III, A.G. & Skelton, N.J. Protein NMR spectroscopy: Principles and Practice. Academic Press, 1996.
- Chang, R. *Chemistry*. 8th edn. McGraw-Hill Education, 2004.
- Drenth, J. Principles of Protein X-ray Crystallography. Springer-Verlag, New York, 1994
- Fasman, G.D. (ed) Circular Dichroism and the Conformational Analysis of Biomolecules. Plenum Publishers, 1996.Ferry, G. Dorothy Hodgkin: A life. Granta Books, 1999.

498 BIBLIOGRAPHY

Harrison, S.C. Whither structural biology? *Nat. Struct. Mol. Biol.* 2004, **11**, 12–15.

- Nat. Struct. Biol. 1997, **4**, 841–865 and Nat. Struct. Biol. 1998, **5**, 492–522. (Series of short NMR reviews)
- Rhodes, G. Crystallography made crystal clear. Academic Press 2nd edn, San Diego, 2000.
- Wider, G. & Wüthrich, K. NMR spectroscopy of large molecules and multimolecular assemblies in solution. *Curr. Op. Struct. Biol.* 1999, 9, 594–601.

#### Chapter 11

- Caughey, B. (ed) Prion Proteins. Adv. Protein Chem. 57.
  Academic Press, 2001
- Creighton, T.E. *Protein Folding*. W.H.Freeman, New York, 1992.
- Daggett, V. & Fersht, A.R. Is there a unifying mechanism for protein folding? *Trends Biochem. Sci.* 2003, 28, 18–25.
- Horwich, A.L. (ed) Protein folding in the cell. Adv. Protein Chem. 59. Academic Press, 2001.
- Dobson, C.M. Protein Misfolding, Evolution and Disease Trends Biochem. Sci. 1999, 24, 329–332.
- Ladbury, J.E & Chowdhry, B.Z. (eds) Biocalorimetry: Applications of Calorimetry in the Biological Sciences. John Wiley & Sons, Chichester, 1998.
- Matthews, B.W. Structural and genetic analysis of protein stability. *Annu. Rev. Biochem.* 1993, **62**, 139–160.
- Matthews, C.R. (eds) Protein Folding Mechanisms. *Adv. Protein Chem.* 2000, **53**.

Pain, R. (ed) *Mechanisms of Protein Folding* (Frontiers in Molecular Biology Series). Oxford University Press, 2000.
Saibil, H.R. & Ranson, N.A. The chaperonin folding machine. *Trends Biochem. Sci.* 2002, 27, 627–632.

#### Chapter 12

- Crystal, R. G. The α<sub>1</sub>-antitrypsin gene and its deficiency states. *Trends Genet.* 1989, **5**, 411–417.
- Culotta, E. & Koshland, D. E., Jr. p53 sweeps through cancer research. *Science* 1993, 262, 1958–1959.
- Fauci, A. S. HIV and AIDS: 20 years of science. *Nature Medicine* 2003, **9**, 839–843. (and subsequent articles)
- Lane, D. & Lain, S. Therapeutic exploitation of the p53 pathway. Trends Molec. Med. 2002, 8, S38-S42.
- Gouras, G.K. Current theories for the molecular and cellular pathogenesis of Alzheimer's disease. *Expert Rev. Mol. Med.* 2001. http://www.expertreviews.org/010 03167h.htm
- Perutz, M.F. Protein Structure: New Approaches to Disease and Therapy. W.H. Freeman, 1992.
- Rowland-Jones, S.L. AIDS pathogenesis: what have two decades of HIV research taught us? *Nature Rev. Immunol*. 2003, 3, 343–348.
- Prusiner, S. Prion diseases and the BSE crisis. *Science* 1997, **278**, 245–251.
- Varmus, H. Retroviruses. Science 1988, 240, 1427–1435.
- Wiley, D.C. & Skehel, J.J. The Structure and Function of the Haemagglutinin Membrane Glycoprotein of Influenza Virus. Annu. Rev. Biochem. 1987, 56, 365–394.

### References

- Abrahams, J. P., Leslie, A. G. W., Lutter, R. & Walker, J. E. Structure at 2.8 Å resolution of F1-ATPase from bovine heart mitochondria. *Nature* 1994, **370**, 621–628.
- Abramson, J., Svensson-Ek, M., Byrne, B. & Iwata, S. Structure of cytochrome *c* oxidase: a comparison of the bacterial and mitochondrial enzymes *Biochim*. *Biophys. Acta* 2001, **1544**, 1–9.
- Agarraberes, F. A., & Dice, J. F. Protein translocation across membranes. *Biochim. Biophys. Acta* 2001, **1513**, 1–24.
- Agarwal, M. L., Taylor, W. R., Chernov, M. V., Chernova, O. B. & Stark, G. R. The p53 network. *J. Biol. Chem.* 1998, **273**, 1–4.
- Aguzzi, A., Glatzel, M., Montrasio, F., Prinz, M. & Heppner, F. L. Interventional strategies against prion diseases. *Nature Rev. Neurosciences* 2001, **2**, 745–749.
- Aguzzi, A., Montrasio, F., & Kaeser, P. S. Prions: Health scare and biological challenge. *Nature Reviews Molecular Cell Biology* 2002, **2**, 118–126.
- Albright, R. A., & Matthews, B. W. How Cro and λ repressor Distinguish Between Operators: The Structural Basis Underlying a Genetic Switch. *Proc. Natl. Acad. Sci USA* 1996, **95**, 3431–3436.
- Allen, T. D., Cronshaw, J. M., Bagley, S. Kiseleva, E. & Goldberg, M. W. The nuclear pore complex: mediator of translocation between nucleus and cytoplasm. *J. Cell Sci.* 2000, **113**, 1651–1659.
- Als-Nielsen, J. & McMorrow, D. *Elements of Modern X-ray Physics*. John Wiley & Sons, Chichester, 2001.
- Altman, S. & Kirsebom, L. Ribonuclease P. in Gesteland, R. F., Cech, T. R. and Atkins, J. F. (eds), *The RNA World*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1999.
- Altschul, S. F. Amino acid substitution matrices from an information theoretic perspective. *J. Mol. Biol.* 1991, **219**, 555–665.

- Amit, A. G., Mariuzza, R. A., Phillips, S. E. V. & Poljak, R. J. Three dimensional structure of an antigenantibody complex at 2.8Å resolution. *Science* 1986, 233, 747–750.
- Andrade, C., A peculiar form of peripheral neuropathy: familial atypical generalised amyloidosis with special involvement of peripheral nerves. *Brain* 1952, **75**, 408–427.
- Andrews, D. W. & Johnson, A. E. The translocon: more than a hole in the ER membrane? *Trends Biochem. Sci.* 1996, **21**, 365–369.
- Anfinsen, C. B. Principles that govern the folding of protein chains. *Science* 1973, **181**, 223–230.
- Arakawa, T & Timasheff, S. N. Theory of protein solubility. *Methods Enzymol.* 1985, **114**, 49–77, Academic Press.
- Babcock, G. & Wikström, M. Oxygen activation and the conservation of energy in cellular respiration. *Nature* 1992, **356**, 301–309.
- Baldwin, R. L. & Rose. G. D, Is protein folding Hierarchic?
  I. Local structure and peptide folding. *Trends Biochem. Sci.*1999 24, 26–33 II. Folding Intermediates and transition states. *Trends Biochem. Sci.* 1999 24, 77–83.
- Baltimore. D. Our genome unveiled. *Nature* 2001, **409**, 814–816.
- Ban, N. Nissen, P., Hansen, J., Moore, P. B. & Steitz, T. A. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. *Science* 2000, **289**, 905–920.
- Barber, M & Quinn, G. B. High-Level Expression in *Escherichia coli* of the Soluble, Catalytic Domain of Rat Hepatic Cytochrome *b*<sub>5</sub> Reductase. *Protein expression and purification* 1996, **8**, 41–47.
- Bardwell, J. C. A. & Beckwith, J. The bonds that tie: catalyzed disulfide bond formation *Cell* 1993, **74**, 769–771.
- Batey, R. T., Sagar M. B., & Doudna J. A. Structural and energetic analysis of RNA recognition by a universally

conserved protein from the signal recognition particle. *J. Mol. Biol.* 2001, **307**, 229–246.

- Baum, J. & Brodsky, B. Folding of peptide models of collagen and misfolding in disease. *Curr. Opin. Struct. Biol.* 1999, **9**, 122–128.
- Baumeister, W. & Steven, A. C. Macromolecular electron microscopy in the era of structural genomics. *Trends Biochem. Sci.* 2000, 25, 625–631.
- Bax, A. Multi-dimensional nuclear magnetic resonance methods for protein studies. *Curr. Opin. Struct. Biol.* 1994, **4**, 738–744.
- Bergfors, T. Protein Crystallization Techniques, Strategies, and Tips. A Laboratory Manual 1999.
- Berry, E. A., Guergova-Kuras, M., Huang, L. -S. & Antony R. Crofts, A. R. Structure and function of cytochrome bc complexes *Annu. Rev. Biochem.* 2000, **69**, 1005–1075.
- Billeter, M., Kline, A. D., Braun, W., Huber, R., & Wüthrich, K. Comparison of the High-Resolution Structures of the α-Amylase Inhibitor Tendamistat Determined by Nuclear Magnetic Resonance in Solution and by X-ray Diffraction in Single Crystals. *J. Mol. Biol.* 1989, **206**, 677–687.
- Blobel, G. & Dobberstein, B. Transfer of proteins across membranes. I. Presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane-bound ribosomes of murine myeloma, *J. Cell Biol.* 1975, **67**, 835–851.
- Bockaert, J., & Pin, J. P. Molecular tinkering of G proteincoupled receptors: an evolutionary success. *EMBO J.* 1999, 18, 1723–1729.
- Bokman S. H., Ward W. W. Renaturation of *Aequorea* green fluorescent protein. *Biochem. Biophys. Res. Commun.* 1981, **101**, 1372–1380.
- Bolton, W. & Perutz. M. F. Three dimensional Fourier synthesis of horse deoxyhaemo-globin at 2.8 Å resolution. *Nature* 1970, **228**, 551–552.
- Booth, P., Templer, R. H., Curran, A. R. & Allen, S. J. Can we identify the forces that drive the folding of integral membrane proteins? *Biochem Soc. Trans.* 2001, **29**, 408–413.
- Boriack-Sjodin, P. A., Zeitlin, S., Chen, H. -H., Crenshaw, L., Gross, S., Dantanarayana, A., Delgado, P., May, J. A., Dean, T. & Christianson, D. W. Structural analysis of inhibitor binding to human carbonic anhydrase II. *Protein Science* 1998, 7, 2483–2489.
- Bowie, J. U., Clarke, N. D., Pabo, C. O. & Sauer, R. T. Deciphering the message in protein sequence: tolerance to amino acid substitutions. *Science* 1990, **247**, 1306–1310.

- Boyer, P. D. The binding change mechanism for ATP synthase Some probabilities and possibilities. *Biochim. Biophys. Acta* 1993, **1140**, 215–250.
- Boyer, P. D., The ATP synthase a splendid molecular machine, *Annu. Rev. Biochem.* 1997, **66**, 717–749.
- Braig, K., Menz R. I., Montgomery M. G., Leslie A. G., & Walker J. E. Structure of bovine mitochondrial F<sub>1</sub>-ATPase inhibited by Mg<sup>2+</sup> ADP and aluminium fluoride. *Structure* 2000, **8**, 567–573.
- Braig, K., Otwinowski, Z., Hegde, R., Boisvert, D. C., Joachimiak, A., Horwich, A. L & Sigler, P. B. The crystal structure of the bacterial chaperonin GroEL at 2.8 Å. *Nature* 1994, **371**, 578–586.
- Brandts, J. F., Halvorson, H. R., & Brennan, M. Consideration of the possibility that the slow step in protein denaturation reactions is due to *cis-trans* isomerism of proline residues. *Biochemistry* 1975, **14**, 4953–4963.
- Brandts, U. Bifurcated ubihydroquinone oxidation in the cytochrome bc 1 complex by protongated charge transfer. *FEBS Lett.* 1996, **387**, 1–6.
- Brejc, K., Sixma, T. K., Kitts, P. A., Kain, S. R., Tsien, R. Y., Ormo, M., Remington, S. J. Structural basis for dual excitation and photoisomerization of the Aequorea victoria green fluorescent protein. *Proc. Natl. Acad. Sci U* S A 1997, 94, 2306–2311.
- Brenner, S., Jacob, F. & Meselson, M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. *Nature* 1961, **190**, 576–581.
- Brodersen, D. E., Carter, A. P., Clemons Jr, W. M.,
  Morgan-Warren, R. J., Murphy IV, F. V. Ogle, J. M.,
  Tarry, M. J. Wimberley, B. T. & Ramakrishnan, V.
  Atomic Structures of the 30S Subunit and Its Complexes with Ligands and Antibiotics. *Cold Spring Harbor Symp*. 2001, 66, 17–32.
- Browner, M. F. & Fletterick, R. J. Phosphorylase: a Biological Transducer. *Trends Biochem. Sci.* 1992, **17**, 66–71.
- Burley, S. K. The TATA box binding protein. *Curr. Opin. Struct. Biol.* 1996, **6**, 69–75.
- Butler, P. J. G., Klug, A. The assembly of a virus. *Sci. Amer.* Nov. 1978
- Byrne, B. & Iwata, S. Membrane protein complexes. *Curr. Opin. Struct. Biol.* 2002, **12**, 239–243.
- Cahn, R. S., Ingold, C. K. & Prelog, V. Specification of Molecular Chirality. Angew. Chem. 1966, 78, 413–447.
- Cammack, R. & Cooper, C. E. Electron paramagnetic resonance spectroscopy of iron complexes and ironcontaining proteins. *Methods Enzymol*. 1993, 22, 353–384, Academic Press.
- Campbell, I. D. & Dwek, R. Biological Spectroscopy. Benjamin Cummings, New York, 1984.
- Capaldi, R. A. Structure and function of cytochrome oxidase. Annu. Rev. Biochem. 1990, 59, 569–96.

- Carter, C. W. Cognition, Mechanism, and Evolutionary Relationships in Aminoacyl-tRNA Synthetases. *Ann. Rev. Biochem.* 1993, 62, 717–748.
- Cavanagh, J., Fairbrother, W. J., Palmer III, A. G. & Skelton, N. J. Protein NMR spectroscopy: Principles and Practice. Academic Press, 1996.
- Chaddock, J. A., Herbert, M. H., Ling, R. J., Alexander, F. C. G., Fooks, S. J., Revell, D. F., Quinn, C. P., Shone, C. C. & Foster, K. A. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of *Clostridium botulinum* toxin type A. *Protein Expression and Purification* 2002, 25, 219–228.
- Chalfie, M., Tu, Y., Euskirchen, G., Ward W. W., Prasher D. C. Green fluorescent protein as a marker for gene expression. *Science* 1994, 263, 802–805.
- Cheetham, G. M., Jeruzalmi, D. & Steitz, T. A. Structural basis for initiation of transcription from an RNA polymerase- promoter complex *Nature* 1999, 399, 80–84.
- Chen, S., Roseman, A. M., Hunter, A. S., Wood, S. P., Burston, S. G., Ranson, N. A., Clarke, A. R. & Helen R. Saibil, H. R. Location of a folding protein and shape changes in GroEL–GroES complexes imaged by cryo-electron microscopy *Nature* 1994, 371, 261–264.
- Chevet, E., Cameron, P. H., Pelletier, M. F., Thomas D. Y. & Bergeron, J. J. M. The endoplasmic reticulum: integration of protein folding, quality control, signaling and degradation. *Curr. Opin. Struct. Biol.* 2001, **11**, 120–124.
- Cho, Y., Gorina, S., Jeffrey, P. D., Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. *Science* 1994, **265**, 346–355.
- Chothia, C & Finkelstein, A. V. The classification and origins of protein folding patterns. *Annu. Rev. Biochem.* **59**, 1007–1039, 1990.
- Chou, P. Y. & Fasman, G. D. Empirical Predictions of Protein Conformation. Annu. Rev. Biochem. 1978, 47, 251–276.
- Cingolani, G., Petosa, C., Weis, K., & Müller, C. W. Structure of importin-β bound to the IBB domain of importin-α. *Nature* 1999, **399**, 221–229.
- Cohen, C. & Parry, D. A. D. α helical coiled coils and bundles: how to design an α helical protein. *Prot. Struct. Funct. Genet.* 1990, **7**, 1–15.
- Cohen, F. E. & Prusiner, S. B. Pathologic conformations of prion proteins. Annu. Rev. Biochem. 1998, 67, 793–819.
- Collinge, J. Human prion diseases and bovine spongiform encephalopathy (BSE). *Hum. Mol. Genet.* 1997, **6**, 1699–1705.
- Coux, O., Tanaka, K. & Goldberg, A. L. Structure and Functions of the 20S and 26S Proteasomes. *Annu. Rev. Biochem.* 1996, 65, 801–847.

Cowan, S. W., Schirmer, T., Rummel, G., Steiert, M., Ghosh, R., Pauptit, R. A., Jansonius N. J. & Rosenbusch, J. P. Crystal structures explain functional properties of two *E. coli* porins. *Nature* 1992, 358, 727–733.

- Crick, F. H. C. The packing of α helices: simple coiled coils. *Acta Cryst.* 1953, **6**, 689–697.
- Crick, F. H. C., Barnett, L., Brenner, S. & Watts-Tobin, R. J. General nature of the genetic code for proteins. *Nature* 1961, **192**, 1227–1232.
- Crystal, R. G. The α<sub>1</sub>-antitrypsin gene and its deficiency states. *Trends Genet.* 1989, **5**, 411–417.
- Cserzo, M., Wallin, E., Simon, I., von Heijne, G. & Elofsson, A. Prediction of transmembrane α helices in prokaryotic membrane proteins: the Dense Alignment Surface method. *Prot. Eng.* 1997, **10**, 673–676.
- Cullen, B. R, Nuclear RNA export pathways. *Mol. Cell. Biol.* 2000, **20**, 4181–4187.
- Dalbey, R. E, Chen, M. Y., Jiang, F. & Samuelson, J. C. In vivo Assembly of Transporters and other Membrane Proteins. Curr. Opin. Cell Biol. 2000, 12, 435–442.
- Dalbey, R. E. & Robinson, C. Protein translocation into and across the bacterial plasma membrane and the plant thylakoid membrane. *Trends Biochem. Sci.* 1999, **24**, 17–24
- Danna, K. & Nathans, D. Specific cleavage of Simian virus 40 DNA restriction endonuclease of *Haemophilus* influenzae. Proc. Natl. Acad. Sci. USA 1971, 68, 2913–2917.
- Davie, E. W. Introduction to the blood clotting cascade and the cloning of blood coagulation factors. *J. Prot. Chem.* 1986, 5, 247–253.
- Davies, D. R. The structure and function of the aspartic proteinases. Ann. Rev. Biophys. Biophys. Chem. 1990, 19, 189–215.
- Davies, D. R. & Chacko, S. Antibody structure. Acc. Chem. Res. 1993, 26, 421–427.
- Dayhoff, M. The origin and evolution of protein superfamilies. *FASEB J.* 1976, **35**, 2132–2138.
- Dayhoff, M. O., R. M. Schwartz and B. C. Orcutt. 1978. A model of evolutionary change in proteins. In *Atlas of Protein Sequence and Structure* Vol. 5 suppl. 2 (ed. M. O. Dayhoff), 345–352. National Biomedical Research Foundation, Washington DC.
- DeBondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O. & Kim, S. H. Crystal structure of cyclin-dependent kinase 2. *Nature* 1993, **363**, 595–602.
- Deisenhofer, J., Epp, O., Miki, K., Huber, R. & Michel, H. Structure of the protein subunits in the photosynthetic reaction centre of R. viridis at 3 Å resolution. *Nature* 1985, **318**, 618–624.

- Deisenhofer, J., Epp, O., Miki, K., Huber, R. & Michel, H. X-ray structure analysis of a membrane protein complex. Electron density map at 3 Å resolution and a model of the chromophores of the photosynthetic reaction center from *Rhodopseudomonas viridis*. *J. Mol. Biol.* 1984, **180**, 385–398.
- Deisenhofer, J., Epp, O., Sinning, I. & Michel, H. Crystallographic refinement at 2.3 Å resolution and refined model of the photosynthetic reaction centre from *Rhodopseudomonas viridis*. J. Mol. Biol. 1995, 246, 429–457.
- DeRose, V. J. & Hoffman, B. M. Protein structure and mechanism studied by electron nuclear double resonance spectroscopy *Methods Enzymol*. 1995, **246**, 554–589 Academic Press.
- Dill, K. A. & Chan, H. S. From Levinthal to pathways to funnels. *Nature Struct. Biol.* 1997, 4, 10–19.
- Dill, K. A. Dominant Forces in Protein Folding. Biochemistry 1990, 29, 7133-7155.
- Dinner, A. R. & Karplus. M. The roles of stability and contact order in determining protein folding rates. *Nature Struct. Biol.* 2001, 8, 21–22.
- Ditzel, L., Löwe, J. Stock, D., Stetter, K.-O., Huber, H., Huber, R. & Steinbacher, S. Crystal structure of the thermosome, the archaeal chaperonin and homolog of CCT. *Cell* 1998, 93, 125–138.
- Dobson, C. M. Protein Misfolding, Evolution and Disease *Trends Biochem. Sci.* 1999, **24**, 329–332.
- Dobson, C. M., Evans, P. A., & Radford, S. E. Understanding How Proteins Fold: The Lysozyme Story so Far, *Trends Biochem. Sci.* 1994, 19, 31–37.
- Dodson, G. & Wlodawer, A. Catalytic triads and their relatives. *Trends Biochem. Sci.* **23**, 347–352, 1998.
- Dohlman et alBiochemistry 1987, 26, 2660-2666.
- Doolittle, R. F. The multiplicity of domains in proteins. *Annu. Rev. Biochem.* 1995, **64**, 287–314.
- Doudna, J. A. & Batey, R. T. Structural insights into the signal recognition particle. *Annu. Rev. Biochem.* 2004, **73**, 539–557.
- Downing, A. K., Knott, V., Werner, J. M., Cardy, C. M., Campbell, I. D., & Handford, P. A., Solution structure of a pair of Ca<sup>2+</sup> binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders. *Cell* 1996, **85**, 597–605.
- Drenth, J. Principles of Protein X-ray Crystallography, Springer-Verlag. New York 1994
- Dunbrack, Jr. R. L., & Karplus, M. Conformational analysis of the backbone-dependent rotamer preferences of protein sidechains. *Nature Struct. Biol.* 1, 334–340, 1994.
- Eckert, D. M. & Kim, P. S. Mechanisms of viral membrane fusion and its inhibition. *Annu. Rev. Biochem.* 2001, 70, 777–810.

- Edman, P. & Begg, G. A protein sequenator. *Eur. J. Biochem.* 1967, 1, 80–91.
- Eisenberg, D. The discovery of the α-helix and β-sheet, the principal structural features of proteins. *Proc. Natl. Acad. Sci. USA.* 2003. **100**, 11207–11210.
- Ellenberger, T. E., Brandl, C. J., Struhl, K. & Harrison, S. C. The GCN4 basic region leucine zipper binds DNA as a dimer of uninterrupted alpha helices: crystal structure of the protein-DNA complex. *Cell* 1992, **71**, 1223–1237.
- Ellis, R. J. Chaperone substrates inside the cell. *Trends Biochem. Sci.* 2000, **25**, 210–212.
- Elrod-Erickson, M., Benson, T. E., Pabo, C. O.: High-resolution structures of variant Zif268-DNA complexes: implications for understanding zinc finger-DNA recognition. *Structure* 1998, **6**, 451–464.
- Englander S. W., Mayne, L., Bai, Y. & Sosnick T. R. Hydrogen exchange: the modern legacy of Linderström-Lang. *Protein Sci.* 1997, **6**, 1101–1109.
- Englander, S. W. & Kallenbach, N. R. Hydrogen exchange and structural dynamics of proteins and nucleic acids. *Quart. Rev. Biophys.* 1984, 16, 521–655.
- Evans, J. N. S. *Biomolecular NMR spectroscopy*. Oxford University Press. 1995.
- Evans, P. R. Structural aspects of allostery. *Curr. Opin. Struct. Biol.* 1991, 1, 773–779.
- Farquhar, M. G. Progress in Unraveling Pathways of Golgi Traffic. *Annu. Rev. Cell Biol.* 1985, **1**, 447–488.
- Ferguson, M. A. J. & Williams, A. F. Cell surface anchoring of proteins via glycosyl-phosphatidylinositol structures. *Annu. Rev. Biochem.* 1988, **57**, 285–320.
- Ferre-D'Amare, A. R., Prendergast, G. C., Ziff, E. B., Burley, S. K. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. *Nature* 1993, **363**, 38–45.
- Ferrell, K. Wilkinson, C. R. M., Dubiel, W., & Gordon. C. Regulatory subunit interactions of the 26S proteasome, a complex problem *Trends Biochem. Sci.* 2000, **25**, 83–88.
- Fersht, A. R. Protein folding and stability: the pathway of folding of barnase. *FEBS Lett.* 1993, **325**, 5–16.
- Fersht, A. R., Knill-Jones, J. W., Bedouelle, H., & Winter G. Reconstruction by site-directed mutagenesis of the transition state for the activation of tyrosine by the tyrosyltRNA synthetase: A mobile loop envelopes the transition state in an induced-fit mechanism. *Biochemistry* 1988, 27, 1581–1587.
- Fersht, A. R., Matouschek, A. & Serrano, L Folding of an enzyme: Theory of protein engineering of stability and pathway of protein folding. *J. Mol. Biol.* 1992, **224**, 771–782, 783–804, 805–818, 819–835, 836–846, 847–859.
- Findlay, J. B. C. & Geisow, M. J. (eds) *Protein Sequencing*. *A practical approach* IRL press 1989.

- Fischmann, T. O., Bentley, G. A., Bhat, T. N., Boulot, G., Mariuzza, R. A., Phillips, S. E. V., Tello, D., & Poljak, R. J. Crystallographic Refinement of the Three-dimensional Structure of the FabD1.3-Lysozyme Complex at 2.5-Å Resolution. *J. Biol. Chem.* 1991, 266, 12915–12920.
- Frankel, A. D. & Young, J. A. T. HIV-1: Fifteen Proteins and an RNA. *Annu. Rev. Biochem.* 1998, **67**, 1–25.
- Gesteland, R. F., Cech, T. R., & Atkins, J. F. *The RNA World*. Cold Spring Harbor Press, New York 1999.
- Gether, U. Uncovering Molecular Mechanisms Involved in Activation of G Protein-Coupled Receptors. *Endocrine* Rev. 2000, 21, 90–113.
- Gething, M. J. & Sambrook, J. Protein folding in the cell. Nature 1992, 355, 33-45.
- Glover, J. N., & Harrison, S. C., Crystal structure of the heterodimeric bZIP transcription factor c-Fos c-Jun bound to DNA. Nature 1995, 373, 257–260.
- Gorlich, D. & Rapoport, T. A, Protein translocation into proteoliposomes reconstituted from purified components of the endoplasmic reticulum membrane. *Cell* 1993, **75** 615–630.
- Gould, K. L. & Nurse, P. Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis. *Nature* 1991, 342, 39–45.
- Green, A. A., J. Biol. Chem. 95, 47, 1932.
- Griffiths, W. J., Jonsson, A. P., Liu, S., Rai, D. K. & Wang, Y. Electrospray and tandem mass spectrometry in Biochemistry. *Biochem. J.* 2001, **355**, 545–561.
- Grigorieff, N., Ceska, T. A., Downing, K. H., Baldwin, J. M. & Henderson, R. Electron-crystallographic refinement of the structure of bacteriorhodopsin. *J. Mol. Biol.* 1996, 259, 393–421.
- Guidotti, G. Membrane proteins. Annu. Rev. Biochem. 1972, 41, 731–752.
- Guijarro, J. I. Guijarro, I., Sunde, M., Jones, J. A., Campbell, I. D. & Dobson, C. M. Amyloid fibril formation by an SH3 domain. *Proc. Natl. Acad. Sci. USA.* 1998, 95, 4224–4228.
- Hames, B. D. & Rickwood, D. (Eds.), Gel Electrophoresis of proteins. A Practical Approach (2<sup>nd</sup> Ed). 1990 IRL press.
- Handford, P. A. Fibrillin-1, a calcium binding protein of extracellular matrix. *Biochim. Biophys. Acta*, 2000, **1498**, 84–90.
- Hansen, J. C., Lebowitz, J. & Demeler, B. Analytical ultracentrifugation of complex macromolecular systems. *Biochemistry* 1994, 33, 13155–13163.
- Hartl F. U. & Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to folded protein. *Science* 2002, 295, 1852–1888.

Hartl. F. U. Molecular chaperones in cellular protein folding Nature 1996, 381, 571–580.

- Heijne, von G. Patterns of amino acids near signal cleavage sites. *Eur. J. Biochem.* 1983, **133**, 17–21.
- Henderson, R. & Unwin, P. N. T. Three-dimensional model of purple membrane obtained by electron microscopy. *Nature* 1975, **257**, 28–32.
- Henderson, R., Baldwin, J. M., Ceska, T. A., Zemlin, F., Beckmann, E. & Downing, K. H. Model for the Structure of Bacteriorhodopsin Based on High-Resolution Electron Cryo-microscopy. *J. Mol. Biol.* 1990, 231, 899–929.
- Henikoff, S. & Henikoff, J. G. Amino acid substitution matrices from protein blocks. *Proc. Natl. Acad. Sci. USA* 1992, 89, 10915–10919.
- Hensley, P. Defining the structure and stability of macromolecular assemblies in solution: the re-emergence of analytical ultracentrifugation as a practical tool. *Structure* 1996, **4**, 367–373. 1996.
- Hershko, A., & Ciechanover, A. The ubiquitin system. *Annu. Rev. Biochem.* 1998, **67**, 425–479.
- Hill, A. F., Desbruslais, M., Joiner, K., Sidle, C. L., Gowland, I., Collinge, J., Doey, L. J. & Lantos, P. The same prion strain cause nvCJD and BSE. *Nature* 1997, 389, 448–450.
- Hochstrasser, M. Ubiquitin-dependent protein degradation. Annu. Rev. Genet. 1996, **30**, 405–439.
- Hofmeister, F. On the understanding of the effects of salts. *Arch. Exp. Pathol. Pharmakol. (Leipzig)* 1888, **24**, 247–260.
- Holley, R. W., Everett, G. A., Madison, J. T. & Zamir, A. Nucleotide sequences in yeast alanine transfer RNA. J. Biol. Chem., 1965, 240, 2122–2127.
- Homans, S. W. A dictionary of concepts in NMR. Oxford Science Publication. 1992.
- Hong, L., Turner, R. T., Koelsch, G., Shin, D., Ghosh, A. K. & Tang, J. Crystal Structure of Memapsin 2 (β-Secretase) in Complex with Inhibitor Om00-3 Biochemistry 2002, 41, 10963–10967.
- Hubbard, S. R. & Till, J. R. Protein tyrosine kinase structure and function *Annu. Rev. Biochem.* 2000, **69**, 373–398.
- Huffman, J. L. & Brennan, R. G. Prokaryotic transcription regulators: more than just the helix-turn-helix motif. *Curr. Opin. Struct. Biol.* 2002, **12**, 98–106.
- Hunkapiller, M. W., Strickler, J. E., & Wilson, K. E. Contemporary methodology for protein structure determination. *Science* 1984, **226**, 304–311.
- Ingram, V. A case of sickle-cell anemia. *Biochem. Biophys. Acta* 1989, **1000**, 147–150.
- Iwata, S., et al. Complete structure of the 11-subunit bovine mitochondrial cytochrome bc<sub>1</sub> complex. Science 1998, 281, 64-71.

- Iwata, S., Ostermeier, C., Ludwig, B., & Michel, H. Structure at 2.8 Å resolution of cytochrome c oxidase from Paracoccus denitrificans. Nature 1998, 376, 660–669.
- Jackson, S. E. & Fersht, A. R. Folding of chymotrypsin inhibitor 2, 1: Evidence for a two-state transition. *Biochemistry* 1991, 30, 10428-10435.
- Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J. & Pavletich, N. P.: Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. *Nature* 1995, 376, 313–320.
- Jencks, W. P. Economies of enzyme catalysis. *Cold Spring Harbor Symp. Quant. Biol.* 1987, **52**, 65–73.
- Jimenez, J. L., Tennent, G., Pepys, M & Saibil, H. R. Structural Diversity of *ex vivo* Amyloid Fibrils Studied by Cryo-electron Microscopy. *J. Mol. Biol.* 2001, 311, 241–247.
- Johnson L. N. Jenkins J. A. Wilson K. S. Stura E. A. & Zanotti G. Proposals for the catalytic mechanism of glycogen phosphorylase b prompted by crystallographic studies on glucose 1-phosphate binding. *J. Mol. Biol.* 1980, **140**, 565–580.
- Johnson, W. C. Jr. Protein secondary structure and circular dichroism. A practical guide. *Proteins Struct. Funct. Genet.* 1990, 7, 205–214.
- Jones, D. T., Taylor, W. R. & Thornton. J. M. The rapid generation of mutation data matrices from protein sequences. *Computer Applied Biosciences* 1992, 8, 275–282.
- Jordan, P., Fromme, P., Witt, H. T., Klukas, O., Saenger, W., & Krauss, N. Three-dimensional structure of cyanobacterial photosystem I at 2.5 Å resolution. *Nature* 2001, 411, 909-917.
- Kalies, K. -U. & Hartmann, E. Protein translocation into the endoplasmic reticulum (ER) Two similar routes with different modes. *Eur. J. Biochem.* 1998, 254, 1–5.
- Karwaski, M. F., Wakarchuk, W. W. & Gilbert, M. Highlevel expression of recombinant *Neisseria CMP*-sialic acid synthetase in *Escherichia coli*. *Protein Expression and Purification* 2002, 25, 237–240.
- Kauzmann, W. Some factors in the interpretation of protein denaturation. *Adv. Prot. Chem.* 1959, **14**, 1–63.
- Kay, L. E., Clore, G. M., Bax, A & Gronenborn, A. M. Four-dimensional heteronuclear triple-resonance NMR spectroscopy of interleukin 1β in solution. *Science* 1990, **249**, 411–414.
- Kay, L. E., D. Marion, D. & Bax, A. Practical aspects of three-dimensional heteronuclear NMR of proteins. J. Magn. Reson. 1989, 84, 72–84.
- Kay, L. E., Ikura, M., Tschudin, R. & Bax, A. Threedimensional triple resonance NMR spectroscopy of isotopically enriched proteins. *J. Magn. Reson.* 1990, 89, 496–514.

- Keenan, R. J., Freymann, D. M., Stroud, R. M., & Walter, P. The signal recognition particle. *Annu. Rev. Biochem.* 2001, 70, 755–775.
- Keleti, T. Two rules of enzyme kinetics for reversible Michaelis-Menten mechanisms. FEBS Lett. 1986, 208, 109–112.
- Kelly, J. W. Alternative conformations of amyloidogenic proteins govern their behavior, *Curr. Opin. Struct. Biol.* 1996 **6**, 11–17.
- Kelly, J. W. Towards an understanding of amyloidosis. *Nature Struct. Biol.* 2002, **5**, 323–324.
- Kendrew, J. C., Bodo, G., Dintzis, H. M., Parrish, R. G., Wyckoff, H., and Phillips, D. C. A Three-Dimensional Model of the Myoglobin Molecule Obtained by X-ray Analysis. *Nature*, 1958, 181, 662.
- Kim P. S. & Baldwin R. L. Intermediates in the Folding Reactions of Small Proteins *Annu Rev. Biochem.* 1990, 59, 631–660.
- King, R. W., Deshaies, R. J., Peters, J. M. & Kirschner, M. W. How proteolysis drives the cell cycle. *Science* 1996, 274, 1652–1659.
- Kirby, A. J. The lysozyme mechanism sorted after 50 years. *Nat. Struct. Biol.* 2001, **8**, 737–739.
- Knoll, A. H. The early evolution of eukaryotes: A geological perspective, Science 1992, 256, 622–627.
- Knowles, J. R & Albery, W. J. Perfection in enzyme catalysis, the energetics of triose phosphate isomerase. *Acc. Chem. Res.* 1977, 10, 105–111.
- Knowles, J. R. Tinkering with enzymes: what are we learning? *Science* 1987, **236**, 1252–1257.
- Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. *Science* 1992, **256**, 1783–1790.
- Kraut, J. How do enzymes work? *Science* 1988, **242**, 533–540.
- Kwong, P. D., Wyatt, R., Majeed, S., Robinson, J. Sweet,
  R. W., Sodroski, J. & Hendrickson, W. A. Structures of
  HIV-1 Gp120 Envelope Glycoproteins from LaboratoryAdapted and Primary Isolates. Structure 2000, 8,
  1329–133X.
- Kyte J., Doolittle R. F. A simple method for displaying the hydropathic character of a protein. *J. Mol. Biol.* 1982, **157**, 105–132.
- Ladbury, J. E & Chowdhry, B. Z. (eds) *Biocalorimetry: Applications of Calorimetry in the Biological Sciences*. John Wiley & Sons Chichester 1998.
- Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970, 227, 680–685.

- Lander, E. S. Linton, L. M., Birren, B et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860–921.
- Lander, E. S. The new genomics: global view of biology. *Science* 1996, **274**, 536–539.
- Larrabee, J. A. & Choi, S. Fourier transform infrared spectroscopy. *Methods Enzymol*. 1993, 226, 289–305, Academic Press.
- Lashuel, H. A., Lai, Z. & Kelly, J. W. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation, *Biochemistry* 1998, 37, 17851–17864.
- Leatherbarrow, R. J., Fersht, A. R., & Winter, G. Transitionstate stabilization in the mechanism of tyrosyl-tRNA synthetase revealed by protein engineering. *Proc. Natl. Acad. Sci. USA* 1985, 82, 7840–7844.
- Lee, A. G. A calcium pump made visible. *Curr. Opin. Struct. Biol.* 2002, **12**, 547–554.
- Lemmon M. A., Flanagan J. M., Treutlein H. R., Zhang J., & Engelman D. M. Sequence specificity in the dimerization of transmembrane alpha-helices *Biochemistry* 1992, **31**, 12719–12725.
- Lin. L. N. & Brandts, J. F. Isomerization of proline-93 during the unfolding and refolding of ribonuclese A. *Biochemistry* 1983, 22, 559–563.
- Lipschutz, R. J. & Fodor, S. P. A. Advanced DNA technologies. *Curr. Opin. Struct. Biol.* 1994, **4**, 376–380.
- Lipscomb, W. N. Aspartate Transcarbamylase from Escherichia Coli: Activity and Regulation Adv. Enzymol. 1994, 73, 677–751.
- Ludwig, S., Pleschka, S., Planz, O., & Wolff, T. Influenza virus induced signalling cascades: targets for antiviral therapy? *Trends Mol. Medicine* 2003, 9, 46–52.
- Luecke, H., Schobert, B., Richter, H. T., Cartailler, P. & Lanyi, J. K. Structure of bacteriorhodopsin at 1.55 Å resolution. J. Mol. Biol. 1999, 291, 899–911.
- Luecke, H., Schobert, B., Richter, H. T., Cartailler, P. & Lanyi, J. K. Structural changes in bacteriorhodopsin during ion transport at 2 Å resolution. *Science* 1999, 286, 255–260.
- Luong, C., Miller, A., Barnett, J., Chow J., Ramesha C., & Browner M. F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. *Nature Struct. Biol.* 1996, **3**, 927–933.
- Lupas, A. Coiled coils new structures and new functions. *Trends Biochem. Sci.* 1996, **21**, 375–382.
- Lynch, D. R. & Synder, S. H. Neuropeptides: multiple molecular forms, metabolic pathways and receptors. *Annu. Rev. Biochem.* 1986, 55, 773–799.

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A. & Friend, S. H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990, **250**, 1233–1238.

- Mallucci, G. R., Ratte, S., Asante, E. A., Linehan, J., Gowland, I., Jefferys, J. G. R., Collinge, J. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. *EMBO J.* 2002, 21, 202–210.
- Mann, M., Hendrickson, R. C & Pandey, A. Analysis of proteins and proteomes by mass spectrometry. *Annu. Rev. Biochem.* 2001, 70, 437–473.
- Margulis, L & Sagan, C. What is Life. Simon & Schuster. 1995.
- Marquart, M., Walter, J., Deisenhofer, J., Bode, W., & Huber, R. The Geometry of the Reactive Site and of the Peptide Groups in Trypsin, Trypsinogen and its Complexes with Inhibitors *Acta Crystallogr.*, Sect. B 1983, 39, 480–484.
- Martin, G. R., Timple, R., Muller, P. K. & Kuhn, K. The genetically distinct collagens. *Trends Biochem. Sci.* 1985, 10, 285–287.
- Martoglio, B. & Dobberstein, B. Snapshots of membranetranslocating proteins. *Trends Cell Biol.* 1996, 6, 142–147.
- Masters, C. L.; Simms, G.; Weinman, N. A.; Multhaup, G.; McDonald, B. L.; Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Nat. Acad. Sci. USA 1985*, 82, 4245–4249.
- McPherson, A. *Crystallization of Biological Macromolecules*. Cold Spring Harbor Laboratory Press, 1999.
- McRee, D. E. *Practical Protein Crystallography*. 2<sup>nd</sup> edn. Academic Press, 1999.
- Meselson, M. & Stahl. F. The replication of DNA in *Escherichia coli*. *Proc. Natl Acad. Sci. USA 1958*, **44**, 671–682.
- Michel, H. Three dimensional crystals of a membrane protein complex. The photosynthetic reaction centre from *Rhodopseudomonas viridis*. *J. Mol. Biol.* 1982, **158**, 567–572.
- Miller, S. Cold Spring Harbor Symp. Quant Biol. 1988, **52**, 17–28.
- Miller, S. J. & Orgel, L. E. The Origins of Life, Prentice-Hall, New Jersey, 1975.
- Miranker, A., Radford, S. E., Karplus, M., & Dobson, C. M. Demonstration by NMR of Folding Domains in Lysozyme. *Nature*, 1991, **349**, 633–636.
- Miranker, A., Robinson, C. V., Radford, S. E., Aplin R. T., Dobson C. M. Detection of Transient Protein Folding Populations by Mass Spectrometry. *Science* 1993, 262, 896–900.

- Moore, P. B. & Steitz, T. A. The structural basis of large ribosomal subunit function. *Annu. Rev. Biochem.* 2003, 72, 813–850.
- Moore, P. B. The ribosome at atomic resolution. *Biochemistry* 2001, 40, 3243–3250.
- Morgan, D. A. Cyclin dependant kinases: Engines, Clocks, and Microprocessors. Ann Rev. Cell Dev. Biol. 1997, 13, 261–291.
- Morgan. D. G., Menetret, J. F., Neuhof, A., et al, Structure of the Mammalian Ribosome–Channel Complex at 17 Å Resolution. J. Mol. Biol. 2002, 324, 871–886.
- Morimoto, R., Tissieres, A & Georgopoulos, C, (eds). The biology of heat shock proteins and molecular chaperones. Cold Spring Harbour Laboratory Press 1994.
- Morise, H., Shimomura, O., Johnson, F. H., & Winant, J. Intermolecular energy transfer in the bioluminecent system of *Aequorea*. *Biochemistry* 1974, 13, 2656–2662.
- Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B. & Lannfelt, L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. *Nature Genet*. 1992, **1**, 345–347.
- Newman, M., Strzelecka, T., Dorner, L. F., Schildkraut, I. & Aggarwal, A. K. Structure of restriction endonuclease *Bam*HI and its relationship to *Eco*RI, *Nature* 1994, 368, 660–664.
- Nikolov, D. B. & and Burley, S. K. RNA polymerase II transcription initiation: A structural view. *Proc. Natl. Acad* Sci. 1997, 94, 15–22.
- Nissen, P., Hansen, J., Ban, N., Moore, P. B. & Steitz, T. A. The structural basis of ribosome activity in peptide bond synthesis. *Science* 2000, **289**, 920–930.
- Noel, J. P. Hamm, H. E. & Sigler, P. B. The 2.2 Å crystal structure of transducin-α complexed with GTPγS. *Nature* 1993, **366**, 654–658.
- Nogales, E., Wolf, S. G. & Downing. K. H. Structure of the aβ-tubulin dimer by electron crystallography. *Nature* 1998, **391**, 199–203.
- Nogales. E. Structural insight into microtubule function. *Annu. Rev. Biophys. Biomol. Struct.* 2001, **30**, 397–420.
- Noiva, R., & Lennarz, W. J. Protein Disulfide Isomerase A Multifunctional Protein Resident in the Lumen of the Endoplasmic Reticulum. J. Biol. Chem. 1992, 267, 3553–3556.
- Nugent, J. H. A. Oxygenic photosynthesis: electron transfer in photosystem I and photosystem II. *Eur. J. Biochem.* 1996, 237, 519–531.
- Nurse, P. Genetic control of cell size at cell division in yeast. *Nature* 1975, **256**, 547–551.
- O'Farrell, P. H. High resolution two dimensional electrophoresis. *J. Biol. Chem.* 1975, **250**, 4007–4021.

- O'Shea, E. K. Rutkowski, R. & Kim, P. S., Evidence that the leucine zipper is a coiled coil. *Science* 1989, **243**, 538–542.
- Oliver, J., Jungnickel, B., Gorlich, D., Rapoport, T., & High S. The Sec61 complex is essential for the insertion of proteins into the membrane of the endoplasmic reticulum. *FEBS Lett.* 1995, **362**, 126–30.
- Onuchic, J. N., Wolynes, P. G., Luthey-Schulten, Z. & Socci, N. D. Towards an Outline of the Topography of a Realistic Protein-Folding Funnel. *Proc. Natl. Acad. Sci* USA 1995, 92, 3626–3630.
- Orengo, C. A., Michie, A. D., Jones, S., Jones, D. T., Swindells, M. B., & Thornton, J. M. CATH – A Hierarchic Classification of Protein Domain Structures. *Structure* 1997, 5, 1093–1108.
- Orgel, L. E. Molecular replication. *Nature* 1992, **358**, 203–209.
- Orlova, E. V. & Saibil, H. R. Structure determination of macromolecular assemblies by single-particle analysis of cryo-electron micrographs. *Curr. Opin Struct. Biol.* 2004, 14, 584–590.
- Pace, C. N. Conformational stability of proteins. *Trends Biochem. Sci.* 1990, 15, 14–17.
- Pace, C. N., and Scholtz, J. M. A Helix Propensity Scale Based on Experimental Studies of Peptides and Proteins. *Biophys. J.* 1998, 75, 422–427.
- Padlan, E. Anatomy of the Antibody Molecule. *Molecular Immunology* 1994, 31, 169–178.
- Parry, D. A. D. The molecular and fibrillar structure of collagen and its relationship to the mechanical properties of connective tissue. *Biophys. Chem.* 1988, 29, 195–209.
- Passner, J. M., Ryoo, H. D., Shen, L., Mann, R. S. & Aggarwal, A. K. Structure of a DNA-bound Ultrabithorax-Extradenticle homeodomain complex. *Nature* 1999, 397, 714–719.
- Pauling, L. & Corey, R. B. Atomic Coordinates and Structure Factors for Two Helical Configurations of Polypeptide Chains. *Proc. Natl. Acad. Sci. USA* 1951, **37**, 235–240.
- Perl, D. Welker, C., Schindler, T., Schroder, K., Marahiel, M. A., Jaenicke, R., and Schmid, F. X. Conservation of rapid two-state folding in mesophilic, thermophilic and hyperthermophilic cold shock proteins. *Nature Structural Biology* 2000, 7, 380–383.
- Perutz, M. F., Rossmann, M. G., Cullis, A. F., Muirhead, H., Will, G. & North, A. C. T. Structure of haemoglobin. A three-dimensional Fourier synthesis at 5.5 Å resolution, obtained by X-ray analysis. *Nature* 1960, **185**, 416–422.
- Perutz, M. F., Wilkinson, A. J., Paoli, M., & Dodson, G. The stereochemical mechanism of cooperative effects in

- hemoglobin revisted. *Annu Rev. Biophys. Biomol. Structure* 1998, **27**, 1–34.
- Pfanner, N. & Neupert, W. The mitochondrial protein import apparatus. *Annu. Rev. Biochem.* 1990, **59**, 331–353.
- Phillips, M. A. & Fletterick, R. J. Proteases. Cur. Opinion. Struct. Biol. 1992, 2, 713–720.
- Picot, D., Loll P. J., & Garavito R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-l. *Nature* 1994, **367**, 243–249.
- Plaxco, K. W., Simons, K. T., & Baker, D. Contact order, transition state placement and the refolding rates of single domain proteins. J. Mol. Biol. 1998, 277, 985–994.
- Poignard, P., Saphire, E. O., Parren, P. W. H. I. & Burton, D. R. GP120: Biologic Aspects of Structural Features. Annu. Rev. Immunol. 2001, 19, 253–74.
- Ponder, J. W. & F. M. Richards. Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. *J. Mol. Biol.* 1987, 193, 775–791.
- Popot, J.-L. & Engelman, D. M. Helical membrane protein folding, stability and evolution *Annu. Rev. Biochem.* 2000, 69, 881–922.
- Privalov, P. L. Stability of proteins: Small globular proteins. *Adv. Protein Chem.* 1979, **33**, 167–241.
- Privalov, P. L. & Gill, S. J. Stability of protein structure and hydrophobic interaction. Adv. Prot. Chem. 1988, 39, 191–234.
- Prusiner, S. B., Novel proteinaceous infectious particles cause scrapie. *Science* 1982, **216**, 136–144.
- Radford. S. Protein folding: progress made and promise ahead. *Trends Biochem. Sci.* 2000, **25**, 611–618.
- Ramachandran, G. N. & Sasiskharan, V. Conformation of polypeptides and proteins. Adv. Protein Chem. 1968, 23, 283–437.
- Ramakrishnan, V. & Moore, P. B. *Curr. Opin. Struct. Biol.* 2001, **11**, 144–154, 2001
- Rao, S. T. & Rossmann M. G. Comparison of supersecondary structure in protein *J. Mol. Biol.* 1973, 76, 241–256.
- Rapoport, T. A., Jungnickel, B. & Kutay, U. Protein transport across the eukaryotic endoplasmic reticulum and bacterial inner membranes, *Annu. Rev. Biochem.* 1996, 65, 271–303.
- Rappsilber, J. & Mann, M. What does it mean to identify a protein in proteomics? *Trend Biochem. Sci.* 2002, 27, 74–78.
- Rath, V. L., Silvian, L. F., Beijer, B., Sproat, B. S., Steitz, T. A. How glutaminyl-tRNA synthetase selects glutamine. *Structure* 1997, **6**, 439–449.
- Rechsteiner, M. & Rogers, S. W. PEST sequences and regulation by proteolysis. *Trends Biochem. Sci.* 1996, **21**, 267–271.

Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R. & Wüthrich, K. NMR structure of the mouse prion protein domain PrP (121–231). *Nature* 1996, **382**, 180–184.

- Roder, H., Elöve, G., & Englander, S. W. Structural characterization of folding intermediates in cytochrome c by H-exchange labeling and proton NMR. *Nature* 1888, 335, 700–704.
- Roeder, R. G. The role of general initiation factors in transcription by RNA polymerase II. *Trends Biochem. Sci.* 1996, **21**, 327–335.
- Rose, G. N. Turns in peptides and proteins *Adv. Protein Chem.* 1985, **37**, 1–109.
- Rosenberg, J. M. Structure and function of restriction endonucleases. *Curr. Opin. Struct. Biol.* 1991, **1**, 104–113.
- Rould, M. A., Perona, J. J., Soll, D., & Steitz, T. A. Structure of E. coli glutaminyl-tRNA synthetase complexed with tRNA(Gln) and ATP at 2.8 A resolution. *Science* 1989, 246, 1135–1141.
- Rowland-Jones, S. L. AIDS pathogenesis: what have two decades of HIV research taught us? *Nature Rev. Immunol.* 2003, **3**, 343–348.
- Rupp. B., http://www-structure.llnl.gov.
- Russell, P. & Nurse, P. cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 1986, 45, 145–153.
- Russo, A. A., et al. Nat. Struct. Biol. 3, 696-XXX 1996
- Rutherford, A. W. & Faller, P. The heart of photosynthesis in glorious 3D. *Trends Biochem. Sci.* 2001, **26**, 341–344.
- Saibil, H. Molecular chaperones: containers and surfaces for folding, stabilizing or unfolding proteins. *Current Opinion in Struct. Biol.* 2000, **10**, 251–258.
- Sambrook, J. & Russell, D. Molecular Cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, 2001
- Sambrook, J., Fritsch, E. F. & Maniatis, T. Molecular Cloning. Cold Spring Harbor Laboratory Press, 1989.
- Sanger, F. Sequences, sequences, sequences. *Annu. Rev. Biochem.* 1988, **57**, 1–28.
- Saraiva, M. J. M. Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Rev. Mol. Med. 2002. http://www.expertreviews.org/ 02004647h.htm
- Schekman, R. Dissecting the membrane trafficking system. *Nature Medicine* 2002, **8**, 1055–1058.
- Schellman, J. A. The thermodynamic stability of proteins. *Ann. Rev. Biophys. Biophys. Chem.* 1987, **16**, 115–137.
- Schmid F. X., Mayr L. M., Mucke, M., & Schonbrunner, E. R. Prolyl isomerases: role in protein folding. Adv. Prot. Chem. 1993, 44, 25–66.
- Schopf, J. W. Microfossils of the early Archaen Apex chert: New evidence of the antiquity of life. *Science* 1993, **260**, 640–646.

Schramm, V. L. Enzyme transition states and transition state analog design. Annu. Rev. Biochem. 1998, 67, 693–720.

- Schulz, G. E. Structure of porin refined at 1.8 Å resolution. J. Mol. Biol. 1992, 227, 493–509.
- Schuster, T. M. & Toedtt, J. M. New revolutions in the evolution of analytical ultracentrifugation. *Curr. Opin. Struct. Biol.* 1996, 6, 650–658.
- Scopes, R. Protein purification: principles and practice. Springer-Verlag, Berlin 1993.
- Selkoe, D. J. Amyloid β-protein and the genetics of Alzheimer's disease. *J. Biol. Chem.* 1996, **271**, 18295–18298.
- Shine, J. & Dalgarno, L. The 3' terminal sequence of *E.coli* 16S rRNA: Complementary to nonsense triplets and ribosome binding sites. *Proc. Natl. Acad. Sci USA* 1974, 71, 1342–1346.
- Sidransky, D & Hollstein, M. Clinical implications of the p53 gene. *Annu. Rev. Med.* 1996, **47**, 285–30.
- Siebert, F. Infrared spectroscopy applied to biochemical and biological problems. *Methods Enzymol*. 1995, 246, 501–526 Academic Press.
- Sigler, P. B., Xu, Z. Rye, H. S. Burston, S. G., Fenton, W. A & Horwich, A. L. Structure and function in GroELmediated protein folding *Annu. Rev. Biochem.* 1998, 67, 581–608.
- Silver, P. A. How proteins enter the nucleus. *Cell* 1991, **64**, 489–497.
- Silverman, G. A. et al. The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins. J. Biol. Chem. 2001, 276, 33293–33296.
- Simons K. T., Ruczinski, I., Kooperberg, C., Fox, B., Bystroff, C., & Baker, D. Improved Recognition of Native-like Protein Structures using a Combination of Sequence-dependent and Sequence-independent Features of Proteins. *Proteins* 1999, 34, 82–95.
- Singer, S. J. The molecular organization of membranes. *Annu. Rev. Biochem.* 1974, 805–833.
- Singer, S. J. & Nicolson, G. The fluid mosaic model of the structure of cell membranes. *Science* 1972, **175**, 720–731.
- Skehel, J. J., Bayley, P. M., Brown, E. B., Martin, S. R., Waterfield, M. D., White, J. M., Wilson, I. A., and Wiley, D. C. Changes in the conformation of influenza virus haemagglutinin at the pH optimum of virus-mediated membrane fusion *Proc. Natl. Acad. Sci. USA* 1982, 79, 968–972.
- Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza haemagglutinin. *Annu. Rev. of Biochem.* 2000, **69**, 531–569.
- Smith, W. L., DeWitt, D. L. & Garavito, R. M. Cyclooxygenase: Structural, Cellular, and Molecular Biology *Annu. Rev. Biochem.* 2000, 69, 145–182.

- Song, L., Hobaugh, M. R., Shustak, C., Cheley, S., Bayley, H., & Gouaux J. E. Structure of staphylococcal αhemolysin, a heptameric transmembrane pore, *Science* 1996, 274, 1859–1866.
- Steinhauer, D. A. & Skehel, J. J. Genetics of influenza viruses. *Annu. Rev. Genet.* 2002, **36**, 305–332.
- Steitz, T. A. & Schulman, R. G. Crystallographic and NMR studies of the serine proteases. *Annu. Rev. Biophys. Bioenerg.* 1982, 11, 419–464.
- Stock, D., Gibbons, C., Arechaga, I., Leslie, A. G. W. & Walker, J. E. The rotary mechanism of ATP synthase. *Curr. Opin. Struc. Biol.* 2000, 10, 672–679.
- Stock, D., Leslie, A. G. W., & Walker, J. E. Molecular Architecture of the Rotary Motor in ATP Synthase. *Science* 1999, 286, 1700–1705.
- Stoeckenius, W. Bacterial rhodopsins: Evolution of a mechanistic model for the ion pumps Prot. Sci., 1999, 8, 447–459.
- Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., & Banks, L. Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. *Nature* 1998, 393, 229–234.
- Studier, F. W., Rosenberg, A. H., Dunn, J. J., & Dubendorff, J. W. Use of T7 RNA polymerase to direct expression of cloned genes. *Methods in Enzymology* 1990, 185, 60–89, Academic Press.
- Sunde, M., Serpell, L. C., Bartlam, M., Fraser, P. E., Pepys, M. B., & Blake C. C. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. *J. Mol. Biol.* 1997, 273, 729–739.
- Tanford, C. The Hydrophobic Effect; formation of micelles and biological membranes. 2<sup>nd</sup> ed. Wiley 1980.
- Tarn W.-Y. & Steitz. J. A. Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge *Trends Biochem. Sci.* 1997, 22, 132–137.
- Taylor, K. A. & Glaeser, R. M. Electron diffraction of frozen, hydrated protein crystals *Science* 1974, 186, 1036–1037.
- Toyoshima, C., Nakasako, M., Nomura, H. & Ogawa, H. Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution. *Nature* 2000, 405 647
- Trabi, M., & Craik, D. J. Circular proteins no end in sight. *Trends Biochem. Sci.* 2002, **27**, 132–138.
- Tsukihara, T. Aoyama, H., Yamashita, E., Tomizaki, T., Yamaguchi, H., Shinzawa-Itoh, K., Nakashima, R., Yaono, R., & Yoshikawa, S. The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 Å. *Science*, 1996, 272, 1136–1144.
- Tugarinov, V., Hwang, P. M. & Kay, L. E. Nuclear magnetic resonance spectroscopy of high-molecular weight proteins. *Annu. Rev. Biochem.* 2004, 73, 107–146.

- Turner, B. G. & Summers, M. F. Structural biology of HIV. J. Mol. Biol. 1999, 285, 1–32.
- Unger, V. M. Electron cryomicroscopy methods. *Curr. Opin. Struct. Biol.* 2001, **11**, 548–554.
- Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. *Nature*, 1971, 231, 232–235.
- Varghese, J. N., Colman, P. M., van Donkelaar, A., Blick, T. J., Sahasrabudhe, A., & McKimm-Breschkin, J. L. Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. *Proc Natl Acad Sci USA* 1997, **94**, 11808–11812.
- Varghese, J. N., McKimm-Breschkin, J. L., Caldwell, J. B., Kortt, A. A. & Colman, P. M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. *Proteins* 1992, 14, 327–332.
- Varghese, J. N. & Colman, P. M. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 Å resolution. *J. Mol. Biol.* 1991, **221**, 473–486.
- Varghese, J. N., Laver, W. G. & Colman P. M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. *Nature* 1983, 303, 35–40.
- Varshavsky. A., The ubiquitin system. *Trends Biochem. Sci.* 1997, **22**, 383–387.
- Verméglio, A & Joliot, P. The photosynthetic apparatus of *Rhodobacter sphaeroides Trends Microbiol*. 1999, 7, 435–440.
- Viadiu, H., & Aggarwal, A. K. The role of metals in catalysis by the restriction endonuclease BamHI. *Nat. Struct. Biol.* 1998, **5**, 910–6.
- Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. *Nature* 2000, **408**, 307–310.
- Voges, D., Zwickl, P. & Baumeister, W. The 26S proteasome: a molecular machine designed for controlled proteolysis Annu. Rev. Biochem. 1998, 68, 1015–1068.
- Voos, W. Martin, H., Krimmer, T. & Pfanner, N., Mechanisms of protein translocation into mitochondria *Biochim. Biophys. Acta*, 1999, 1422, 235–254.
- Walter, P. & Johnson, A. E. Signal sequence recognition and protein targeting to the endoplasmic reticulum membrane. *Annu. Rev. Cell Biol.* 1995, 10, 87–119.
- Wang, J., Smerdon, S. J., Jager, J., Kohlstaedt, L. A., Rice, P. A., Friedman, J. M., Steitz, T. A. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. *Proc Natl Acad Sci USA* 1994, 91, 7242–7246.
- Wang, Y. & van Wart, H. E. Raman and resonance Raman spectroscopy *Methods Enzymol*. 1993, 226, 319–373, Academic Press.
- Warren, A. J. Eukaryotic transcription factors. *Curr. Opin. Struct. Biol.* 2002, **12**. 107–114.

Watson J. D. & Crick. F. H. C. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. *Nature* 1953, 171, 737–738.

- Weis, W., Brown, J. H., Cusack, S., Paulson, J. C., Skehel, J. J., & Wiley, D. C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid *Nature* 1988, **333**, 426–431.
- Weis. K. Importins and exportins: how to get in and out of the nucleus *Trends Biochem. Sci.* 1998, **23**, 185–189.
- Weiss M. S., Olson, R., Nariya, H., Yokota, K., Kamio, Y., & Gouaux, E. Crystal structure of Staphylococcal Lukf delineates conformational changes accompanying formation of a transmembrane channel. *Nat. Struct. Biol.* 1999, **6**, 134–140.
- Weissmann, C., Enari, M., Klöhn, P.-C., Rossi, D. & E. Flechsig. E. Transmission of prions. *Proc. Natl. Acad. Sci. USA* 2002, 99, 16378–16383.
- Weissmann, C., Molecular Genetics of Transmissible Spongiform Encephalopathies. *J. Biol. Chem.* 1999, **274**, 3–6.
- Wetlaufer, D. B. Ultraviolet spectra of proteins and amino acids. *Adv. Prot. Chem.* 1962, **17**, 303–390.
- White, S. H. & Wimley, W. C. Membrane protein folding and stability: Physical principles. Ann. Rev. Biophys. Biomol. Struct. 1999, 28, 319-6.
- Wiley D. C., & Skehel J. J. The structure and function of the haemagglutinin membrane glycoprotein of influenza virus. *Annu. Rev. Biochem.* 1987, **56**, 365–94.
- Wilmot, C. M. & Thornton, J. M. Analysis and prediction of the different types of beta-turn in proteins. *J. Mol. Biol.* 1988, 203, 221–232.
- Wimberley, B. T., Brodersen, D., Clemons, W., Morgan-Warren, R., Carter, A., Vonrhein, C., Hartsch, T. & Ramakrishnan, V. Structure of the 3OS Ribosomal Subunit. *Nature* 2000, **407**, 327–339.
- Wimley, W. C. The versatile β-barrel membrane protein *Curr. Opin. Struct. Biol.* 2003, **13**, 404–411.
- Wlodawer. A. & Erickson, J. W. Structure based inhibitors of HIV-1 proteinase. *Annu. Rev. Biochem.* 1993, **62**, 543–585.
- Woody, R. W. Circular dichroism. *Methods Enzymol*. 1995, **246**, 34–71, Academic Press.
- Wower, J. Rosen, K. V., Hixson, S. S. & Zimmermann, R. A. Recombinant photoreactive tRNA molecules as probes for cross-linking studies. *Biochimie* 1994, **76**, 1235–1246.
- Wuthrich, K. NMR of Proteins and Nucleic Acids. John Wiley & Sons. 1984.
- Xu, Z., Horwich A. L., & Sigler P. B. The crystal structure of the asymmetric GroEL-GroES-(ADP)<sub>7</sub> chaperonin complex. *Nature*. 1997, **388**, 741–750.
- Yates. J. R. Mass spectrometry: from genomics to proteomics. *Trends Genet*. 2000, **16**, 5–8.

- Yoshida, M., Muneyuki, E., & Hisabori, T. ATP synthase–a marvellous rotary engine of the cell. *Nat. Rev. Mol. Cell Biol.* 2001, 2, 669–77.
- Yoshikawa, S. Beef heart cytochrome oxidase. *Curr. Opin. Struct. Biol.* 1997, **7**, 574–579.
- Zahn, R., Liu, A., Luhrs, T., Riek, R., von Schroetter, C., López García, F., Billeter, M., Calzolai, L., Wider, G. & Wüthrich, K. NMR solution structure of the human prion protein. *Proc. Natl. Acad. Sci USA* 2000, 97, 145–150.
- Zhang, D., Kiyatkin, A., Bolin, J. T. & Low, P. S. Crystallographic Structure and Functional Interpretation of the Cytoplasmic Domain of Erythrocyte Membrane Band 3. *Blood* 2000, 96, 2925–2933.
- Zouni, A., Horst-Tobias, W., Kern, J., Fromme, P., Krauss, N., Saenger, W., & Orth, P. Crystal structure of photosystem II from Synechococcus elongatus at 3.8 Å resolution. *Nature* 2001, **409**, 739–743.

Entries are arranged alphabetically with page numbers in italic indicating a presence in a figure whilst bold type indicates appearance in a table. Greek letters and numbers are sorted as if they were spelt out; β sandwich becomes beta-sandwich, 5S rRNA appears where five S rRNA is normally located in listings. Positional characters are ignored; so 2-phosphoglycolate appears under phosphoglycolate.

A site, 273	A2451, 279	Albumin, 1, 33
$A_{\beta}$ protein, 430, 468–470	A2439, 279	Aldol condensation, 97
AAA superfamily, 308	A2486, 282	Alignment methods, 172
Ab intio, 186	Adenosine monophosphate	Aliphatic amino acids, 2
Abrin, 228	pK of N1 atom, 280	Alkaline phosphatase, 20
Absorbance, 379–381	structure of AMP, 282	Allele, 475, 476
aromatic amino acids, 381	Adenosine triphosphate, synthesis	Allosteric regulation, 72-
Beer-Lambert's Law, 32	allosteric activation, 234	Allostery, 189
data on aromatic amino acids, 30	transition state analogue, 148	Allysine, 97
excitation and emission, 380	Adenylate cyclase, 116–117, 439–440	$\alpha$ helix, 41–45
heme groups, 67	signaling pathway, 120	dihedral angles, 43
spin multiplicity, 380	Adenylation, 292	dimensions, 43
vibrational states, 380	5-adenylyl-imidophosphate, 148	dipole moment, 56
wavenumber, 381	Adiabatic chamber, 399	formation, 409
Acetazolamide, 205	Adrenaline, 116	hydrogen bonding, 41-
Acetylation, 270, 292	Aequorea victoria, 383-384	side chains, 42-43
Acetylcholinesterase, 191	Aerobic, 126	space-filling view, 4
specificity constant, 201	Affinity chromatography, 332–334	structure, 42
Acid base catalysis, 203–204	types of ligands, 334	α-secretase, 469
Acid base properties of amino acids,	Affinity labeling, 216, 279	$\alpha_1$ -antitrypsin, 475–478
14–15	Aggregation, 416–417	α-haemolysin, 130–131
Acquired immune deficiency syndrome,	in disease states, 427–428	Alveoli, 475
443-457	Agonists, 116	Alzheimer's disease, 422
recognition and identification, 443	AIDS, see Acquired immune deficiency	468-470
Acrylamide, 335, 381	syndrome	diagnostic markers, 46
Activated state (complex), 196	Alanine	genetic basis, 468-470
Activation energy, 195–196	chemical properties, 24	Amidation, 292
Active site	D isomer, 35	Amide exchange, 411–4
Gln-tRNA synthetase, 221	data, <b>18</b>	Amide, 25–26, 43, <b>56</b>
lysozyme, 210	genetic code specification, 268	Amino acid residue, 17
serine proteases, 212	helix/sheet propensity, 41	Amino acids
triose phosphate isomerase, 216	hydropathy index, 112	acid-base properties, 1
tyrosyl tRNA synthetase, 219	optical rotation, 34	chemical and physical
Acyl chains, 107	prevalence in secondary structure,	detection of, 32–34
unsaturation, 106	180	formation of peptide b
Acyl-enzyme intermediate, 214	spatial arrangement of atoms, 16	genetic code specificat
Adenine, 247	stereoisomers, 34	non-standard, 35–36
A76, 269–270	titration curve, 14	optical rotation, 34

ent methods, 172-173 c amino acids, 24 phosphatase, 207, 339 175, 476 ic regulation, 72-74, 231-237 y, 189 , 97 41 - 45ral angles, 43 sions, 43 moment, 56 tion, 409 gen bonding, 41-43 hains, 42-43 -filling view, 4 ure, 42 ase, 469 ypsin, 475-478 olysin, 130–*131* 475 ner's disease, 422, 427, 430, -470ostic markers, 468 ic basis, 468-470 on, 292 exchange, 411-412 25–26, 43, **56** acid residue, 17 acids pase properties, 14–15 ical and physical properties, 23-32 ion of, 32–34 tion of peptide bonds, 16-17 ic code specification, 268 tandard,  $\bar{3}5-36$ l rotation, 34

Amino acids (continued)	APP see amyloid precursor protein,	ATP synthetase, 132, 144–152, 173
pK values for ionizable groups, <b>15</b>	468-469	Boyer model, 146
quantification, 34	Aquaporin, 377	chemical modification, 146, 151
reaction with tRNA,	Arabidopsis thaliana, 169	composition, 145
single letter codes, 40	Arachidonic acid, <b>107</b> , 229–230	conformational changes in, 146-148
solubility, 13	Arber, W., 221	cooperativity, 146
stereochemical representation, 15	Archae, 128, 304, 309, 417, 422	γ subunit, 150
stereoisomerism, 34–35	Archaebacteria see archae	mechanism of ATP synthesis, 146-147
three letter codes, 40	Arginine	nucleotide binding site, 149
Amino acyl AMP, 268	charge-charge interactions, 55–56	proton translocation, 149
Amino acyl tRNA synthetases, 218,	chemical properties, 28–29	structure of F <sub>1</sub> ATPase, 147–151
268–269	data, 18	structure of $F_0$ , 150–152
catalysis, 268	genetic code specification, 268	yeast enzyme, $156$
class I and class II tRNA synthetases, 220	helix/sheet propensity, <b>41</b>	ATP, see adenosine triphosphate
classification, 220, 269	hydropathy index, 112	ATPase family, 152–156, 308
glutaminyl tRNA synthetase, 220–221	optical rotation, 34	•
transition state analogue, 221	prevalence in secondary structure, <b>180</b>	Autolysis, 238, 449
tyrosyl tRNA synthetase, 218–220	trypsin substrate, 227	Aval, 222
AMP, see Adenosine monophosphate,	Armadillo motifs, 301	3'-azido-3_deoxythymidine, see AZT
Amphiphiles, 122	Aromatic amino acids,	AZT, 453
Ampicillin, 315	Aromatic residues, 30	Azurin, 359
Amplification (PCR), 169–170		
Amplitude, 353–354	Arrhenius equation, 195 Arrhenius, S.A., 195	B cells, 75
AMP-PNP, see 5-adenylyl-imidophosphate		BACE, see β secretase
• • • • • • • • • • • • • • • • • • • •	Arylation, 29	Bacillus caldolyticus, 397–398
Amyloid precursor protein, 469	Ascorbate, 289	Bacillus subtilis, 397–398
Amyloid, 427	Asparagine chemical properties, 25	Bacterial reaction centre, 119–126
structure of fibril, 431	data, 18	crystallization, 123
plaques, 468	helix/sheet propensity, 41	cytochrome subunit, 125
Amyloidogenesis, 427–431	hydropathy index, 112	electron transfer, 121–122
diseases arising from, 428	genetic code specification, 268	transmembrane helices, 125
involving transthyretin, 428–430	prevalence in secondary structure, <b>180</b>	Bacteriochlorophyll, 121
prion based, 431–435	location in turns, 47–48	protein crystallization of, 359
Anacystis sp., 164	N linked glycosylation, 98, 290	Bacteriophage $\lambda$ , 64
Analytical centrifugation, 322–323	Aspartate	defective groE operon, 416
Anfinsen cage, 420	binding domain in ATCase, 236	Bacteriophage T4, 266
Anfinsen, C., 402, 416, 423	chemical properties, 25	Bacteriophage T7, 256
Angiotensin, 287	data, <b>18</b>	Bacteriorhodopsin, 114–115
Angstrom, 18	genetic code specification, 268	light driven pump, 115
Angstrom, A.J., 478	helix/sheet propensity, 41	
Anisotropy, 383	hydropathy index, 112	protein folding, 422–425
Ankyrin, 111	in HIV protease, 450–452	structure, 117
Anoxygenic photosynthesis, 128	in lysozyme catalysis, 211–212	transmembrane organization, 116
Antagonists, 116	in T7 RNA polymerase, 256	Baldwin, R., 414
Antechambers, 306	prevalence in secondary structure, 180	BamHI, 222
Antibiotics, 278–279,	Aspartate transcarbamoylase, 6, 234–237	signature sequence, 224
selection of transformants, 315	allosteric behaviour, 234	Band 3 protein, 111
studying ribosomal structure, 279	binding of carbamoyl phosphate, 234	Barnase, 405–408
Antibody, 75–80 see immunoglobulins	conformational change, 237	Beer Lamberts Law, quantification of amino
Anticodon loop, 268–269	feedback inhibition, 235	acids, 32
Anticodon, 283	quaternary structure, 235	Benzamidine, 227
Antigen, 75	Aspartic acid see aspartate	Benzene, 55
flu virus antigens, 464	Aspartyl protease, 450–452, 470	Benzopyrene, 454
Antigenic determinants, 77	Aspirin, 228–230	Bernal, J.D., 353
Antigenic drift, 464	AspN, 166	Berzelius, J. J., 1
Antigenic shift, 464	Astbury, W.T., 92	β adrenergic receptor, 117
Antigenic sub-types, 465	Astrocytosis, 434	β barrel, 47, 180
Antimycin A, 134	Asymmetric centres, 37	GFP, 383
Antiport, 154	Ataxia, 433	gp120 454-455
Apoenzyme, 192	Atherosclerosis, 99	Gro-ES, 417
Apoptosis, 238–239, 310, 471	ATP synthase, see ATP synthetase	α-haemolysin, 130–131

ODCase, 205	Bromoaspirin, 228	Catalytic triad, 213
porins, 128–132	Brønsted equation, 407	CBCA(CO)NH, 373
triose phosphate isomerase, 47	Brownian diffusion, 320, 382	CBCANH, 373
β blocker, 116	Browsers, 185	CCD, see charge coupled device
β endorphin, 289	BSA, see bovine serum albumin	CCK motif, 81
β helix, 61–62, 430–431	BSE, see bovine spongiform encephalopathy	CCM, see common core motif
β lactamase, 181	Buchner, E., 2, 189	CD4, 446
β lipotrophin, 289	Buoyant density, 320	cdc genes, 249
β meander, 59, 61, 222	Burley, S.K., 259	Cdks see Cyclin dependant kinases,
β propeller motif, 61, 180, 463	Burnet, M., 75	Celebrex <sup>©</sup> 231
β sandwich, 59, 180	Bursa of Fabricius, 75	Cell cycle, 247–250
gp120, 454-455		DNA replication, 253
p53, 472		mitosis, 247
β scaffold, 430	C peptide, 456	Cell disruption, 319
β secretase, 469–470	Caenorhabditis elegans, collagen genes, 93	Cell division, 249, 253
β sheet, 45–47	genome, 169	Cell membrane, 110
β strand, 45–46	Cahn Ingold Prelog, 34	Centrifugation, 320–323,
dimensions, 43	Calcium binding domains, 101,415	Chair conformation, 211
β turn, 47	Calmodulin, 25	Chaotropes, 326
$\beta$ - <i>N</i> -oxalyl L- $\alpha$ , $\beta$ -diamino propionic acid,	Calorimetry, 109	Chaperones, 416–422
36	differential scanning, 399-400	catalytic cycle, 419–422
B factor, 357	Canavanine, 36	crystal structure, 420
Bilayers, 107–109	Cancer, 11, 441	domain movements, 418
Bimolecular reactions, 194–195, 208,	cdk-cyclin complex regulation, 252-253	
	cervical, 475	electron microscopy, 417–419
382 Bi-information 50, 184, 187	involvement of p53, 474	GroEL-GroES, 417–422
Bioinformatics, 50, 184–187	Kaposi's sarcoma, 445	mitochondrial, 297–298
Biotin, 193	Cannibalism, 433	organization, 418
2,3-bisphosphoglycerate, 73, 74	Capsid, 377	small heat shock proteins, 417
Bisacrylamide, 335	TMV, 443	thermosome, 422
Biuret, 33	HIV, 445, 446	Chaperonin, 416
Blobel, G., 293		Charge coupled devices, 170,
Bloch, F., 360	p17, 446–447	349
BLOCKS database, 175	Carbania anhydraga 74 170	Charge-charge interactions, 55–56
Blood clotting cascade, 237, 239	Carbonic anhydrase, 74, <b>179</b>	Checkpoints, 249
Blood clotting factors, 318, 239	catalysis by, 204–207	Chemical kinetics, 192–195
BLOSUM, 175	imidazole ligands in active site, 206	Chemical modification, 29, 205
Blue green algae, 126	pH dependent catalysis, 205	in RNase A, 202
Boat conformation, 211	specificity constant, 201	Chemical shift, 362
Bohr effect, 74	Carboxypeptidase A, 25, 192, 193	table of <sup>13</sup> C chemical shifts, 372
Bohr, C., 74	Cardiac glycosides, 154	table of <sup>15</sup> N chemical shifts, 371
Boltzmann distribution, 380	Cargo proteins, 300	table of <sup>1</sup> H chemical shifts, 366
Boltzmann's constant, 196, 323	Carotenoids, 121	Chemiosmosis, 145
Bombyx mori, 92, 93	Cartoon representation, 13, 46	Chevron plot, 405
Bordetella pertussis, 440	Cascade, 237, 239	χ angle, 43
Bovine pancreatic trypsin inhibitor, 53, 224,	CASP, 186	Chiral, 19, 34–35
468	Caspases, 238–239, 310	Chitinase, 319
Bovine serum albumin, 33	Catabolism, 189	Chloroamphenicol, 278, 279
Bovine spongiform encephalopathy,	Catalase, sedimentation coefficient, 324	Chlorophyll, 121
466-468	specificity constant, 201	in photosystem II, 127
Boyer, P.D., 146	Catalysts, 197	special pair, 125
BPTI, see Bovine pancreatic trypsin	Catalytic mechanisms, 202-209	voyeur, 125
inhibitor	acid-base catalysis, 202-203	Chloroplast
Bragg, W.H., 349	covalent catalysis, 203	lipid:protein ratios, 109
Bragg, W.L. 349	electrostatic catalysis, 205	RNA polymerases, 257
Branch point, 266	metal ion catalysis, 204–205	schematic diagram, 299
Brandts, J.F., 414	preferential binding of transition state,	sorting and targeting, 299
Bravais Lattices, 352	207–209	stromal proteins, 299
Brenner, S., 266	proximity and orientation effects,	Tic system, 299
Briggs, G.E., 199	206–207	Toc complexes, 299
Bromelain, 459, 460	rate enhancements, 197	Cholera toxin, 120, 439–440
	, */'	

Coiled coil, 86–90 Chou, P.Y., 182 Chou-Fasman algorithm, 183–184 Chromatography, 250–333 affinity, 352–333 cation exchange, 167, gel filtration principle, 330 hydrophobic interaction, 331 ideal separation, 327 ion exchange, 329–330 molecular mass estimation, 331 response place, 331–332 size exclusion, 328 Chromophore, 33, 12 Chromosome, 247 Chromosome			
Chon-fasman algorithm, 183–184 Chromatography, 326–333 affility, 332–333 cation exchange, 167, gel filtration principle, 320 hydrophobic interaction, 331 ideal separation, 327 ion exchange, 239–330 molecular mass estimation, 331 protein hydrophost, 167 reverse plause, 331–332 size exclusion, 330–331 system and instrumentation, 328 Chromophore, 33, 121 Chromosome, 247 Chromicobstructive pulmonary disease, (COPD) 475 Chrymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of exters, 201 inhibitor, 466 PDB file, 57 proteohytic activation, 237–238 structural homology, 177, 179 PCK binding, 213 cf repressor, 64 Croke, F.H.C., 2, 87, 247, 266, 267 Chromophore, 331 coldas exparation, 327 cloid shock proteins, 89 connective tissue, 93 disease states associated with, 99–100 genes, 93 hydrolystation, 289 procollagen, 22–100 abundance, 93 bigorythesis, 97–99 connective tissue, 93 disease states associated with, 99–100 genes, 93 hydrolystation, 289 procollagen, 22–100 abundance, 93 bigorythesis, 97–99 connective tissue, 93 disease states associated with, 99–100 genes, 93 hydrolystation, 289 procollagen, 22–100 abundance, 93 bigorythesis, 97–99 connective tissue, 93 disease states associated with, 99–100 genes, 93 hydrolystation, 289 procollagen, 22–100 structure and function, 94–97 thermal denaturation, 96 PDB file, 57 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cf repressor, 64 Crock, F.H.C., 2, 87, 247, 266, 267 hydrolystation, 89 procollagen, 22–100 abundance, 93 bigorythesis, 97–99 connective tissue, 93 disease states associated with, 99–100 genes, 93 hydrolystation, 289 procollagen, 22–100 structure and function, 94–97 thermal denaturation, 96 triple helix, 95 competent leels, 35 Competent leels, 315 Com	Cholera, 439	Coiled coil, 86–90	Creutzfeldt, H.G., 433
Chromatography, 326–333 adinity, 323–333 cation exchange, 167, gel filtration principle, 330 hydrophobic interaction, 331 ideal separation, 327 ion exchange, 329–330 molecular mass estimation, 331 protein hydrolysate, 167 reverse phase, 331–332 size exclusion, 330–331 system and instrumentation, 328 Chromophore, 33, 121 chromosome, 247 Chronic obstructive pulmonary disease, (COPD) 475 Chymotrypsin, 46, 287 active sites substrate specificity, 272 arrangement of catalytic triad, 213 hydrolysis of selers, 201 inhibitor, 406 eTP family, 252 crice effect, 205 Circular dichroism, 387 spectra, 387 circe effect, 205 Circular dichroism, 387 spectra, 387 circe for footing of Darvulins, 416 Extrase peptidy protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 spectra, 387 cis somer cis ring, 418, 419 Circi acid cycle, 190 Circuline, 38 (Clostripan, 166 Cloverleaf structure, 268, 269 Codon, 268, Coelemetrazine, 288 (Coolen, 268, Coelemetrazine, 286, Coelemetrazine, 286 (Coolen, 268, Coelemetrazine, 286 (Coolen, 268 (Coolen, 268 (Coolen, 269 (Coolen, 268 (Coolen, 269 (Co	Chou, P.Y., 182	ATP synthetase, 147, 150	Creutzfeldt-Jakob disease, 433
Chromatography, 326–333 adinity, 323–333 cation exchange, 167, gel filtration principle, 330 hydrophobic interaction, 331 ideal separation, 327 ion exchange, 329–330 molecular mass estimation, 331 protein hydrolysate, 167 reverse phase, 331–332 size exclusion, 330–331 system and instrumentation, 328 Chromophore, 33, 121 chromosome, 247 Chronic obstructive pulmonary disease, (COPD) 475 Chymotrypsin, 46, 287 active sites substrate specificity, 272 arrangement of catalytic triad, 213 hydrolysis of selers, 201 inhibitor, 406 eTP family, 252 crice effect, 205 Circular dichroism, 387 spectra, 387 circe effect, 205 Circular dichroism, 387 spectra, 387 circe for footing of Darvulins, 416 Extrase peptidy protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 spectra, 387 cis somer cis ring, 418, 419 Circi acid cycle, 190 Circuline, 38 (Clostripan, 166 Cloverleaf structure, 268, 269 Codon, 268, Coelemetrazine, 288 (Coolen, 268, Coelemetrazine, 286, Coelemetrazine, 286 (Coolen, 268, Coelemetrazine, 286 (Coolen, 268 (Coolen, 268 (Coolen, 269 (Coolen, 268 (Coolen, 269 (Co	Chou-Fasman algorithm, 183-184	gp41 of HIV, 456	Crick, F.H.C., 2, 87, 247, 266, 267
affinity, 332–333 cation exchange, 167, gel filtration principle, 320 hydrophobic interaction, 331 ideal separation, 237 ion exchange, 239–330 molocular mass estimation, 331 protien hydrophosic interaction, 331 system and instrumentation, 328 Chromophore, 33, 121 Chromosome, 247 Chromo			
cation exchange, 167, ged filtration principle, 330 hydrophobic interaction, 331 cleal separation, 327 join exchange, 29–300 molecular mass estimation, 331 protein hydrolysate, 167 reverse phase, 331–332 size exclusion, 330–331 system and instrumentation, 328 exchange, 247 Chromosome, 247 Chromosome, 247 Chromosome, 247 Chromosome, 247 Chromosome, 247 Chromosome, 248 procedingen, 289 procedingen, 280 procedinge			
gel filtration principle, 330 hydrophobic interaction, 331 ideal separation, 327 ion exchange, 329–330 molocular mass estimation, 331 protein hydrophysite, 167 reverse phase, 331–332 system and instrumentation, 328 Chromophore, 33, 121 Chromosome, 247 Chromic obstructive pulmonary disease, (COPD) 475 Chromic obstructive pulmonary disease, (COPD) 475 Chromic obstructive pulmonary disease, (COPD) 475 Chromophore, 34, 213 hydrolysis of esters, 201 inhibitor, 40, 60 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 phydrolysis, 64 esters, 201 croplect and factorion-dopsin, 423 folding of Omph, 424 folding of Omph, 424 for studying protein folding, 414–416 parvalins, 416 Est-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvalins, 416 Est-trans peptidyl proline isomerase, 59 in protein folding, 314–316 Cloring al. 416 FKS06 binding proteins, 416 Cloring al. 416 FKS06 binding proteins, 416 Cloring al. 416 PkS06 binding proteins, 416 Cloring al. 416 Cloring al. 416 Cloring al. 416 PkS06 binding proteins, 416 Cloring al. 416 Cloring			
hydrophobic interaction, 331 ideal separation, 327 join exchange, 329–330 molecular muss estimation, 331 protein hydrolysate, 167 teverse phase, 331–332 size exclusion, 330–331 system and instrumentation, 328 Chromophore, 33, 121 Chromosome, 247 Chromosome, 247 Chromosome, 247 Chromosome, 247 Chromosome, 247 Chromosome, 247 Chromosome, 248 procedlagen, 289 processing, 98 procedlagen, 289 processing, 98 proce			
ideal separation, 327 ion exchange, 329–330 molecular mass estimation, 331 protein hydrohysate, 167 reverse phase, 331–332 size exclusion, 330–331 system and instrumentation, 328 Chromophore, 33, 121 Chromosome, 247 Chromic obstructive pulmonary disease, (COPD) 475 Chymotrysin, 46, 287 clive site substrate specificity, 212 arrangement of catalytic triad, 213 hydrohysis of setsers, 201 inhibitor, 406 CPP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of DompA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis sing, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein jodding, 415–416 parvalins, 416 Circi acid cycle, 190 Circuliars, 82 ClD see Creutzfeld Jacob disease Clathrates, 54 Clathria coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 286 Clostripain, 166 Cloverleal structure, 268, 269 CMC, see critical micelle concentration Cobat, 193 Convergent case also cyclo-oxygenases, 230 Convergent case oxygenases, 230 Convergent case oxygenases, 230 Cox2-see also cyclo-oxygenases, 230 Cox2-see also cyclo-oxygenases		• .	
ion exchange, 329–330 molecular mass estimation, 331 protein hydrolysate, 167 reverse phase, 331–332 size exclusion, 330–331 system and instrumentation, 328 Chromospore, 33, 121 Chromosome, 247 Chromosome, 248 Chromosome, 249 Crystal luttice, 372 Crystal violate, 377 sinstrumentation, 376 proteosome, 308, 399, 418 ribosome, 271 sample proparation, 376 Crystal violate, 377 sinstrumentation, 376 proteosome, 308, 399, 418 ribosome, 271 sample proparation, 376 Crystal violatice, 377 sinstrumentation, 369 Crystal violatice, 377 chromosome, 299 related disorders, 100–102 Competitive and function, 94–97 thermal denaturation, 96 triple helix, 95 competitive early disorders, 100–102 Competitive early disorders, 100–102 Competitive early minitive and function, 252 Cyclin dependant stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 connective tissue disorders, 100–102 Competitive expression, 385–360 Contoxinos, 385–360 Contoxinos, 385–360 Colonosome, 38, 399, 418 ribosome, 271 sample proparation, 376 crystal luttice, 372 crystal luttice, 352 Crystal violation, 358	* *		•
molecular mass estimation, 331 protein hydrolysate, 167 reverse phase, 331–332 size exclusion, 330–331 system and instrumentation, 328 Chromophore, 33, 121 processing, 98 phydroylation, 289 processing, 98 processing,	<u>*</u>		•
protein hydrolysate, 1.67 reverse phase, 331–332 size exclusion, 330–331 system and instrumentation, 328 Chromophore, 33, 121 Chromosome, 247 Chromic obstructive pulmonary disease, (COPD) 475 Chymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 466 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP family, 252 clircular dichroism, 385–387 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 spectra, 387 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeld Jacob disease Clabrates, 54 Clarbrian, 28 CID see Creutzfeld Jacob disease Clarbrians, 54 Cloning, 314–316 Clostripain, 166 Colevired service, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coenzyme Q, 193, see also ubiquinone  disease states associated with, 99–100 gissees, 93 hydroxylation, 289 processing, 98 procociang, 289 procociang, 280 procociang, 289 procociang, 289 procociang, 289 procociang, 289 procociang, 289 procociang, 289 prococian, 93 prococian	_	•	
disease states associated with, 99–100 genes, 93 system and instrumentation, 328 Chromophore, 33, 121 genes, 93 hydroxylation, 289 processing, 98 procollagen, 289 procollagen,			
size exclusion, 330–331 system and instrumentation, 328 Chromophore, 33, 121 Chromosome, 247 Chronic obstructive pulmonary disease, (COPD) 475 Chymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 spectra, 387 circ is somer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeld Lacob disease Clathrates, 54 Clathrate, 54 Clathrate, 54 Clathrate, 54 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coenzyme Q, 193, see also ubiquinone COX2, see also cyclo-oxygenases, 230 CoX2, see also cyclo-oxygenases, 230 contact order, 410 Cox2, see also cyclo-oxygenases, 230 contact order propertiens, 411 Cox2, and properties, 412 compared properties, 413 complex II, see succinate dehydrogenase complex II, see oycothrome bc; complex complex II, see oycothrome oxidase complex II, see o	protein hydrolysate, 167	dimensions, 94	proteasome, 308, 309, 418
system and instrumentation, 328 Chromophore, 33, 121 Chromosome, 247 Chronic obstructive pulmonary disease, (COPD) 475 Chymotypsin, 46, 287 active sits substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl represor, 64 Clp family, 252 circe effect, 205 Circular dichroism, 385–387 folding of Date-teriorhodopsin, 423 folding of DompA, 424 for studying protein folding, 404, 490 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cist-rans peptidyl proline isomerase, 59 in protein folding, 415–416 ENSO6 binding proteins, 416 EKSO6 binding proteins, 416 EKSO6 binding proteins, 416 EKSO6 binding proteins, 416 Clostria, 28 Cloning, 314–316 Clostria, 38 Colornya, 62, 83 Coevalue (activation), 237–238 corrained (activation)	reverse phase, 331–332	disease states associated with, 99–100	ribosome, 271
Chromophore, 33, 121 Chromosco, 247 Chronic obstructive pulmonary disease, (COPD) 475 Chymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 clarepressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of DmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 FKS06 binding proteins, 416 Citric acid cycle, 190 Cirruline, 38 ClD see Creutzfeld Jacob disease Clathrates, 54 Clathria coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 COMPC Compex II, see socyto-convenients, 363 Covalent catalysis, 204 Cooperativity, 70, Copper, 7 binuclear cluster, 139 co-factor role, 193 Covalent modification, 237–241 Cowpox, 75 C	size exclusion, 330–331	genes, 93	sample preparation, 376–377
Chromicosome, 247 Chromic obstructive pulmonary disease, (COPD) 475 Chrymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of bacteriorhodopsin, 423 folding of bacteriorhodopsin, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein ploling, 415–416 parvulins, 416 FK506 binding proteins, 416 Citric acid cycle, 190 Citruline, 38 Clathrate, 54 Clathria coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 252 Complex IV. see eytochrome oxidase Complex IV. see eytochrome oxidase Complex IV. see eytochrome oxidase Complex IV. see e	system and instrumentation, 328	hydroxylation, 289	tubulin structure, 377–379
Chromicosome, 247 Chromic obstructive pulmonary disease, (COPD) 475 Chrymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of bacteriorhodopsin, 423 folding of bacteriorhodopsin, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein ploling, 415–416 parvulins, 416 FK506 binding proteins, 416 Citric acid cycle, 190 Citruline, 38 Clathrate, 54 Clathria coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 252 Complex IV. see eytochrome oxidase Complex IV. see eytochrome oxidase Complex IV. see eytochrome oxidase Complex IV. see e	Chromophore, 33, 121	processing, 98	Crystal lattices, 352
Chronic obstructive pulmonary disease, (COPD) 475 Chymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 ctrepressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 416 FKS06 binding proteins, 416 Citric acid cycle, 190 Cirruline, 38 Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coloda, 288 Coenzyme Q, 193, see also ubiquinone COX-2, see also cyclo-oxygenases, 230 Concaryon COX-2, see also cyclo-oxygenases, 230 conficuation, 94–97 thermal denaturation, 96 types, 94 Citry, 49 Common core motif, 22 Commence rells, 315 Compentity enzyme inhibition, 225–226, 453 compentity enzyme inhibition, 225–226, 453 Competitive enzyme inhibition, 225–226			•
COPD) 475 Chymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of Dapha, 424 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis is ing, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Cist-cand performance, 59 in protein folding, 416 parvulins, 416 Citric acid cycle, 190 Citruline, 38 Clahartas, 54 Claharia coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 28 Coenzyme Q, 193, see also ubiquinnor  thermal denaturation, 96 thermal denaturation, 96 triple helix, 95 types, 94 Common core motif, 222 Competent cells, 315 Competent cells, 315 Competent cells, 315 Competent cells, 315 Complementarity determining regions (CDRs), 77 Complex II, see valcothrome be, complex Complex III, see eytochrome be, complex Complex III, see eytochrome be, complex Conformational stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 Conserved residues, 172 C			
chymotrypsin, 46, 287 active site substrate specificity, 212 arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cf repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of DompA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 spectra, 387 spectra, 387 clistrans peptidyl profine isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citrullare, 38 Clonger as functional stability, 396 Clostrans peptidyl profine isomerase, 59 in protein folding, 38 Clostrans peptidyl profine isomerase, 59 in protein folding, 38 Clostrans petidyl protein sease Clathrates, 54 Clathriac coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Clowerleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coolog, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  thermal denaturation, 96 triple helix, 95 types, 94 Common core motif, 222 Competent cells, 315 Competent cells, 315 Competent cells, 315 Competent cells, 315 Complementarity determining regions (CDRs), 77 Complex II, see vxDH-ubiquinone oxidoreductase Complex II, see eytochrome oxidase Complex II, see cytochrome oxidase Complex II, see cytochrome oxidase Complex III, see cytochrome oxidase Complex III, see cytochrome oxidase Complex IV, see oxidated ehydrogenase Complex IV, see cytochrome oxidase Complex IV, see oxidated ehydrogenase Comple			
arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 Cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of DmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Eirc acid cycle, 190 Citric acid cycle, 190 Compassis Blue, 33, 336 Coupline tyric tyric tyric tyric tyri			
arrangement of catalytic triad, 213 hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 Proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of DmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cls isomer cis ring, 418, 419 Cistrans peptidyl proline isomerase, 59 in protein folding, 715–416 parvulins, 416 EFK506 binding proteins, 416 Citric acid cycle, 190 Citruline, 38 CID see Creutzfeldt Jacob disease Clathrate, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Complex II, see succinate dehydrogenase conformational stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 connective tissue disorders, Contoxins, 178 Conserved residues, 172 Connus, 178 Convergent evolution, 179 Contact order, 410 Comms, 178 Convergent evolution, 179 Cleland's reagent, see also dithiothreitol, 28 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268 Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  vipe, 94 Competitive enzyme inhibition, 225–226, Competitive enzyme inhibition, 225–226, Complex II, see interaction in insignaling, 116–119 Cyclic GMP, 118 Cyclic mucleotides, 202 Cyclic proteins, 81 Cyclic marke, 26 Cyclic proteins, 25 complex II, see succinate dehydrogenase Complex II, see eytochrome oxidase Complex II, see eytochrome oxidase Conformational stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 Connus, 178 Consecuted issue disorders, Connoctive tissue disorders, Connoctive tissue disorders, Conotective tissue disorders, Conotective tissue disorders, Conotective tissue disorde			
hydrolysis of esters, 201 inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of bacteriorhodopsin, 423 folding of DompA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 346 FK506 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Cool, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone Compenentarity determining regions (CDRs), 77 Complementarity determining regions (CDRs), 77 Complementarity determining regions (CDRs), 77 Complementarity determining regions (CDRs), 77 Complex II, see NADH-ubiquinone oxidoreductase Complex II, see veytochrome oxidase Complex II, see cytochrome oxidase Complex II, see eytochrome oxidase Complex IV, see cytochrome oxidase Complex III, see ye cytochrome oxidase Complex III, see cytochrome oxidase Complex III, see ye cytochrome oxidase Complex III, see succinate dehydrogenase Complex III, see succinate dehydrogenase Complex III, see oxtochrome bc <sub>1</sub> complex III, see succinate dehydrogenase Complex III, see oxtochrome oxidase Conformational changes, 251–252 Toomorational chan	- · · · · · · · · · · · · · · · · · · ·	1	
inhibitor, 406 PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP Family, 252 circe effect, 205 Circular dichroism, 385–387 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis is isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 FKS06 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloverleaf structure, 268, 269 Cloverleaf structure, 268, 269 CMC, see critical miscelle concentration Cobalt, 193 Coolenterazine, 383 Coenzyme Q, 193, see also ubiquinone  CON-2, see also cyclo-oxygenases, 230 Coenzyme Q, 193, see also ubiquinone  Compessible with ends, 415 Competitive enzyme inhibition, 225–226, Complex III, see cytochrome oxidase complex II, see whaDH-ubiquinone oxidoverdeutase  Complex II, see PADH-ubiquinone oxidase clambridge enses (Complex III, see cytochrome oxidase  Complex III, see destical dehydrogenase  Complex III, see cytochrome oxidase  Complex III, see disprice in folding, 410  Contact offer, 410  Contact order,	• •	• •	•
PDB file, 51 proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 Cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of DompA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 FFX506 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 CJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coolentervazine, 383 Coenzyme Q, 193, see also ubiquinone  Complex II, see NADH-ubiquinone oxidoreductase Complex III, see eytochrome oxidase Complex III, see eytochr	•		•
proteolytic activation, 237–238 structural homology, 177, 179 TPCK binding, 213 cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of Datcreirorhodopsin, 423 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 ciris isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 416 FK506 binding proteins, 416 Citric acid cycle, 190 Citruline, 38 Clathrates, 54 Clathrin coated vesicles, 297 Clathrin coated vesicles, 297 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Come, 28 Come, 28 Comelex II, see succinate dehydrogenase Complex III, see cytochrome oxidase complex III, see eyetochrome oxidase Complex III, see eyetochrome oxidase Complex IV, see cytochrome oxidase Complex IV, see cytochrome oxidase Complex IV, see cytochrome oxidase Complex III, see veytochrome oxidase Complex IV, see cytochrome oxidase C			, ,
structural homology, 177, 179 TPCK binding, 213 Cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Cirtularic acid cycle, 190 Citrulline, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 CIOning, 314–316 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration CDalt, 193 Coenzyme Q, 193, see also ubiquinone  Complex II, see extochrome bc1 complexs Complex III, see tytochrome bc2 complex Complex III, see tytochrome bc2 complex Complex III, see eytochrome oxidase Complex III, see eytochrome bc2 complex III, see eytochrome oxidase Complex III, see eytochrome bc2 complex III, see eytochrome oxidase Complex III, see eytochrome bc2 complex III, see eytochrome oxidase Complex III, see eytochrome bc2 complex III, see eytochrome oxidase Complex III, see eytochrome bc2 complex III, see eytochrome oxidase		÷ *	Cyclic AMP, 439–440
TPCK binding, 213 Cl repressor, 64 Cl P family, 252 circe effect, 205 Circular dichroism, 385–387 folding of bacteriorhodopsin, 423 folding of DmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cls-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 EFKS06 binding proteins, 416 Clitric acid cycle, 190 Citruline, 38 Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloning, 314–316 Cloostrjani, 166 Clostrjani, 163 Coenzyme Q, 193, see also ubiquinone  (CDR)s, 77 Complex II, see NaChH-ubiquinone oxidoreductase Complex II, see succinate dehydrogenase Complex III, see cytochrome oxidase Conformational stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 connective tissue disorders, Conotoxins, 178 Conotoxins, 179 Conserved residues, 172 Conserved residues, 172 Conserved residues, 172 Contact order, 410 Conus, 179 Coomassie Blue, 33, 336 Cooperative binding curve, 69–70, 396 Cyclohexane, 53 Cyclo-oxygenases, 228-230 active site, 230 tertiary structure, 252 threonine phosphorylation, 252 tyrclohexane, 53 Cyclosyorin A, 81, 416 Cyclophilin, 416 Cyclo			
cl repressor, 64 CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of bacteriorhodopsin, 423 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citruline, 38 CID see Creutzfeldt Jacob disease Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Cloostrjain, 166 Clostrjain, 168 Coelenterazine, 383 Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone oxidoreductase complex II, see cytochrome bc₁ complex Complex III, see cytochrome oxidase Complex III, see clostorhom oxidase Complex III, see cytochrome oxidase Conformational chan	structural homology, 177, 179	Complementarity determining regions	Cyclic GMP, 118
CIP family, 252 circe effect, 205 Circular dichroism, 385–387 folding of bacteriorhodopsin, 423 folding of DompA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 FKS06 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, 193 Coenzyme Q, 193, see also ubiquinone  oxidoreductase Complex II, see succinate dehydrogenase Complex II, see cytochrome bc; complex Complex IV, see cytochrome bc; complex Complex II, see eytochrome bc; complex Complex II, see cytochrome oxidase Complex II, see cytochrome oxidase Complex II, see cytochrome bc; complex Complex IV, see cytochrome oxidase Conformational stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 Connective tissue disorders, Conotoxins, 178 Coneter 410 Conus, 178 Coneter, 410 Conus, 178 Coneter, 410 Conus, 178 Cooperative binding curve, 69–70, 396 Cooperative binding	TPCK binding, 213	(CDRs), 77	Cyclic nucleotides, 202
circe effect, 205 Circular dichroism, 385–387 folding of DompA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coden, 268, 269 Complex II, see succinate dehydrogenase Complex III, see cytochrome bc; complex Conformational changes, 251–252 cyclin boxes, 249 cyclin-boxes, 240 cyclo-cavgenases, 230 cyclo-boxygenases, 230 cyclo-boxygena	cI repressor, 64	Complex I, see NADH-ubiquinone	Cyclic proteins, 81
Circular dichroism, 385–387 folding of bacteriorhodopsin, 423 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 FK506 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coden, 268 Coenzyme Q, 193, see also ubiquinone  Complex III, see cytochrome bc <sub>1</sub> complex domplex complex of complex of complex of this processor (Conserved table) in stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 connective tissue disorders, Connective tissue disor	CIP family, 252	oxidoreductase	Cyclin dependant kinases, 249–253
Circular dichroism, 385–387 folding of bacteriorhodopsin, 423 folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 FK506 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Closverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coden, 268, Coenzyme Q, 193, see also ubiquinone  Complex III, see cytochrome bc1 complex complex IV, see cytochrome oxidase Conformational stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 Connective tissue disorders, Conserved residues, 172 Contact order, 410 Conus, 178 Cooperative binding curve, 69–70, 396 Coperative binding curve, 69–70, 396 Coperative binding curve	circe effect, 205	Complex II, see succinate dehydrogenase	ATP binding, 251
folding of bacteriorhodopsin, 423 folding of OmpA, 424 Complex IV, see cytochrome oxidase Conformational stability, 396–404 estimations from ideal denaturation curves, 401 magnetic circular dichroism, 387 spectra, 387 cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citrulline, 38 CIJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Clostrelaef structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coenzyme Q, 193, see also ubiquinone  Complex IV, see cytochrome oxidase Conformational stability, 396–404 estimations from ideal denaturation curves, 401 linear extrapolation method, 402 table of selected proteins, 402 Connective tissue disorders, Connective tissue disorders, Connective tissue disorders, Connotoxins, 178 Conserved residues, 172 Contact order, 410 Conus, 178 Conserved residues, 172 Coperative binding curve, 6	Circular dichroism, 385–387		•
folding of OmpA, 424 for studying protein folding, 404, 409 magnetic circular dichroism, 387 spectra, 387 cis isomer cis risomer Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citric acid cycle, 190 Citrulline, 38 Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  Conformational stability, 396–404 estimations from ideal denaturation curves, 401 regulation, 250–253 T loop activation, 251–252 Cyclins, 248–249 binding with cdk, 251–252 cyclin boxes, 249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 tructure and function, 250–253 T loop activation, 251–252 cyclins, 248–249 binding with cdk, 251–252 cyclin boxes, 249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 tructure and function, 250–253 T loop activation, 251–252 cyclins, 248–249 conformational stability, 396–404 structure and function, 250–253 T loop activation, 251–252 cyclins, 248–249 conformational function, 251–252 cyclins, 248–249 conformational function, 251–252 cyclins, 248–249 conformational changes, 251–252 cyclins, 248–249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 tructure and function, 250–253 T loop activation, 251–252 cyclins, 248–249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 tertiary structure, 252 threonine phosphorylation, 252 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 tertiary structure, 229 isoformational changes, 251–252 cyclins, 248–249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 cyclin-cdk complexes in cell cycle, 250 regulation, 252 cyclin-cdk complexes in cell cycle, 250 regulation, 252 tertiary structure, 252 threonine phosphorylation, 252 Cyclohexane, 53 Cyclo-oxygenases, 230 Cyclophilin, 416 Cyclosporin A, 81, 416 Cyclosporin A, 81, 416 Cyclosporin A, 81, 416 Cyclosporin		• •	_
for studying protein folding, 404, 409 curves, 401 sinear extrapolation method, 402 spectra, 387 table of selected proteins, 402 connective tissue disorders, contoxins, 178 contact order, 410 contact order, 410 conserved residues, 172 context disclared revolution, 179 conserved residues, 172 conformational changes, 251–252 conformational changes, 250 conformational changes, 250 conformation, 179 cyclin-cdk complexes in cell cycle, 250 regulation, 252 threonine phosphorylation, 252 threonine phosphorylation, 252 cyclonexane, 53 cyclo-oxygenases, 230 correlation time, 363 conforms, 230 correlation time, 363 correlation, 252 stream to the retriary structure and function, 252 stream to the conformation conformation conserved residues, 172 con		÷ • • • • • • • • • • • • • • • • • • •	
magnetic circular dichroism, 387 linear extrapolation method, 402 spectra, 387 table of selected proteins, 402 cis isomer Connective tissue disorders, connective			<u>*</u>
magnetic circular dichroism, 387 spectra, 387 cis isomer cis isomer Connective tissue disorders, cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain and Cobalt, 193 Codon, 268, Codon, 268, Codelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  linear extrapolation method, 402 table of selected proteins, 402 Contact order, 410 Connective tissue disorders, Conotoxins, 178 Conotoxins, 179 conformational changes, 251–252 cyclin boxes, 249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 Ctrulline, 252 Ctrulline, 252 cyclin boxes, 249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 Cyclophilin, 416 Cyclotides, 81 Cyclotides, 81 Cysteine active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41			_
spectra, 387 cis isomer Connective tissue disorders, cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 FK506 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  table of selected proteins, 402 Connective tissue disorders, binding with cdk, 251–252 conformational changes, 251–252 cyclin boxes, 249 cyclin boxes, 249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 tertiary structure, 252 threonine phosphorylation, 252 Cyclohexane, 53 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 tertiary structure, 229 isoforms, 230 Cyclophilin, 416 Cyclostripain, 166 Cyclostripain, 166 Coupling constants, 363 Cyclophilin, 416 Cyclostripain, 46 Cyclotides, 81 Cysteine active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41			
cis isomer cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Citric acid cycle, 190 Citric acid cycle, 190 Citrulline, 38 CiJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Cloostripain, 166 Cloostripain, 166 Cloostripain, 166 Cloostripain, 166 Cloostripain, 166 Clootlit, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  Connective tissue disorders, Connective tissue disorders, Conotoxins, 178 Conserved residues, 172 cyclin boxes, 249 cyclin-cdk complexes in cell cycle, 250 regulation, 252 tertiary structure, 252 threonine phosphorylation, 252 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 tertiary structure, 229 isoforms, 230 Cyclophilin, 416 Cyclophilin,			<u> -</u>
cis ring, 418, 419 Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 Contact order, 410 parvulins, 416 Conus, 178 Citric acid cycle, 190 Citric acid cycle, 190 Citrulline, 38 CJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clovalent modification, 237–241 Cowpox, 75 Cowpox, 75 Cowpox, 75 Cox, G.B., 146 Cowpox, 75 Cox, G.B., 146 Cox, g. B., 146 Cox, g.	•	<u> </u>	•
Cis-trans peptidyl proline isomerase, 59 in protein folding, 415–416 parvulins, 416 FK506 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 CJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coenzyme Q, 193, see also ubiquinone  Conserved residues, 172 Contact order, 410 Coperative volution, 179 tertiary structure, 252 threonine phosphorylation, 252 Cyclohexane, 53 Cyclo-oxygenases, 228–230 cyclo-oxygenases, 228–230 cyclo-oxygenases, 228–230 tertiary structure, 229 isoforms, 230 Cyclophilin, 416 Cyclosporin A, 81, 416 Cyclotides, 81 C			•
in protein folding, 415–416 parvulins, 416 PK506 binding proteins, 416 Citric acid cycle, 190 Citrulline, 38 CJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Coenzyme Q, 193, see also ubiquinone  Contact order, 410 Conus, 178 Conus, 178 Conus, 178 Conus, 179 Conus, 179 Comassie Blue, 33, 336 Cooperative binding curve, 69–70, 396 Cooperative binding curve, 69–70, 396 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 tertiary structure, 252 threonine phosphorylation, 252 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 cyclophilin, 416 Cyclosporin, 29 Cyclophilin, 416 Cyclosporin A, 81, 416 Cyclotides, 81 Cyclotides, 81 Cyclotides, 81 Cyclotides, 81 Cyclotides, 81 Cysteine Covalent modification, 237–241 compox, 75 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41			
parvulins, 416 FK506 binding proteins, 416 Conus, 178 Citric acid cycle, 190 Citric acid cycle, 190 Coomassie Blue, 33, 336 Citrulline, 38 CJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Cowpox, 75 C			
Citric acid cycle, 190 Citric acid cycle, 190 Coomassie Blue, 33, 336 Citrulline, 38 Coperative binding curve, 69–70, 396 CID see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent, see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  Compassie Blue, 33, 336 Coomassie Blue, 33, 336 Cooperative binding curve, 69–70, 396 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 tertiary structure, 229 isoforms, 230 Cyclophilin, 416 Cyclosporin A, 81, 416 Cyclosporin A, 81, 416 Cyclotides, 81 Cyclophilin, 416 Cyclotides, 81 Cyclotides, 81 Cyclophilin, 416 Cyclophili			
Citric acid cycle, 190 Citric acid cycle, 190 Citrulline, 38 CJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  Cooperative binding curve, 69–70, 396 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 tertiary structure, 229 isoforms, 230 Cyclophilin, 416 Cyclosporin A, 81, 416 Cyclosporin A, 81, 416 Cyclotides, 81 Cycloides, 81 Cyclotides, 81 Cyclotides, 81 Cysteine active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41			_
Citrulline, 38 CJD see Creutzfeldt Jacob disease CJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also disease  Cooperative binding curve, 69–70, 396 Cyclohexane, 53 Cyclo-oxygenases, 228–230 active site, 230 tertiary structure, 229 isoforms, 230 Cyclophilin, 416 Cyclosporin A, 81, 416 Cyclosporin A, 81, 416 Cyclotides, 81 Cysteine active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41			
CJD see Creutzfeldt Jacob disease Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  Copper, 7 binuclear cluster, 139 co-factor role, 193	Citric acid cycle, 190		
Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also dithiothreitol, 28 Clathrin coated vesicles, 297 binuclear cluster, 139 co-factor role, 193 co-factor role, 194 co-factor role, 193 coverland role coulonbies and role coulonbies and role coulonbies	Citrulline, 38		Cyclohexane, 53
Clathrates, 54 Clathrin coated vesicles, 297 Cleland's reagent , see also dithiothreitol, 28 Cloning, 314–316 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also dithiothreitol, 28 Clathrin coated vesicles, 297 binuclear cluster, 139 co-factor role, 193 corefactor role, 193 corefactor role, 193 co-factor role, 193 cove	CJD see Creutzfeldt Jacob disease	Cooperativity, 70,	Cyclo-oxygenases, 228–230
Cleland's reagent , see also dithiothreitol, 28 Correlation time, 363 Cyclophilin, 416 Cloning, 314–316 Coulomb's Law, 55 Cyclosporin A, 81, 416 Clostripain, 166 Coupling constants, 363 Cyclotides, 81 Cloverleaf structure, 268, 269 Covalent catalysis, 204 Cysteine CMC, see critical micelle concentration Cobalt, 193 Cowpox, 75 Codon, 268, Cox, G.B., 146 Coelenterazine, 383 COX-1, see also cyclo-oxygenases, 230 Coenzyme Q, 193, see also ubiquinone Co-factor role, 193 isoforms, 230 Cyclophilin, 416 Cyclosporin A, 81, 416 Cyclotides, 81 Cysteine active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41	Clathrates, 54		
Cleland's reagent , see also dithiothreitol, 28 Correlation time, 363 Cyclophilin, 416 Cloning, 314–316 Coulomb's Law, 55 Cyclosporin A, 81, 416 Clostripain, 166 Coupling constants, 363 Cyclotides, 81 Cloverleaf structure, 268, 269 Covalent catalysis, 204 Cysteine CMC, see critical micelle concentration Cobalt, 193 Cowpox, 75 Codon, 268, Cox, G.B., 146 Coelenterazine, 383 COX-1, see also cyclo-oxygenases, 230 Coenzyme Q, 193, see also ubiquinone Co-factor role, 193 isoforms, 230 Cyclophilin, 416 Cyclosporin A, 81, 416 Cyclotides, 81 Cysteine active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41	Clathrin coated vesicles, 297	binuclear cluster, 139	tertiary structure, 229
Correlation time, 363 Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone Coloning, 314–316 Coulomb's Law, 55 Covalent catalysis, 363 Cyclotides, 81 Cysteine Cysteine active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41	Cleland's reagent, see also dithiothreitol,	co-factor role, 193	isoforms, 230
Cloning, 314–316 Clostripain, 166 Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  Collomb's Law, 55 Coulomb's Law, 55 Coupling constants, 363 Cyclosporin A, 81, 416 Cyclotides, 81 Cysteine active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41	_	Correlation time, 363	
Clostripain, 166 Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coordinates, 363 Covalent catalysis, 204 Covalent modification, 237–241 Cowpox, 75 Codon, 268, Coordinates, 383 Coordinates, 363 Covalent catalysis, 204 Covalent modification, 237–241 active site of caspases, 310 chemical properties, 26–28 data, 19 genetic code specification, 268 helix/sheet propensity, 41			• •
Cloverleaf structure, 268, 269 CMC, see critical micelle concentration Cobalt, 193 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  Covalent catalysis, 204 Covalent modification, 237–241 Cowpox, 75 Cox, G.B., 146 COX-1, see also cyclo-oxygenases, 230 COX-2, see also cyclo-oxygenases, 230 COX-2, see also cyclo-oxygenases, 230 COX-1, see also cyclo-oxygenases, 230 COX-2, see also cyclo-oxygenases, 230	•		
CMC, see critical micelle concentration Cobalt, 193 Cowpox, 75 Codon, 268, Coelenterazine, 383 Coenzyme Q, 193, see also ubiquinone  Covalent modification, 237–241 Cowpox, 75 Cox, G.B., 146 COX-1, see also cyclo-oxygenases, 230 COX-2, see also cyclo-oxygenases, 230 COX-2, see also cyclo-oxygenases, 230 helix/sheet propensity, 41	•		
Cobalt, 193 Cowpox, 75 chemical properties, 26–28 data, 19 Codon, 268, Cox, G.B., 146 data, 19 Coelenterazine, 383 COX-1, see also cyclo-oxygenases, 230 Coenzyme Q, 193, see also ubiquinone COX-2, see also cyclo-oxygenases, 230 helix/sheet propensity, 41		•	•
Codon, 268, Cox, G.B., 146 data, <b>19</b> Coelenterazine, 383 COX-1, <i>see also</i> cyclo-oxygenases, 230 Coenzyme Q, 193, <i>see also</i> ubiquinone COX-2, <i>see also</i> cyclo-oxygenases, 230 helix/sheet propensity, 41			<u> •</u>
Coelenterazine, 383 COX-1, see also cyclo-oxygenases, 230 genetic code specification, 268 COX-2, see also cyclo-oxygenases, 230 helix/sheet propensity, 41		± ·	
Coenzyme Q, 193, see also ubiquinone COX-2, see also cyclo-oxygenases, 230 helix/sheet propensity, 41			
Co-factors, 192–193 CPK models, 13 hydropathy index, 112			
	Co-factors, <b>192–193</b>	CPK models, 13	hydropathy index, 112

ligands in Zn fingers, 261, 263	Databases, 184	Dithiothreitol, 27-28
location in turns, 47	Dayhoff. M.O, 174	DNA binding proteins, 64-66, 258-261
optical rotation, 34	ddATP, 171	arc repressor, 261
prevalence in secondary structure, 180	ddCTP, 171	cro repressor, 66
reaction with Ellman's reagent, 28	ddGTP, 171	eukaryotic transcription factors, 261-265
Cystic Fibrosis, 9, 426–427	ddI, 453	met repressor, 261
Cytochrome b, 132–137	ddTTP, 171	molecular saddle, 259-260
absorbance maxima, 133	Deamidation, 25	recognition helix, 65
ligands, 137	Death effector domains, 239	restriction endonucleases, 221-224
redox potential, 133	Debye, P., 325	sequence homology, 66
separation distances, 137	Debye-Huckel Law, 324-325	DNA gyrase, 253
subunit mass, 137	Degradation, see protein degradation	DNA ligase, 254
Cytochrome b <sub>5</sub> , 58, 60, <b>173</b> , 181, 401	$\Delta C_p$ , 55	ligation, 315
Cytochrome b <sub>562</sub> , 59	measurements, 399-400	DNA polymerase, 253–254
Cytochrome bc complex, see cytochrome	table for selected proteins, 401	cloning, 314–315
bc <sub>1</sub> complex	Denaturant	enzyme nomenclature, 191
Cytochrome bc <sub>1</sub> complex, 132–137	concentration dependence, 400-401	PCR, 170
crystal structure, 136	guanidine hydrochloride, 396	specificity constant, 201
cytochrome c <sub>1</sub> , 136	solubility of amino acids, 397	DNA replication, 253–254,
cytochrome b, 137	thermal, 96	semi-conservative model,
electron transfer reactions, 135	urea, 396	DNA sequencing, 168–170
gating, 137	Denaturation in PCR, 169	profiles from, 171
inhibitor binding studies, 133–134	Denaturation, 396–398	DNA structure, 248
Q cycle in, 135	ideal curves, 401	major groove, 222
Reiske protein, 133, 136	linear extrapolation method, 402	dNTP, 170
subunit composition, 137 subunit mass,	Deoxyadenosine, 170	Domains
137	Detergents, 122, 425	b <sub>5</sub> -like proteins, 60
ubiquinone, 134	amphiphiles, 122	death effector, 239
Cytochrome c	critical micelle concentration, 107–108	definition, 58–59
prokaryotic, 176	SDS binding, 335	EGF-like, 101
sequence homology, 175	use of LDAO, 121	extracellular domains in receptor tyrosine
sorting pathway, 299	Dextrorotatory, 34	kinases, 240
structural homology, 176	2'3'-dideoxyinosine, see ddI	folding domains in lysozyme, 415
Cytochrome $c_1$ , $132-137$	Diabetes, 422, type-I, 441	gp120 inner and outer, 454–455
orientation, 136	Dialysis, 333, 359	Gro-EL, 418
signal sequence, 299	Dideoxyadenosine, 170	immunoglobulin domain, 77
sorting pathway, 299	Dideoxynucleotide, 169–170, 171, 453	non receptor tyrosine kinases, 240
subunit mass, 137	Diesenhofer, J.E., 126	nucleotide binding, 62, 148, 155
Cytochrome oxidase, 138-144	Differential scanning calorimetry, 399	p53, 471
catalytic cycle, 138–139	profiles, 400	tyrosine kinases, 240
channels, 144	Diffusion controlled rate, 195, 201	Donnan effect, 333
Cu <sub>A</sub> centre, 139	DIFP, see Diisopropylfluorophosphate	Dopamine, 36
Cu <sub>B</sub> center, 140	Dihedral angle, 41, 43, 46	Double helix, 247–248
enzyme from P.denitrificans, 141	Dihydrouridine, 268	Double reciprocal plot,
isoforms, 141	Diisopropylfluorophosphate, 212, 228	DPPC, see dipalmitoylphosphatidylcholine
mammalian enzyme, 140-141	Dipalmitoylphosphatidylcholine, 107	Drosophila melanogaster, 168, 263, 308
mitochondrial coded subunits, 139	DIPF see di-isopropylphosphofluoridate	Drug resistance, 454 Drugs, 205, 228, 231, 451, 453, 454
monomeric core, 141	Dipole moment, 41, 56	Dsb family, 288
oxygen binding site, 143	D-isoglutamate, 35 Dissociation of weak acids, 478–479	Dso family, 200
proton pump, 142–143		E -it- 272 296
subunit structure, 141	Distal histidine, 68	E site, 272, 286
Cytochrome P450, 241	Disulfide, bond formation, 288–289	Eadie Hofstee plot, 199, 225
Cytosine, 247	bridges in prions 433	Earth, 127 EcoPL 221 224
Cytoskeleton, 111	bridges in prions, 433 bridges, 53	EcoRI, 221–224 cleavage site, <b>222</b>
role of tubulin, 377	chemical properties, ribonuclease,	DNA distortion, 223
Cytotoxic T lymphocytes, 79	neuraminidase, 463	major groove binding, 223
	oxidoreductase, protein disulfide	role of divalent ions in catalysis, 223
D amino acids, 34, 36, 321	isomerase, 288–289	sequence specificity and hydrogen
Dansyl chloride, 33, 167	thioredoxin, 288	bonding, 223
Dansyr Chloride, 33, 107	unoredoxin, 200	boliding, 223

EDI (i1)	Fd 460	ESD E1
EcoRI (continued)	Endosomes, 460	ESR see Electron spin resonance
signature sequence, 224	Enediol intermediate, 208	Ethanolamine, 106
tertiary structure, 223	Energy transfer, 382, 383	Eukaryotic cells, 164
Ectodomain, 455–456	Engelman, D., 423	Eukaryotic RNA polymerases, 257–261
Edelman, G., 76	Engrailed, 263	basal transcription factors, 258
Edman degradation, 165, 340	Enteropeptidase, 237	role and location, 257
Edman, P., 165	Enthalpy, 54	processing, 257
EF-G, 275, 279	Entropy, 54	Evolution, 164
EF-Ts, 275,	activation parameters, 397–398	EX1 mechanism, 412
EF-Tu, 274–275	Enzymes, 188–245	EX2 mechanism, 412
regeneration, 277	allosteric regulation, 231–237	Excited state, 380
structure with Phe-tRNA, 278	catalytic efficiency, 201	Exergonic reaction, 195
EGF, see epidermal growth factor	catalytic mechanisms, 202–209	Exocytosis, 98
Ehlers-Danos syndrome, 99–100	covalent modification, 237–241	Exon, 267
Eighteen 18S rRNA, 257	databases, 192	Exonuclease activity, 254
Elastase	inhibition and regulation, 224–228	Exportins, 300
active site substrate specificity, 212	irreversible inhibition, 227–231	Expression vectors, 316–318
emphysema, 476	isoenzymes, 241–242	Extinction coefficient, see Molar
structural homology, 177	kinetics, 197–202	absorptivity coefficient
Elastin, 101	multicatalytic activities, 305-308	Extrinsic proteins, 110
Electromagnetic spectrum, 348	nomenclature, <b>189</b> , 478–479	Eye, damage in glaucoma, 205
Electron density, 108, 356, 358	preferential binding of transition state,	Eyring, H., 195
Electron microscope, 376	207-209	
Electron microscopy, see also cryoelectron	purification, 343	F 1 146
microscopy, nuclear pore complex, 303	rotary motion, 146	F <sub>1</sub> complex, 146
Electron spin resonance, 390–392	steady state approximation, 199-200	structure, 147–150
ENDOR, 392	subsites, 208	F <sub>ab</sub> fragments, 76–79
ESEEM, 392	Epidermal growth factor, 101–102, <b>369</b>	Fabry disease, 308
iron sulfur proteins, 391	Epitopes, 77, 272	FAD, see flavin adenine dinucleotide
Electron, 31	Equilibrium constant, 194	Familial amyloidotic neuropathy, 428
Electrophile, 205	Equilibrium dialysis, 359	FAP mutations, 430
in covalent catalysis, 203-205	Ernst, R., 360	FAP, see familial amyloidotic neuropathy
Electrophoresis, 333–340	Error rate, 169	Fasman, G.D., 182
isoelectric focusing, 339	Erythrocyte, 110–114	FASTA, 175
SDS-PAGE, 335-338	band, 3	Fatal familial insomnia, <b>428</b> , 434–435, 465
two dimensional electrophoresis, 339	protein, 111	Fatty acids, 105–109
Electroporation, 315	glycophorin, 112–114	F <sub>c</sub> , 76
Electrospray ionization, <b>340</b>	lipid: protein ratio, 109	Feedback mechanisms, 189
Electrostatic catalysis, 205–207	membrane organization, 110–114	Fenn, J., 340
Elements, 9	Erythromycin, 278	Ferredoxin, 128, 299
ELISA, 337-338	Escherichia coli	types of clusters, 391
Ellipticity, 386	ATP synthetase, 144–145	Ferredoxin-NADP reductase, 299
Ellman's reagent, 27, 28, 33	cell division, 247	Ferrimyoglobin, 68
Elongation factors, see also EF-G, EF-Tu	competent cells, 315	Fersht, A.R., 405
and EF-Ts, 274-277	expression host, 313	Fibrillin, 101–102
Eluate, 327	genome, 9	modular organization, 102
Emphysema, 475–478	K12 strain, 168	Fibrils, transthyretin based, 430
Enantiomers, 34	lac operon, 317	Fibrin, 238–239
Encounter complex, 195	met repressor, 261	Fibrinogen, 239
Endergonic process, 195	OmpA, 425	sedimentation coefficient, 324
Endocytosis, 98, 458–459, 459	OmpF, 425	Fibroins, 92
Endoplasmic reticulum, 164	phosphofructo-kinase, 232	Fibrous proteins, 85–103
collagen processing, 97–99	porins, 128–132	amino acid composition, 86
disulfide bond formation, 288–289	protein expression, 314	<sup>15</sup> N, 253,
hydroxylation reactions, 289–290	protein purification, 343	50S subunit, see large subunit, 279–282
insulin processing, 287–288	replication of DNA, 253	First order reaction, 192–194
lumen, 295, 296, 427	restriction endonucleases from, 222	Fischer, E., 2, 189
translocon/SRP interaction, 424–425	ribosomes, 270	5.8S rRNA, 257
unwanted transfer, 426	RNA polymerase, <b>254</b>	5S rRNA, 261, 269
Endoproteolysis, 469	SRP54 M domain, 295	secondary structure prediction, 280

FK506 binding proteins, 416	γ amino butyric acid, 36	helix/sheet propensity, 41
Flavin adenine dinucleotide, 9, 132–133,	γ lipotrophin, 289	optical rotation, 34
162	Gamow, G., 266	prevalence hydropathy index, 112
Flavin, 380	Garavito, R., 228	prevalence in secondary structure,
Flavodoxin, 181, 359	Gaucher's disease, 310	180
Flu, see influenza	GCN4, transcription factor, 263-264	Glutamine, 25–26
Fluid mosaic model, 109-110	Gel electrophoresis, 333–340	chemical properties, 25-26
Fluorescamine, 33	enzyme linked immunosorbent assay, 337	data, 19
Fluorescence, 381–385	instrumentation, 337	genetic code specification, 268
emission anisotropy, 383	polyacrylamide SDS, 336	helix/sheet propensity, 41
Green fluorescent protein, 383–385	two dimensional, 339	hydropathy index, 112
instrumental setup, 382	Western Blotting, 337–338	prevalence in secondary structure, 180
Perrin equation, 383	Gel state, 109	Glutaminyl tRNA synthetase, 220–221
profile from DNA sequencing, 171	Gene fusion, 181	Glutathione binding proteins, 334
Stern-Volmer analysis, 382	Gene,	Glutathionine-S-transferase, 334,
collisional quenching, 382	amyloid precursor protein, 469	SDS-PAGE, 337
Stokes shift, 381	seven transmembrane helices receptors,	Glycerol backbone, 105
Fluoroscein, 167, 170	118	Glycerophospholipid, 106
Flurodinitrobenzene, 33, 37	cdc, 249	Glycine
F <sub>o</sub> , 145,	defective, 441	chemical properties, 24 data, <b>19</b>
Folding, see protein folding	engrailed, 263 env,gag,pol, 445–446	genetic code specification, 268
Folic acid, 193	globin cluster, 442	helix/sheet propensity, <b>41</b>
Folin-Ciocalteau's reagent, 33	p53 location, 471	hydropathy index, 112
Folin–Lowry method, 33	PNRP, 433, 435	prevalence in secondary structure, <b>180</b>
Formylmethionine, 273–274	screening, 441	in collagen structure, 94–96
Forster energy transfer, 382	tumour suppressor, 470	location in turns, 47
4.5S rRNA, 294 Fourier transform, 354, 360, 389	secretion, 424	poly(Gly), 48
Franck, J., 377	Genetic code, 268	Glycogen phosphorylase, 231, 241
Franklin, R., 2, 247	in organelles, 268	Glycogen storage diseases, 309–310
Free energy, 195–197	translation of synthetic nucleotides, 267	Glycogen, 241
contributions to protein folding, 403	start codon, 169,	Glycolysis, 190
transition state profile, 196	Genetic engineering, 222	Glycophorin, 113
Free induction decay, 361–362	Genomes, 168-169	domain labeling, 113-114
Fructose-6-phosphate, 232–233	Haemophilus influenzae, 168	dimerization, 114
FtsY, 295	Helicobacter pylori, 168	Glycophosphatidyl inositol, see GPI anchor
Fumarase, specificity constant, 201	pathogens, 395	Glycoprotein
Fumaroles, 162	RNA based, 444	amyloid precursor protein, 469
Funnel, 411	segmented, 444, 457	prion protein, 433
Fusogenic peptide, 455, 457	sequencing projects, 168, 185	transmembrane receptors, 239
	Genomics, 183	variant surface, 290
C meetain assumed resentan 115 121	Germ line mutations, 473	Glycosidic bonds, 210, 211
G protein coupled receptor, 115–121 cDNA isolation, 115	Gerstmann–Straussler–Scheinker, 434–435	cleavage by neuraminidase, 462–463
G protein, 117–119	GFP, see green fluorescent protein.	Glycosylation, 98–99, 290–292
heterotrimeric, 118	Ghost membranes, 110	adrenergic receptor, 115 glycophorin, 113
Gα structure, 119	Glaesser, R., 376 Glaucoma, 205	N-linked glycosylation, 98
Gβ/Gγ, 118, 120, 439	Gln-tRNA synthetase, 220	prion, 434
EF-Tu, 274	active site pocket with analogue, 221	GM1, 439
Ran, 302	discrimination between substrates, 220	GM2, 310
Ran binding proteins, 302	transition state analogue, 221	Golgi apparatus, 99, 292, 296
G <sub>1</sub> phase, of cell cycle, 247–248	Globin evolution, 182	gp120
G <sub>2</sub> phase, of cell cycle, 247–248	Globin gene cluster, 442	domain organization, 455
GABA, see γ amino butyric acid	Glucokinase, 200	env gene product, 446
GAL4, transcription factor, 262-263	Glucose isomerase, specificity constant, 201	function, 447
Galactolipids, 107	Glucose-6-phosphate, 241	interactions with CD4 receptor, 455
Gallo, R., 443	Glutamate, 25	location within HIV, 446
γ crystallin, 59	chemical properties, 25	structure, 449
γ secretase, 469	data, 19	surface glycoproteins of HIV, 454-455
γ turn, 46–48	genetic code specification, 268	vaccine development, 455

cm41_00	Hamonbiles influence 160	Havakinasa 101 200
gp41, 90 ectodomain region, 456–457	Haemophilus influenzae, 168	Hexokinase, 191, 200
<b>C</b> ,	Hair, see keratins	Hierarchy, 180
env gene product, 446	Hairpin, 456–457	Highly active retroviral therapy, 454
function, 447	Haldane, J.B.S., 199	Hill coefficient, 231
structure, 449	Half-chair conformation, 211	Hill equation, 231
fusogenic sequence, 456	Half-life, 193–194, 305	HindIII, 222
location within HIV, 446	Haloarcula marismortui, 272	Hippocrates, 228
trimer of hairpins, 457	Halobacterium halobium, 114	His-tags, 333–334
GPCR, see G protein coupled receptor	Halophile, 114	Histamine, 36
GPI anchors, 291	Hanging-drop, 359	Histidine
in prion protein, 433	Haplotype, 442	acid catalysis in RNaseA, 203
Gradient gel electrophoresis, 336	Harker construction, 356–357	chemical modification in ribonuclease,
Gram negative, 128, 319	Hartwell, L., 249	202
Gram positive, 35, 319	Heat capacity, 55	chemical properties, 29-30
Gramicidin A, 36	changes in protein folding	data, <b>20</b>
Greek key motif, 59, 61	HEAT motifs, 301	general base catalysis, 202-203
Green fluorescent protein, 383–385	Heat shock proteins, 298, 416	genetic code specification, 268
GroEL-ES, 417–422	Heavy chain, 76	helix/sheet propensity, 41
catalytic cycle, 419–421	Heavy metal derivatives, 357	hydropathy index, 112
domain movements, 418–419	Heisenberg, W., 349	imidazole ligand in globins, 68
hydrophobic interactions, 420–421	Helicases, 253, 258	imidizolate form in catalysis, 215–217
negative staining EM, 417	Helicobacter pylori, 168	optical rotation, 34
tripartite structure, 418	Helix, 41–45	prevalence in secondary structure, <b>180</b>
GroES structure, 418	α helix, 41–44	pros and tele, 30
	other conformations, 45	reaction with TPCK in chymotrypsin,
Ground state, 380	$\pi$ helix, 44	213
GTP	PSTAIRE, 250–251	tagged proteins, 333–334
analogue, 275	reaction center, 115, 125	Zn fingers, 261
GTP binding proteins, 295	restriction endonucleases, 222–223	Histone, 250
hydrolysis of GTP, 274, 294–295, 378	Helix loop helix motif, 263, 264	HIV protease, 446, 449–452
use in capping, 265	Helix propensity, 41	bond specificity, 449
Guanidine hydrochloride, 396–397, 400,		•
412	Helix turn helix motif, 64–66	catalytic mechanism, 450
Guanidinium thiocyanate, 326	eukaryotic, 263–265	inhibitors, 452
Guanidino, 28	Helper T cells, 445, 446	structure, 451
Guanine, 247	Haemagglutinin, 459–462	substrates, 451
	antigenic subtypes, 465	HIV see human immunodeficiency virus
H subunit (Reaction centre), 124	comparison of membrane bound and	HLH motif, see Helix loop helix motif
	protease treated forms, 460	HNCA, 373
H/D exchange, 413	conformational changes, 462	HNCO, 373
HAART, see highly active retroviral therapy	crystal structure, 461	Hodgkin, D., 353
Haemoglobin, 69–74	HA1 monomer, 461	Hofmeister series, 325–326
absorbance spectra, 67	HA2 monomer, 461	Hofmeister, F., 2, 325
allosteric regulation of, 72–74	low pH forms, 462	Holley, R.W., 268
α subunit, 70, 172	organization, 460	Holoenzyme, 260
β subunit, 70, 172	sialic acid binding and the active site,	Homedomains, 264
Bohr effect, 74	460-462	Homeobox, 265
conformational change, 71–72	Heme a, 133, 138	Homeostasis, 189
cooperativity, 72–73	Heme a <sub>3</sub> , 133, 138, 140	Homology, 170–175
deoxy state, 71	Heme, 9, 66, 67	Homopolymer, 40
evolution of globin chains, 181-182	complex III, 132-133	Homoserine lactone, 27
haemoglobin S, 441	cytochrome oxidase, 138	Homotropic effector, 234
hydrophobic pocket, 441	edge to edge distance, 137	Hooke's Law, 388
lamprey protein crystals, 359	Henderson, R., 114, 376	Hormone, 116, 228, 287
mechanism of oxygenation, 71–72	Henderson-Hasselbalch equation, 14,	Horseradish peroxidase, 338, 339
met form, 67	477–478	Host-guest interaction, 40
R state, 73	Hepatitis B, 377	HTH, see Helix turn helix motif
sequence homology, 172	Heptad repeat, 87, 89, 263	Huber, R., 51, 126, 370
spin state changes, 71	Hess' Law, 406–407	Huckel, E., 325
structural homology, 172	Heteronuclear NMR spectroscopy, 370–373	Human diseases and disorders, 10–11, <b>428</b>
solubility of, 325	Heterotropic effector, 234	Alzheimer's, 468–470
50140111ty 01, 525	Teterouopie effector, 257	Maneriner s, 400 470

amyloidogenesis, 427-431	Hydrophobic effect, 53-55	strategies to combat influenza pandemics,
cancer, 10, 470–475	energetics, 54	464–465
cervical carcinoma, 475	folding, 410	symptoms, 457
cholera, 439–440	in chromatography, 331	virus, 457
collagen based, 99–100	interactions in proteins, 54–55, 403,	Infrared spectroscopy, 387–389
Creutzfeldt-Jakob disease, 433	410–411	amide bands, 389
cystic fibrosis, 10, 416–427	Hydrophobic interaction chromatography,	fingerprint region, 389
diabetes, 441	331	regions of interest, 388
emphysema, 475–477	Hydroxylation, 29, 289–290	spectrum of water, 388
familial amyloidotic polyneuropathy,	Hydroxylysine, 97, 289–290	Infrared, 348
428–430	Hydroxyproline, 96, 289	frequency range and measurement,  349
folding diseases, 428	Hyperbolic binding curve, 69, 232	Ingram, V., 10, 441
glaucoma, 205 HIV, 10, 443–457	Hyperthermophile, 306	Inhibition, of enzyme activity, 224–228
influenza, 457–465	Hypervariable regions, 77	Initiation factors, 274–275
kuru, 433		INK4 family, 252
misfolding and disease, 426–435	Iatrogenic transmission, 433, 467	Inositol, 106
neurodegenerative disease, 441, 465–470	Ibuprofen, 228	Insulin, 6,
p53 based, 470–474	Ice, 54	disulfide bridge formation, 287
prion based diseases, 431–435, 466–468	IF-1, 275	proteolytic processing, 287
sickle cell anemia, 10 441–442	IF-2, 274, 275	expression, 318
skin cancer, 445	IF-3, 274, 275	Integral proteins, 109–110
Human Genome Sequencing project, 9	IgG, 76–80	Integrase, 445
Human immunodeficiency virus, 11,	Imidazole, 29, <i>30</i>	Interleukin-1β, structure, 374–375
443–457	catalytic mechanism of triose phosphate	Intermediate filaments, 88–89
epidemic, 445	isomerase, 216–217	classification of, 89
gene products, 447	groups in nucleophilic reactions, 203	Intermembrane space, 298, 299
genome organization, 446	increased basicity, 214	Interphase, 247
gp120, 454-455	ligands in active site of carbonic	Intracellular messengers, 116–119
gp41 structure, 455–457	anhydrase, 206	Intrinsic pathway, 239
helper T cells, 445	Immune response, 74–76	Intrinsic proteins, 109–111
history, 444-445	Immunity, 76	Introns, 265–267
HIV-2, 446	Immunoblotting, 337–339	Invariant residues, 39
opportunistic infections, 445	Immunoglobulins, 74–81	Iodide, 381
protease, 63, 449–452	CDRs, 77	Ion exchange chromatography, 329–330
reverse transcriptase, 452–454	classes, 78–80	Ion pumps, 152–156
role of Vpu, Vif, Vpr, 448	disulfide bridges, 76	Ion, solvation, 324–325
structural proteins, 448–449	heavy and light chains, 74	Ionic atmosphere, 325
structure and function of Rev, Nef, Tat,	hypervariable regions, 77	Ionic strength, 324–325
447–448	immunoglobulin fold, 77	IPTG, see Isopropylthiogalactoside
surface glycoproteins, 454–457	interaction with lysozyme, 78–79 monoclonal antibody, 79	Iron sulfur protein, 132
virus, 446	structure, 76–78	ESR spectra, 391
Hydration, 31 Hydration layer, 324	$V_L$ and $V_H$ domains, 77	Iron, 7, 8, 58 observation by ESR, 391
Hydrogen bonding, 56	Importins, 300–302	Islets of Langerhans, 441
• •	interaction between $\alpha$ and $\beta$ 301	Isoalloxine, 9
examples in proteins, <b>56</b> helices, 41–44	schematic representation, 300	Isoelectric focusing, 339
in $\beta$ sheets, 45–46	Indole, 32	Isoelectric point, 14
restriction endonuclease specificity, 223	Influenza, 457–465	Isoenzymes, 205, 241–242
substrate discrimination in tRNA	avian strains, 465	Isoleucine
synthetases, 220	classification, 458	chemical properties, 24
Hydrogen exchange, 379	entry into cells, 459	data, 20
Hydrolases, 191, 308	epitopes, 464	genetic code specification, 268
Hydrolysis, 202	genome, <b>458</b>	helix/sheet propensity, <b>41</b>
bromophenol esters, 206-208	haemagglutinin, 459–462	hydropathy index, 112
of acyl enzyme intermediate, 214–215	Hong Kong strain, 465	occasional use as start codon, 268
of ATP,152	neuraminidase, 462-464	optical rotation, 34
of NAG-NAM polymers, 211	segmented RNA genome and coding of	prevalence in secondary structure,
Hydropathy index, 112	proteins, 458	180
Hydropathy plot, 111–113	organization, 457	Isomerases, 191

Isomorphous, 26	Lane, D.P., 470	Luminescence, 384
Isoprenoid units, 134	Large (50S) ribosomal subunit, 279–282	Lyases, <b>191</b>
Isopropylthiogalactoside, inducer, 317	peptidyl transferase mechanism, 283	Lymphocytes, 75–76, 443
Isozymes, 205 see also isoenzymes	sedimentation coefficient, 324	B cells, 75
IUPAC, 107,	structure of globular proteins, 282	CD4 bearing, 446
Ivanofsky, D., 442	tertiary structure, 281	Lysine
•	transition state analogue, 280, 282	•
Iwata, S., 132	6	chemical properties, 28–29
	23S rRNA structure, 280	cofactor binding in bacteriorhodopsin,
Jakob, A., 433	Lariat structure, 267	114
Jelly roll motif, 61	Larmor frequency, 361–362	crosslinks, 96–97
Jencks, W.P., 205	Lathyrism, 36	data, <b>20</b>
Jenner, E., 75	Lauryl, <b>107</b>	genetic code specification, 268
	LDAO, 121	helix/sheet propensity, 41
Jerne, N., 75	Lecithin, 105	hydropathy index, <b>112</b>
	Leder, P., 267	hydroxylation, 97, 289–290
Kanamycin, 316	Lentivirus, 448	* *
Kaposi's sarcoma, 445		in collagen structure, 96–97
Karplus Equation, 363	Leonard-Jones potential, 57	oxidation of side chain, 97
$k_{cat}/K_m$ see specificity constant, 201	Leucine, 24	prevalence in secondary structure, 180
KDEL sequence, 296	chemical and physical properties, 24	Lysogenic phase, 64
•	data, <b>20</b>	Lysosome, 296, 308-310
Kendrew, J., 2, 358	genetic code specification, 268	Lysozyme, 79
$K_{eq}$ , (equilibrium constant), 194	helix/sheet propensity, 41	catalysis, 209–212
in oxygen binding, 69	hydropathy index, 112	cell disruption, 319
Keratins, 86–92	optical rotation, 34	•
acidic, 88	prevalence in secondary structure, 180	folding domains, 415
α-keratin, 86–87	± -	glycosyl intermediate, 212
basic, 88	Leucine zipper, 87, 263	interaction with antibody, 78–79
β-keratin, 88	in DNA binding, 264	neutron diffraction, 379
•	Leucocyte, 476	specificity constant, 201
coiled coils, 87–89	Levine, A.P., 470	systemic amyloidogenesis, 428
Distribution of type I and II, 92	Levinthal's paradox, 403–404, 410	tertiary structure, 210
mutations in, 91	Lewis acid, 224	Lysyl hydroxylase, 290
structural organization, 89	Lewis, G.N., 325	Lysyl nydroxylase, 250 Lysyl oxidase, 97
Kevlar <sup>©</sup> , 92	Li-Fraumeni syndrome, 441, 473–474	
Khorana, H.G., 422	Ligands, 262	Lytic phase, 64
Killer T cells, 79		
Kinase, 172	in affinity chromatography, 334	M subunit, 124–125
Kinetic analysis, 192–195	in bacterial reaction center, 125	
The state of the s	in reverse phase chromatography, 332	Macrophages, 445, 454
of protein folding, 405	Ligases, <b>191</b> , 254	Mad cow disease, 466
heterogeneity, 414	Ligation, 315	Magnesium, 221, 271
Kinetic techniques, 413	Light (L) chain, 76	in cytochrome oxidase, 139–140
Kinetics, 192–195	Light harvesting chlorophyll complexes,	Magnetic moment, 391
Klenow fragment, 254, 452	121, 127, 299	Magnetic nuclei, 360
Klug, A. 376	Light, 118	Magnetogyric ratio, 360
$K_m$ , Michaelis constant, 200	Linderström-Lang, K., 412	Malaria, 442
k <sub>obs</sub> , 195	•	Malate synthase, 372
Kohler, G., 75	Lineweaver-Burk plot, 199	
Kosmotropes, 326	inhibition, 225–226	MALDI-TOF, 341–343
	Linoleic acid, 107	Malonate, 226–227
Kuru, 432, 433, 465	Linolenic acid, 107	Maltose binding protein, 334
	Lipid,	Manganese, 193
L isomers, 34–35	phase transition temperatures, 109	Marfan's syndrome, 100–102
L subunit (reaction centres), 124–125	protein ratio, 109	Martin, A.J.P., 326
Lac operon, 317	fluidity, 109–109	Mass spectrometry, 340-343
Lac repressor, 263, 317	bilayer, 108	Matrix protein, 446, 447
Lactate dehydrogenase, <i>61</i> , <b>191</b> , 241–242	Lipid:protein ratios, 109	structure, 448
•		
clinical diagnosis, 242	Lipscomb, W., 234	in influenza virus, 458
different isoenzymes, 242	Liquid crystalline state, 110	Matrix protein, 446–449, 457
sedimentation coefficient, 324	Long terminal repeats (LTRs), 446	Mdm2, 475
Lactocystin, 308	Longitudinal relaxation time, 363	Measles, 442
Laevorotatory, 34	Loop-sheet polymerization, 476-477	Membrane proteins, 105–159
λ-repressor, <i>59</i> , <i>65</i>	Lumen, 296, 303	bacteriorhodopsin, 423-424
=		• '

INDEX 52:

	DV4	N 11: 67 60
crystallography, 119–123	RNA transcripts, 265	Myoglobin, 67–69
expression, 314, 344	7-methylguanylate, 265	absorbance spectrum, 67
folding, 422–426	Metmyoglobin, 68	evolution of globins, 181–182
integral, 110,	Micelles, 107	human and sperm whale, 40
OmpA, 424	Michaelis, L., 198	oxygen binding curve, 69
peripheral, 110	Michaelis-Menten equation, 199	sedimentation coefficient, 324
porins, 128–132	Michel, H., 120, 126	structure, 67
respiratory complexes, 132–144	Microfibril, 88, 89, 101	superposition of polypeptide chains, 70
topology, 110	Microwaves, 348	Myristoylation, 240, 292
two stage model, 423	frequency range and measurement, 349	of Nef, 447
with globular domains, 111–114	use in ESR, 391	Myxathiazol, 134,135
Membranes, 105–110	Miller, S., 162	
fluid mosaic model, 109-110	Milstein, C., 75	N
ghosts, 110	Mitchell, P., 145	N acetyl glucosamine, 209–210, <b>321</b>
molecular organization, 105-108	Mitochondria, 132–144	N acetyl muramic acid, 209–210, <b>321</b>
Memory cells, 75	complex I, 132-133	N peptide, 456
Menaquinone, 125	complex II, 133	N terminal nucleophile hydrolases, 303
Menten, M., 198	cristae, 145	N terminal see Amino terminal
$m_{eq}$ , dependence of $\Delta G$ on denaturant	cytochrome bc <sub>1</sub> complexes, 132–137	Na <sup>+</sup> -K <sup>+</sup> ATPase, 153–155
concentration, 400-402, 405	cytochrome oxidase, 138-144	reaction stoichiometry, 153
table for selected proteins, 401	inner mitochondrial membrane	subunit composition, 153
Mercaptoethanol, 27	translocase system, 298	transport of ions, 154
Meselson, M., 254	inter-membrane space, 133	use of cardiac glycosides, 154
Meselson-Stahl experiment, 254	lipid:protein ratio, 109	N-acetyl neuraminic acid, 462
Messenger RNA capping, 265	matrix, 133	NAD+, see Nicotinamide adenine
methylaton, 265	outer-membrane, 133	dinucleotide
viral, 443	proteases, 298	NADH/NADPH, 132
plus (+)strand, 443	respiratory complexes, 132–144	NADH-ubiquinone oxidoreductase,
Metal ion catalysis, 204–205	RNA polymerases, 257	132–133
Metal ions, 6, 8,	targeting, 297–299	NAG, see N acetyl glucosamine
activity of restriction endonucleases, 221,	Mitosis, 247–248	NAM, see N acetyl muramic acid
223	Mixed disulfide, 28	Nathans, D., 221
carbonic anhydrase, 205 ribosome	Molar absorptivity coefficient, 32,	<i>N</i> -bromosuccinimide, 32
assembly, 271	Molar extinction coefficients, 30–31, 385	NcoI, 222, 317
catalysis, 204–205	globins, 67	NdeI, 317
co-factors, 192, <b>193</b>	Molecular evolution, 161–165, 189	Nef, 446–448
Metalloenzyme, 193, 204	Molecular graphics, 52, 478	Nestin, 87
Metalloproteinase, 99, 136, 469	Molecular mass, 7	Neuraminidase, 61, 462–464
Metarhodopsin II, 118	Molecular medicine, 441	active site, 464
Metazoa, 133	Molecular orbitals, 31	crystal structure, 463
Methanococcus jannaschii, 417	theory, 380	enzyme activity, 462
Methanol, 55	Molecular saddle, 259–260	tetrameric state, 463
Methionine, 26–28	Molecular weight, see molecular mass	Neurodegenerative disease, 441, 465-470
alternative genetic code, 268	Molten globule, 409–410	Alzheimer's, 468–470
chain initiation, 273–274	Molybdenum, 7, 58, 193	BSE, 466
chemical and physical properties,	in sulfite oxidase, 181	Lou Gehrig's disease, 441
26–27	Monochromators, 355, 404	scrapie, 466
data, <b>21</b>	Monod, Wyman and Changeaux (MWC)	vCJD, 467
genetic code specification, 268	model, 71	Neurotoxicity, 212
helix/sheet propensity, <b>41</b>	Montagnier, L., 443	Neurotoxins, 212
hydropathy index, 112	Moore, P., 272	Neutron diffraction, 379
interactions with heavy metal derivatives,	Moore's Law, 185	Nevirapine, 454
26	Motifs, 173	Niacin, 193
prevalence in secondary structure, <b>180</b>	mRNA see messenger RNA	Nicolson, G., 109
reaction with cyanogens bromide, 27	Mulder, G. J., 1	Nicotinamide adenine dinucleotide, 9, 162,
side chain oxidation, 26	Multiple anomalous dispersion, 357	<b>193</b> , 439–440
SRP54, 294	Mumps, 442	19S regulatory complex, 308
Methylation, 29, 292	Mutagenesis, 307, 406–408	Ninhydrin, 33, 167
by restriction endonucleases, 221	Mutational hot spots, 474	Nirenberg, M., 267
lysine sidechains, 28	Myelin sheath, <b>109</b>	Nitrate reductase, <b>173</b> , 181
1,5me sidecilanis, 20	mijonii siicuui, 107	1 1111111 100001000, 110, 101

Nitrocellulose, 337, 339	Nuclei, <b>360</b>	binding to hemoglobin, 69
Nitrothiobenzoate, 27	Nucleocapsid, 443	oxidation of methionine side chains,
Nitrotyrosine, 32	Nucleocytoplasmic transport, 299-302	26
N-linked glycosylation, 290	importin α structure, 301	production from water splitting, 126
NMR structures, BUSI IIa, 370	importin β structure, 301	Oxygenic photosynthesis, 126–128
interleukin 1β, 375	involvement of Ran binding proteins, 302	Ozone, 32
tendamistat, 370	localization signals, 300	
thioredoxin, 375	pores, 299, 302–303	
NMR, see Nuclear magnetic resonance	Ran-GDP structure, 302	P site, 273
spectroscopy	Nucleophile, 32, 202–205	p17, 446–449
N-myristoyltransferase, 292	Nucleoplasmin, 299–300	P22 tail spike protein, 61
Nobel Prize, 2, <b>4–5</b> , 126, 340	Nucleoporins, 302–303	p51, see reverse transcriptase
NOE, see also Nuclear Overhauser effect,	-	p53, 11, 265, 470–475
364	Nucleoprotein, 457	crystal structure, 472-473
regular secondary structure, 369	Nucleoside analogues, 453	domain structure, 472
Non steroidal anti-inflammatory agents, 230	Nucleoside inhibitors, 453	function, 471
	Nucleotides, 169	Li Fraumeni syndrome, 473-474
Non Watson-Crick base pairs, 268	Nucleus, 299	linked to cancer, 474
Non-competitive enzyme inhibition,	Nups, see nucleoporins	malfunctions, 474
226–227	Nurse, P., 249	mutation, 474
Non-competitive inhibition, 226,		organization, 471
Non-covalent interactions, 403	O linked glycosylation, 290–291	primary sequence, 472
Non-nucleoside inhibitors, 454	Octapeptide repeat, 434, 436	1 2 1
Nonsense codons, 268	1 1 1	regulation, 474
Nostoc sp., 164	ODAP see $\beta$ -N-oxalyl L- $\alpha$ , $\beta$ -diamino	smoking, 474
NSAIDs, see non steroidal	propionic acid	transcription factor, 265
anti-inflammatory agents	ODCase, see Orotidine 5-monophosphate	p66, <i>see</i> reverse transcriptase
NTN hydrolases, see N terminal nucleophile	decarboxylase	P870, 121
hydrolases	Okazaki fragments, 254–255	PALA, 235–236
Nuclear envelope, 299,	Oleic acid, 107	Palindromic sequence, 222
Nuclear localization signals, 300	Oligomerization domain, 473	Palmitic acid, 107
Nuclear magnetic resonance spectroscopy,	Oligomycin, 145	Palmitoyl transferase, 292
360-375	OmpA, 424	Palmitoylation, 240, 292
<sup>13</sup> C chemical shifts for amino acid	OmpF, 129–131	PAM matrices, 174
residues, 372	Oncogene, 470	Pancreas, 237, 287, 441
<sup>15</sup> N 2D connectivity patterns, <b>368</b>	Oncoprotein, 250	Pandemics, 443, 445, 457
<sup>1</sup> H chemical shifts for amino acid	Operon, 317	Papain, 76
residues, 366	Opiomelanocortin, 288	Para substitution, 31
amide exchange, 411-412	processing of, 289	Paracoccus denitrificans, 138, 140
assignment problem, 364–370	Opsin, 117	cytochrome oxidase, 141, 144
chemical shifts for amino acid residues,	Optical isomers, 34	Parvalbumin, 415
371	Optical rotation, 34	Parvulins, 416
COSY, 368	Optical spectroscopy, 379–390	Pasteur, L., 75
generating protein structures, 373–375	absorbance, 381–385	Pauling, L. 14, 41, 67
heteronuclear methods, 370–373	absorbance spectra, 67, 381	Pavletich, N., 472
instrumentation, 365	circular dichroism, 385–387	pBR322, 316
magnetogyric ratio, 360	fluorescence, 381–385	p-bromophenylacetate, 206
national facilities, 392	fluorescence polarization, 382–383	PCR, <i>see</i> polymerase chain reaction,
NOESY, 368	Raman, 389–390	PDI <i>see</i> protein disulfide isomerase,
nuclear Overhauser effect, 364, 373–374	Orbitals, 31, 380	Penicillin, 228
	Organization, 37	Pepsin, 237, 287
practical biomolecular NMR, 364	Orientation effects, 206–207	
relaxation, 363–364		catalytic mechanism, 450
spectra, 367, 371	Orotidine 5-monophosphate decarboxylase,	specificity constant, 201
structure calculations in, 374–375,	205	structure, 449–450
TOCSY, 367–368	Osteogenesis imperfecta, 100, 428	Peptide bond formation, 16–17
triple resonance experiments, 373	Osteoporosis, 99	cis/trans isomerization, 23
Nuclear Overhauser effect, 364	Oubain, 154	ribosome, properties, 17–23
Nuclear pore complexes, 302–303	Oxidoreductases, 191	Peptide fragments, 166
Nucleation,	Oxygen, 8,	Peptidoglycan layer, 320, 321
crystal formation, 359	binding site in cytochrome oxidase, 143	Peptidomimetic, 451
helix formation, 409	binding to myoglobin, 69	Peptidyl proline isomerase, 415–416

Peptidyl transferase, 273, 275	Photobleaching, 115	Porter, R., 76
inhibition of, 280	Photocycle, 115	Post translational modification, 287–293
mechanism, 282	Photon, 121	covalent modification, 237-241
Periodic table of elements, 8	Photosynthetic reaction centres, 119–128	Ppi, see peptidyl proline isomerase
Peripheral proteins, 110	bacterial reaction center, 123-126	Pre-steady state, 200
Periplasm, 121, 288, 320	chromophores, 121	Prebiotic synthesis, 161–163
Perrin equation, 383	cytochrome subunit, 125	demonstration of, 162
Pertussis toxin, 440	electron transfer pathway, 122, 125	yields of biomolecules from, 162
Perutz, M.F., 2, 71, 352, 356, 358	fractionation with detergents, 121	Precipitation, 343
PEST sequences, 305	H subunit, 123–124	Pre-initiation complex, 258–260
pET vector, 319	kinetics, 122	Preproprotein, 287, 402
PFK, see phosphofructokinase	L and M subunits, 124-125	Preproteins, 287
PGH synthase, 229	organization, 121	N terminal sequences, 293
pH, 14-15	photosystems I and II, 126-128	Presenilins, 470
Phase angle, 353–354	special pair, 121, 125	Pribnow box, 64, 256
Phase problem, 356–357	structure, 123–126	Primary sequence, 39–40
Phenylalanine	Photosystem I, 126–127	cytochromes c, 175
absorbance spectrum, 381	Photosystem II, 126	haemoglobin, 172
chemical properties, 31	$\pi$ helix, 43–44	myoglobins, 40
data, <b>21</b>	pI, see isoelectric point	unknown, 167
DNA distortion, 259	Pichia pastoris, expression system,	ubiquitin, 304
genetic code specification, 268	314	Primase, 254
helix/sheet propensity, 41	Pigment, 115	Primers, 169– <i>170</i>
hydropathy index, 112	Ping-pong mechanism, 215	Primosome, <b>254</b> –255
mutation in CFTR gene, 427	Pituitary, 288	Prion, 431–435
optical rotation, 34	pK, 14–15	cellular, 433–434
$\pi$ - $\pi$ interactions, 31	Planck's constant, 196, 348	glycosylation sites, 434
secondary structure preference,	Planck's Law, 348	knockout mice, 435
180	Plaques, 431, 432, 434	mutations of PNRP gene, 435
spectroscopic properties, 30	Plasma membrane, 109, 164, 320	primary sequence, 434
Phenylalanine ammonia lyase, <b>191</b>	Plasmids, 315–316	scrapie, 433–434
Phenylisothiocyanate, 165–166	Plasmodium falciparum, 442	structural properties, 433
Pheophytin, 121, 124	Plastocyanin, 59, 299, 369	structure, 434
Phe-tRNA, 278	Pneumonia, 445, 457	Prokaryotic cells
φ angle, 41–44	Polarization, 382–383	Proline chemical properties, 29
Phillips, D., 210	Polyacrylamide gel electrophoresis,	cis-trans isomerization, 412–415
2-phosphoglycolate, 209, 233	335–338	collagen structure, 94–96
Phosphatase, 258, 290	polymerization reactions, 335	data, 21
Phosphatidylcholine, 105	Polyalanine, 40	genetic code specification, 268
Phosphatidylethanolamine, 105	Polymerase chain reaction, 169–170	globin helices, 68
Phosphatidylglycerol, 105	Polymorphism, 442	helix/sheet propensity, <b>41</b>
Phosphatidylinositol, 105, 291	Polypeptide, 39–50	hydropathy index, 112
Phosphatidylserine, 105	cleavage by enzymes, 166–167	hydroxylation, 96, 289
Phosphodiester bond, 267	folding kinetics, 408–410	location in turns, 47
cleavage, 224	hydrolysis, 167	peptidyl isomerases, 415–416
Phosphodiesterase, 118	permutations, 40	poly(Pro), 48
-	Polyprotein, 289, 445, 448,449	prolyl hydroxylase, 289
Phosphoenolpyruvate, 233 Phosphofructokinase, 231–234	Polysaccharide coat, 319	pyrrolidone ring, 94, 289
domain organization and movement,	Pompé disease, 308	transmembrane helices, 124
232–233	Porins, 128–132	Promoter, 256
regulation by ATP/ADP, 232–233	biological unit, 130	inducible, 317
transition state analogue, 232	channel selectivity, 128	prokaryotic, 64–66
Phosphorylase <i>a</i> , 241	constriction site, 130	Proof reading, 169, 275
Phosphorylase $b$ , 241		
÷ •	folding properties, 424	Propranolol, 116
Phosphorylation, 153–154	hydrophobic residues, 129	Pros, 30 Prostaglandins, 228–239
as post translational event, 290	OmpA, 424 OmpF, 129–130	
enzyme, 241	Ompr, 129–130 PhoE, 130	Protease inhibitors, 451–452, 476
Phosphoserine, 25, 290	secondary structure, 129	Proteasome, 305–308
in glycogen phosphorylase, 241	trimeric unit, 130	heptameric ring structures, 306
Phosphotyrosine, 25, 241, 290	umene um, 150	multiple catalytic activities, 305

Proteasome (continued)	Protein stability	R/S isomers, 24, 34, 38
mutagenesis, 307	conformational stability of proteins,	Racker, E., 114
19S regulatory complex, 308	402	Radiation, 348
regulation of activity, 308	contributions to free energy, 403	Radio waves, 348
structural organization, 309	factors governing, 403	Ramachandran plot, 48, 186
subunit structure, 307	Protein synthesis,	Ramachandran, G.N. 48
three dimensional structure, 307	chain initiation, 273–274	Ramakrishnan, V., 283
Protein crystallization, 358–360	elongation, 274–277	Raman spectroscopy, 389–390
Protein DataBank, 50-51, 105, 180, 347	molecular mimicry in, 277	Raman, C.V., 389
Protein databases, 180–181	outline of reaction, 273	Ran binding proteins, 302
Protein degradation, lysosomal, 308–310	role of soluble factors, 275	Ran, 302
proteasome, 305–308	termination, 277–278	Random coil, 396
ubiquitin, 305	Protein turnover, 303–310	Rapoport, T., 424
Protein disulfide isomerase, 288–289		<u> </u>
in vivo protein folding, 416	half-lives, 303–304	Rate constant, 192
	Protein/lipid ratio, 108	first order, 193
sorting pathway, 296	Proteinase K, 467	pseudo-first order, 195
Protein evolution,	Proteinase, see protease	second order, 195
convergent, 179	Proteins,	Rayleigh scattering, 389
gene duplication, 181	cyclic, 81	RCF, 322
rates of, <b>178</b>	estimation of, 33	Reaction centres, type I and type II, 128
Protein expression, 313–318	function, 5–6	Reaction controlled rate, 195
Protein folding, 395–438	isolation and characterization, 313	Reaction coordinate, 195–196
ab initio, 185–186	size, 6	Reaction rate, 194
amide exchange, 411–412	Proteolysis, 304	enhancement of, 202-209
barnase, 405–408	limited proteolysis, 237–239	Reactive center loop, 476–477
Brønsted equation, 407	Proteolytic processing, 287	Receptor, 115
databases, 180	Proteomics, 184, 339	acetylcholine, 377
denaturant dependence, 405	Protofilaments, 88, 89, 431	adrenergic, 115
diversity, 161–187	Proton pumping, 114-115, 142-144	bacterial, 295
energy landscapes, 411	Protonation, 30	chemokine, 454
GroEL-ES mediated, 417–422	Protoporphyrin IX, 9, 66–67	genes, 119
Hess' Law, 406-407	Proximal histidine, 68	hormone binding, 119
in vivo, 415-422	Prusiner, S., 433	seven transmembrane, 115
intermediates, 415	Pseudomonas aeruginosa, 168	tyrosine kinases, 239–240
kinetics, 404–406	ψ angle, 41–44	SRP54, 295
membrane proteins, 422-426	PTC, see phenylisothiocyanate	Recognition helix, 263
misfolding and disease, 426–435	Pterin, 9	Recombinant DNA technology, 313–318
models, 408–411	Purcell, E., 360	Red blood cell, see erythrocyte
molten globule, 409-410	Puromycin, 278, 279, 282	Redox reactions, 193
motifs, 173		and metal ion catalysis, 203
stopped flow kinetics, 404	Purple membrane, 114	Reiske protein, <i>126</i> , 133–137
structure prediction, 186	Pyridoxal phosphate, 29, 193	targeting sequence, 299
techniques, 413	Pyrimidine biosynthesis, 207, 234	Relaxation times, 363–364
temperature dependence, 400	Pyrrolidine ring, 16, <i>21</i> , 29	Release factors, see RF-1, RF-2 RF-3
Protein purification, 313–346		Replication origin, 316, 318
affinity chromatography, 332–333	Q cycle, 135	Repressor, <i>see also</i> DNA binding proteins,
centrifugation, 320–323	Quality control, 296	64–66
6 .	Quantum mechanics, 379	
chromatography, 326–333	Quantum yield, 30	Residue, 17
dialysis, 333	Quaternary structure of proteins, 62–81	Resins, 326
electrophoresis, 333–340	hemoglobin, 70	polystyrene, 332
ion-exchange chromatography, 328–329	aspartate transcarbamoylase, 235	Resolving gel, 336
reverse phase methods, 331–332	Quench cooling, 355, 377	Resonance, 23, 28
salting-out, 323–326	Quenching, 381–382	Respiratory complexes, 132–144
size exclusion chromatography, 330–331	Quinone, 105, 124–125,	Restriction endonucleases, 221–224
ultrafiltration, 333	Zamone, 100, 121 120,	cleavage sites, 315
Protein solubility, 325	T 4	multicloning sites, 317
Protein sorting and targeting, 293–303	R factor, 358	signature sequence, 224
chloroplast, 299	R group, 23–32	table of selected enzymes with cleavage
mitochondrion, 297-299	properties, 18–22	sites, <b>222</b>
nuclear targeting, 299–302	R state, 71, 235	type II in cloning, 314

Retinal, 114	RNA polymerase, 64	Ramachandran plot, 48
isomerase, 118	T7 enzyme, 256	regular NOEs and distances, 369
11-cis, 117–118	eukaryotic, 257	supersecondary, 58
trans, 117–118	RNA recognition motif, 270	translation distance, 43
Retinol binding protein, 428,429	conserved sequences, 271	turns as elements of, 46
Retrovirus, 443	RNA transcript, 265	Secretory granules, 287
Rev, 446–448	RNase A, see ribonuclease	Sedimentation coefficient, 323–324
Reverse phase chromatography, 331–332	RNase H, 452–453	identification of rRNA, 269
Reverse transcriptase, 452–454	Roeder, R.G., 259	Sedimentation velocity, 323
AZT binding, 453	Röntgen, W., 349	Selectable markers, 318
p51 crystal structure, 453	Rossmann fold, 58, 148, 180, 218, 220, 378	Selection rules, 380
p66 crystal structure, 452		Selenomethionine, 357
RF-1, 278	Rossmann, M. 60	Semi-conservative model, 253
RF-2, 278	Rotamer, 43, libraries, 49–50	Semiquinone, 134
	Rotary motion, 146	Sequence homology, 170–176
RF-3, 278	Rotational states, 380	1 65
Rheumatoid arthritis, 99	rRNA, see ribosomal RNA	c type cytochromes, 175
Rhodamine 6G, 170	RS (Cahn Ingold Prelog) system, 34	cro repressor, 66
Rhodobacter viridis, 120		Sequence identity, 222
Rhodopsin, 117–119	S (Svedburg), 323	Sequencing, protein, 165–168
Riboflavin, 193	S phase, of cell cycle, 247	DNA, 168–171
Ribonuclease, 6, 288	Sabatini, D., 293	Serine
active site chemistry, 202–203		active site serine in cyclo-oxygenases,
protein folding, 402–403	Saccharomyces cerevisiae,	230
sedimentation coefficient, 324	expression system, 314	catalytic triad, 25, 177, 179, 212-213
structure, 203	genome sequencing, 9	chemical properties, 25
Ribonucleoprotein, 265, 458	secretion mutants, 424	covalent catalysis by, 214
Ribosomal RNA, 257, 261	Salicylate, 230	genetic code specification, 268
Ribosome, 269–287	Salt bridges, in chymotrypsin, 55	helix/sheet propensity, 41
A site, 273	Salting in, 323–326	hydropathy index, 112
affinity labeling and footprinting, 279	Salting out, 323–326	lipid headgroup, 106
anatomical features, 271	Sanger, F., 169	location in turns, 47
assembly, 271	Saquinavir, 452	nucleophile, 25, 214
complex with SRP, 293	Sarcoplasmic reticulum, 155	O linked glycosylation, 290–291
composition of prokaryotic, 269–271,	$Ca^{2+}$ transport, 155–156	phosphorylation, 25
composition of eukaryotic, 269–270	lipid:protein ratio, 109	proteases, 212–215
E site, 272, 286	Saturation curve, 198, 325	secondary structure preferences, <b>180</b>
18S rRNA, 257	Scalar coupling, 363	Serine carboxypeptidase II, 179
electron microscopy of, 272	Scattering, 351	Serine proteases, 25, 177, 212–215
5.8S rRNA, 257	Schiff base, 29, 203	active site, 212
5.85 IRNA, 257 5S rRNA, 269	Schizosaccharomyces pombe, 249	catalytic mechanism, 214–215
	Scissile bond, 212	•
Haloarcula marismortui, 272	Scrapie, 433–434, 466	catalytic triad, 212
large and small subunit, 282–287	Scurvy, 289	convergent evolution, 179
mechanism of protein synthesis, 208–282	SDS PAGE, 111, 335–337	inactivation by DIPF, 213
P site, 273,	identification of vCJD, 467	reaction of chymotrypsin with TPCK,
peptidyl transferase site, 273–275		213
RNA recognition motifs, 270	purification using, 344	studied using neutron diffraction, 379
role of antibiotics, 278–279	principles of, 335–336	superposition, 177
sedimentation coefficient, 324	use with mass spectrometry, 342	Serpinopathies, 478
16S rRNA, 269	SDS, use in protein folding, 396, 423	Serpins, 224, 238
soluble factors interacting with, 275	Sea urchin, 248	7S rRNA, 294
surface epitopes, 272	Sec61, 295, 424–426	Seven transmembrane helices, 115
Thermus thermophilus, 272	Second messengers, 119	SH2 domains, 241
transition state analogue, 282	Second order reaction, 195	SH3 domains, 172, 241, 433
28S rRNA, 257	Secondary structure, 37–50	formation of amyloid fibrils, 431
23S rRNA, 269,	additional, 48	Shine-Dalgarno sequence, 273–274,
Ribosylation, 439	α helix, 41	317
Ribozymes, 162, 192, 242, 287	β strand, 45	SI units, 477
Ricin, 228	dihedral angles, 43	Sialic acid, 458, 464
RNA binding protein, 271	other helical conformations, 44	Sickle cell anemia, 9, 441–442
RNA hydrolysis, 202	prediction, 181-183	haplotypes, 442

C: 1 D 417	0 : 1 4: - 1 - 4: - 4: - 262 201	G II T 222
Sigler, P., 417	Spin-lattice relaxation time, 363, 391	Svedburg, T., 323
Sigmoidal binding curve, 69, 231, 232, 234	Spin-spin relaxation time, 363–364	Swiss roll motif, 61, 460
Signal hypothesis, 293	Splice sites, 266	Symmetry-forbidden transitions, 380
Signal peptidase, 295–296	Spliceosome, 265–267	Symport, 154
Signal peptide, 288, 293	branch point, 266	Synchotron, 357
SRP54 binding, 294	composition, 265	Synechococcus sp., 164
	1	*
Signal recognition particle, 293–295	consensus sequence, 266	photosystem structure, 126
E.coli homologue, 294	lariat structure, 267	Synge, R.L.M., 326
pathway, 293	SR Ca <sup>2+</sup> ATPase, 155–156	Syrian hamster, 434
receptor structure and function, 295	Src homology domains, 172	
signal peptide, 293	SRP, see signal recognition particle	
Signal sequence peptidase, <b>293</b> , 295–296	SRP54, 294–295	T cells, 75, 443, 445
SRP54, 294–295	Stacking gel, 336	T loop, 251
structure and organization, 294		T state, 71
	Stahl, F., 254	$T_1$ , 363
translocon interaction, 424–426	Stanley, W.M., 443	T <sub>2</sub> , 363-364
Signature sequence, 224	Staphylococcus aureus, 35, 130	<del></del>
Silk, 86, 92–93	hemolysin structure, 130–131	T4 DNA ligase, <b>191</b>
Silver staining, 337	Start codon, 268, 273-274	T7 RNA polymerase, 256, 313
Simian immunodeficiency virus, 447, 456	Start sequences, 426–427	structure, 256
Sinapinic acid, 341	Steady state approximation, 199–200	Tanaka, K., 340
Singer, S.J., 109	Stearic, 107	Tanford, C., 396
•		Taq polymerase, 169
Single particle analysis, 377	Steitz, T., 272	Targeting, see protein sorting and targeting
Singlet, 380	Stem loop structure, 269	
SIV, see simian immunodeficiency virus	Stereochemistry, 15–16, 34–35	Tat, 446–448
16S rRNA, 269	Stereogenic, 35	TATA binding protein (TBP), 258-261
complementarity, 318	Stern-Volmer equation, 382	TATA box, 64, 256
helix44, 279	Steven, A.C. 377	recognition by transcription factors, 258
the 530 loop, 279,	Sticky ends, 222, 314	Tautomerization, 202
helix34, 279	Stigmatellin, 135, 137	Taxol, 378–379
	E	Taylor, K., 376
secondary structure, 284	Stoeckenius, W., 114	Tay-Sachs disease, 309–310, 428, 441
tertiary structure, 284	Stokes Law, 323, 363	•
surface location of ends of molecule, 272	radius, 330	TCA cycle, see citric acid cycle
Size exclusion chromatography, 330–331	Stokes shift, 381	tele, 30
Skehel, J., 459	Stop codons, 268, 318	Template, 169
Sleeping sickness, 290	Stop transfer sequences, 426–427	Tertiary structure, 50–62
SmaI, 222	Stopped flow analysis, 404–405	globular proteins, 52
Small subunit (30S), 282-286	double mixing experiments, 415	hydrogen bonding, 56
anatomical features, 284	Streptomycin, 278	hydrophobic effect, 53–55
decoding process, 286	Stroma, 128, 299	reformation, 402
• .		stabilizing interactions, 53–58
functional activity, 285–287	Structural homology, 175–177	van der Waals interactions, 56–58
IF-3 binding, 283	Structure factor, 355	
protein composition, 284–286	Subsites, 208, 212	Tetracyline, 315
16S rRNA structure, 284	Substitution reactions, 32	Tetrahedral intermediates, 214
Smallpox, 75, 442	Substrate discrimination, 220	Tetramerization domain, 473
Smith, H.O., 221	Subtilisin, 179, 402	Tetrapyrrole,
Smoking, effects on p53, 474	Succinate dehydrogenase, 226	TFIIA, 258–261
emphysema, 478	Succinate, 227	TFIIB, 258–261
S <sub>N</sub> 2-type reaction, 211	Sulfation, 292	TFIID, 258-261
snRNPs, 265	Sulfite oxidase, 58, 181	TFIIE, 258-261
Sorting, see protein sorting and targeting	Sulfolipids, 107	TFIIF, 258-261
Southern Blotting, 337	Sulfonamide, 205	TFIIH, 258–261
•		
Southern, E.M., 337	Sulfone, 26	TFIIIA, <b>173</b> , 262
Soyabean lipoxygenase, 44	Sulfoxide, 26	Thermal denaturation, 97
Spanish flu, 457	Sumner, J., 358	Thermoplasma acidophilum, 306
Special pair, 121	Super secondary structure, 37, 58	thermosome, 422
Specificity constant, 201	Superconducting magnet, 364	Thermosome, 422–423
Sphingolipids, 107	Superfamily, 180	Thermus aquaticus, 169
Spin multiplicity, 380	Superoxide dismutase, 193,	Ffh subunit, 295
Spin state, 71	SV40 T antigen, 299	M domain, 295
Spin-forbidden transitions, 380	Svedburg constant, 323	Thermus thermophilus, 272
Spin rotoraden nanoratino, 500	S. Sacuis Constant, SES	1 incrinopinuo, 212

Thiamine, see vitamin B1	structure, 267–269	Trypanosoma brucei, 290
Thiol, 26–28, 288	synthetases, 220	Trypsin, 287
formation of mixed disulfides, 27	variable loop, 268–269	activation of other proteolytic enzymes,
ionization, 27	Transferases, 191	238
Thiolate, 27	Transformation, 315	active site substrate specificity, 212
Thioredoxin, 59, <b>369</b> , 375, <b>401</b>	Transition metals, 7, 26, 193	catalytic mechanism, 212–215
conserved motif, 416	Transition state analogue, 209, 221, 233,	inhibitor, 224
30S subunit, <i>see also</i> small subunit,	282	protein sequencing, 166, 167
282–286 Thaman J.J. 240	Transition state, 195–197	structural homology, 177
Thomson, J.J. 340	bond energies, 207	Tryptophan
Threading, 185	preferential binding to enzymes, 207–209	aborbance spectrum, 381
3 <sub>10</sub> helix, 43–44 in glycogen phosphorlase, 241	two stage reactions, 197 Transition temperature, 108	anisotropy, 383 blue shift, 381
Threonine	phase changes for diacyl-phospholipids,	chemical properties, 32
[2S-3R], <b>35</b>	109	data, 22
chemical properties, 25	protein denaturation, 397–398,	fluorescence, 381
data, 22	Transitions, 380	genetic code specification, 268
genetic code specification, 268	in CD spectra, 386	helix/strand propensity, 41
helix/sheet propensity, <b>41</b>	Translation distance, 94	hydropathy index, 112
hydropathy index, 112	Translation, 266–287	optical rotation, 34
O linked glycosylation, 290–291	arrest, 424	secondary structure preference, 180
optical rotation, 34	of synthetic polynucleotides, 267	spectroscopic properties, 30
phosphorylation in cdk, 251–252	Translocases, 297–299	TSEs see transmissible spongiform
secondary structure preference, 180	tom, 297	encephalopathies
use as nucleophile in catalysis, 303	tim, 298	Tuberculosis, 445
Thrombin, 212, 238-239	tic, 299	Tubulin, 377–379
Thylakoid membrane, 128, 299	toc, 299	Tumour suppressor genes, 252, 470, 474
Thymine, 247	Translocon, 295, 424–426	Turns, 46–48
Thyroxine, 36, 428	organization, 426	β-bends, 48
TIM, see triose phosphate isomerase	Transmissable spongiform encephalopathies,	γ-turns, 47
Tm, see transition temperature	431, 434	28S rRNA, 257
Tobacco mosaic virus, 443	BSE, 466–468	23S rRNA, 269
Topogenic sequences, 426–427	incidence in UK, 467	secondary structure prediction, 280
Topoisomerases, 253	inherited forms associated with PNRP	tertiary structure, 281
Torsion angle, 41, 48–49 Tosyl-L-phenylalanine chloromethylketone,	mutations, 435	Two dimensional gel electrophoresis, 270
211, <b>228</b>	UK advisory committee, 467 Transport, 153	Two dimensional NMR spectroscopy,
Toxin, 228	Transhyretin, 428–430	365–370
TPCK, see tosyl-L-phenylalanine	mutations and disease progression, 430	H/D exchange measurements, 412–413
chloromethylketone	complex with RBP, 429	Twort, F., 443
Trace elements, 7	Tricarboxylic acid cyle (TCA) see Citric	Tyrosine kinases, 239–241
trans ring, 419	acid cycle	Tyrosine
Transaminase, 193	Triglycerides see Triacylglycerols	aborbance spectrum, 381
Transcription factors, 258	Triose phosphate isomerase, 179, 215–218	chemical properties, 31–32
basal components, 258-261	catalytic fine tuning, 218	data, <b>22</b>
structures, 261–265	catalytic reaction, 209	formation of tyrosyl adenylate, 218
TBP, 258–261	imidizolate in catalysis, 215-217	genetic code specification, 268
Transcription, 254–265	mechanism of conversion of DHAP,	helix/strand propensity, 41
control in prokaryotes, 64–65	217	hydropathy index, 112
cI repressor, 64	pH dependence of catalysis, 216	phosphorylation, 239
cro repressor, 66	transition state analogues, 208	reaction with nucleophiles, 31
terminators, 318	Triple helices, 94–97	secondary structure preference, 180
Transducin, 118–119	cross-linking, 97	spectroscopic properties, 30
Transfer RNA (tRNA), 267–270	thermal denaturation, 96	Tyrosyl tRNA synthetase, 218–221
acceptor stem, 268–269	structure, 95	active site structure, 219
anticodon, 269	Triple resonance experiments, 373	binding affinities for substrates, 218–219 characteristic motifs, 219–220
binding to amino acyl tRNA CCA region, 220, 270	Triplet, 380 of genetic code, 268	mutagenesis of critical residues, 219
D arm and loop, 269	tRNA, see transfer RNA	three dimensional enzyme structure,
discrimination against, 286	Tropocollagen, 6, 94	218
	· r · · · · · · · · · · · · · · · · · ·	

U1-snRNA, 265, 270	Vectors, 313–319	World wide web, 185
U2-snRNA, 265	pBR322, 316	Wuthrich, K., 369
U4/U6-snRNA, 265	pET, 319	
U5-snRNA, 265	Vibrational states, 380	Xenopus laevis, 261, 308
Ubiquinol-cytochrome c oxidoreductase, see	Vibrio cholerae, 439	X-ray crystallography, 349–359
also cytochrome bc1 complex,	Vif, 446, 448	Bravais lattices and unit cells, 351–352
132-137	Viral fusion, 456–457,	experimental set-up, 350
Ubiquinone, 133–134, 193	Viruses, 442–443	frequency range and measurement, 349
Ubiquitin, 304-305	Baltimore classification, 444	isomorphous replacement, 356-357
addition to CFTR, 427	flu virus, 458	multiple anomalous dispersion, 357
ATP dependent activation, 305	human papilloma, 475	national facilities, 392
E1 enzymes, 304	tobacco mosaic, 443	phase problem, 356-357
E2 enzymes, 304	Viscosity, 383	protein crystallization, 358–360
E3 enzymes, 304	Visual cycle, 118	R factor, 358
NMR spectrum, 367	Vitamin B <sub>6</sub> (pyridoxine), 29, <b>193</b>	refinement of structures, 357–358
sequence, 304	Vitamin C and scurvy, 193, 429	synchotron radiation, 357
tertiary structure, 304	Vitamin K <sub>3</sub> , 105, <b>193</b>	wavelengths, 350
Ultracentrifugation, 322–323	Vitamins, 193	X-ray, 348
Ultrafiltration, 333	Vitrified water, 377	•
Uncertainty principle, 349	V <sub>max</sub> , maximal enzyme catalysed velocity,	Yarus inhibitor, 280
Unimolecular reaction, 192, 195, 208	198-202	Yeast genome sequencing, 9
Uniport, 154	competitive inhibition, 225-226	flavocytochrome b <sub>2</sub> , 299
Unit cell, 351	non-competitive inhibition, 226–227	secretion mutants, 424
Unsaturation, 107	Vogelstein, B., 470	tRNA structure, 269
Unwin, N., 114, 376	Voyeur chlorophylls, 125	Yersenia pestis, 168
Urea, 193, 396, 400	Vpr, 446, 448	$YO_2$ (fractional saturation with $O_2$ ), $68-70$
Urease, 207, 358	Vpu, 446, 448	Yonath, A., 283
Urey, H., 162	· <u>r</u> · · · ·	Yoshikawa, S., 138
Uridine monophosphate, 207	Walker, J.E., 147	
1 1	Water elimination of, 16	Zanamivir, 464, 465
Vaccination, 75, 440	Water splitting reaction, 193	Zif268, 262
Valine	Water, metastable form, 377	Zinc fingers, 261–263
chemical properties, 24	Watson, J.D., 2, 247	HIV proteins, 449
data, 22	Wavelength, 348	primary sequence, 262
genetic code specification, 268	Wavenumber, 381	Zinc ion
helix/strand propensity, 112	Waves, 353–354	carbonic anhydrase, 206
hydropathy index, 41	Western Blotting, 337, 465	carboxypeptidase, 192, 193
secondary structure preference, <b>180</b>	WHO, see world health organization	cytochrome oxidase, 139
Van der Waals interactions, 53, 56–58	Whooping cough, see pertussis,	p53, 472
in collagen structure, 95	Wiley, D., 459	proteases, 136
Van der Waals volume, 18–22	Wilkins, M.F., 2, 247	regulation of activity of aspartate
Vapour diffusion, 359	Wilm's tumour, 265	trans-carbamoylase, 235
Variable domain, in gp120, 454–455	Wilson, I., 459	tubulin assembly, 377–379
Variable loop, 268–269	Wohler, F., 1	Zn fingers, 261
Variant CJD, 466–468	World Health Organization, 11,	Zwitterion, 13, 15
vCJD, see variant CJD	465	Zymogens, 237-238, 287, 310
. Cob, see furfull Cob	.00	• •